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Abstract
Leydig cell hyperplasia and adenomas are frequently observed during chronic 
carcinogenicity studies with new therapeutic agents, however, the significance of this 
effect to humans is unknown. Many compounds that produce Leydig cell tumours 
also induce hepatic cytochromes P450 (CYP) but it is unknown whether these two 
phenomena are causally related. The aim of this project was to investigate the 
existence o f a liver-testis axis wherein microsomal enzyme inducers enhance 
testosterone metabolic clearance, resulting in a drop in circulating hormone levels and 
a consequent hypertrophic response from the hypothalamic-pituitary axis.
Lansoprazole was selected as the model compound as it induces hepatic CYPs and 
produces LCTs in rats (Atkinson et al., 1990; Masubuchi et al., 1997a). Effects of 
lansoprazole treatment (150 mg/kg/day for 14 days) on the liver, testis and 
endocrine control o f the testis in male rats were investigated. The effects of 
lansoprazole were compared to model CYP inducers (P-NF, PB, PCN and 
ciprofibrate), the latter not being associated with LCTs.
Lansoprazole produced effects on the liver consistent with an increased metabolic 
capacity, including an increase in total microsomal CYP content, CYP induction 
(CY PlA l, CYP1A2, CYP2B1, CYP3A and CYP4A1) and enhanced CYP- 
dependent testosterone metabolism in vitro (i.e. 6 ^-, 7a-, 16a-, 16p-, 2a- and 2p- 
OHT and androstenedione formation). Furthermore, lansoprazole-treated rats 
exhibited a significantly smaller AUCiast and significantly higher plasma clearance 
and volume of distribution (Vgg) following intravenous administration of ^ "^C- 
testosterone. Reductions in plasma testosterone levels were observed in 
lansoprazole-treated animals but no significant changes in plasma LH or FSH levels 
were detected. Lansoprazole-treated animals exhibited lower plasma prolactin and 
intratesticular testosterone concentrations, which might play a role in LCT 
development. No marked effects on testicular CYP-dependent testosterone 
metabolism were observed.
In conclusion, these findings are consistent with the hypothesis that hepatic CYP 
induction contributes to the reduction in circulating testosterone levels in 
lansoprazole-treated animals, which might play a role in LCT development.
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Chapter 1
Introduction
1.1 Preface
1.1.1 The Liver-Testis Axis and Leydig Cell Tumours
Leydig cell hyperplasia and adenomas are frequently observed during chronic toxicity 
and carcinogenicity studies with a diverse range of compounds. One common 
property of such chemicals is that they induce hepatic cytochromes P450 (CYPs) 
(e.g. oxazepam, felbamate, ammonium perfluorooctanoate (C8 ), lansoprazole and 
methyl tert-buXyl ether (MTBE)) (Diwan et al., 1986; reviewed by Glue et al., 1997; 
Biegel et al., 1995a; Masubuchi et al., 1997a; Williams & Borghoff, 2000). It is 
currently unclear whether these two phenomena are causally related.
CYPs play a role in steroid hormone homeostasis through their ability to metabolise 
steroids, such as testosterone. Exposure of rodents to microsomal enzyme inducers 
alters the composition o f the hepatic CYP complement, resulting in concomitant 
changes in metabolism. It has been hypothesised that hepatic microsomal enzyme 
inducers produce Leydig cell tumours (LCTs) in rodents through their ability to 
increase the metabolic clearance o f testosterone (Figure 1.1). The resultant decrease 
in circulating hormone levels would stimulate a compensatory increase in luteinising 
hormone (LH) secretion from the pituitary gland. It is widely accepted that chronic 
elevation o f circulating LH levels is associated with induction o f Leydig cell 
hyperplasia and tumours in rodents (Christensen & Peacock, 1980; Chatini et al., 
1990; reviewed by Cook et al., 1999).
At present, very little research has been conducted to determine whether such a liver- 
testis axis exists. A limited number of studies have been performed to investigate the 
impact of microsomal enzyme inducers on androgen homeostasis in rodents. Wilson 
& Le Blanc (1998) examined the effects of the organochloride pesticide, endosulfan, 
on the rate o f steroid hormone metabolism in female CD-I mice. Endosulfan-induced 
increases in the rate of hepatic testosterone metabolism were associated with enhanced 
urinary elimination of ^^"^C-testosterone (-3.6 fold). This increase in androgen 
clearance was associated with a small non-significant decrease in serum testosterone 
levels, suggesting that homeostatic feedback mechanisms were able to compensate for 
the effects o f this compound in female mice. MTBE is an oxygenated fuel additive, 
which produces a dose-dependent increase in the incidence o f LCTs in rats (Bird et al..
Figure 1.1 : Schematic representation of the liver-testis axis, a potential
mechanism through which hepatic microsomal enzyme inducers 
might produce Leydig cell tumours.
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o f the Leydig cells
1997; Belpoggi et al., 1995). Studies designed to investigate the mechanism of LCT 
induction revealed that MTBE induces CYPs involved in testosterone metabolism 
(e.g. CYP2B1/2, CYP3A1/2 and CYP2A1) and produces a significant reduction in 
serum testosterone levels (Williams & Borghoff, 2000; Williams et al., 2000). It is 
currently unknown whether the MTBE-induced decrease in circulating androgen 
levels occurs due to enhanced clearance o f testosterone.
Further research is required to investigate the impact of microsomal enzyme inducers 
on androgen homeostasis and the potential of these compounds to produce LCTs 
secondary to increased metabolic clearance of steroid hormones.
1.1.2 The Liver-Thyroid Axis
The concept o f the liver-testis axis is analogous to the liver-thyroid axis, which has an 
established role in the induction of thyroid follicular cell hyperplasia and tumours by 
microsomal enzyme inducers in rats (reviewed by McClain, 1992; Hard, 1998).
The thyroid gland is composed of two distinct cell types: the follicular cells and 
parafollicular cells (also called C-cells). The follicular cells synthesise and secrete the 
thyroid hormones T4  (thyroxine) and T3 (triiodothyronine) under the influence of the 
pituitary factor, thyroid-stimulating hormone (TSH). This forms part of the 
hypothalamic-pituitary-thyroid axis, which maintains the appropriate levels of 
circulating thyroid hormones (Figure 1.2). TSH is the primary regulator of thyroid 
growth and differentiated function but a variety o f local regulatory factors have also 
been identified (e.g. insulin-like growth factor-1 (IGF-1), transforming growth factor 
beta (TGF-P) and basic fibroblast growth factor (bFGF)) (reviewed by Hard, 1998).
Three major pathways are involved in the inactivation and excretion o f thyroid 
hormones (Eelkman Rooda et al., 1989; De Herder et al., 1988). The first pathway 
involves sequential deiodination catalysed by microsomal monodeiodinase enzymes, 
which are expressed in tissues such as the liver, kidney and brain. The second and 
third pathways involve conjugation with glucuronic acid or sulfate, catalysed by 
uridine diphosphoglucuronosyltransferase (UDP-GT) and sulfotransferase (ST) 
enzymes respectively. These reactions occur predominantly in the liver and facilitate
Figure 1.2: Regulation of the thyroid gland by the hypothalamic - anterior 
pituitary - thyroid axis
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biliary and urinary excretion of the conjugated hormone. Other pathways, such as 
deamination and decarboxylation are quantitatively less important.
Long term exposure to a diverse range of compounds induces thyroid follicular cell 
hyperplasia and tumours in rodents. Many of these chemicals are hepatic microsomal 
enzyme inducers, which produce histological changes in the thyroid gland secondary 
to increased metabolic clearance of thyroid hormones (e.g. l-methyl-3- 
propylimidazole-2-thione (PTI), phénobarbital (PB) and ciprofibrate) (McClain et al., 
1989; Visser et al., 1991; Biegel et al., 1995b; Schuur et al., 1997). The consequent 
reduction in circulating thyroid hormone levels stimulates a compensatory increase in 
TSH secretion. The role o f sustained elevation o f serum TSH levels in thyroid gland 
neoplasia is a well-established phenomenon (reviewed by McClain, 1992).
PB is an example of a well-characterised hepatic microsomal enzyme inducer, which 
acts as a tumour promoter in the rodent thyroid gland (McClain et al., 1988). 
Treatment of rats with PB increases the plasma clearance of thyroxine through marked 
induction of hepatic UDP-GT activity and increased biliary flow (McClain et al., 
1989). PB-treated rats show characteristic reductions in plasma T4  and T3 levels and 
elevated TSH levels (McClain et al., 1989). These endocrine changes are 
accompanied by an increase in thyroid weight and follicular cell hyperplasia and 
tumours (McClain et al., 1989). McClain et al. (1988) demonstrated that 
administration of thyroxine to PB-treated rats completely blocked the tumour 
promoting effect of this compound. In humans, several studies have shown that PB 
induces hepatic microsomal enzymes and increases thyroid hormone turnover, but 
circulating thyroid hormone and TSH levels are generally unaffected (reviewed by 
Curran & Degroot, 1991). Consistent with these findings, there is no epidemiological 
data linking PB with an increased incidence o f thyroid cancer in humans (reviewed by 
Curran & DeGroot, 1991).
For the current project, the concept of the liver-thyroid axis was used as a model to 
investigate the existence of a liver-testis axis in rats.
1.2 Testicular Physiology and Function
1.2.1 Anatomy
The male reproductive system is composed of the testes, a system of ducts, the 
accessory sex organs (prostate, seminal vesicles and bulbourethral glands) and several 
supporting structures. The testes have both endocrine and reproductive functions as 
they produce male sex hormones (mainly testosterone) and mature sperm cells. The 
system of ducts store and transport the sperm, while secretions from the accessory sex 
organs provide optimal conditions for sperm motihty, survival and transport.
Figure 1.3: The structure of the mammahan testis
a) A sagittal section of the testis and associated epididymis
b) A transverse section through a seminiferous tubule
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The testes are paired oval glands enclosed in a scrotal sac that lies outside of the 
abdominal cavity (Figure 1.3). A thick connective tissue capsule made up of three 
tunica layers surrounds each testis: tunica vasculosa (innermost), tunica albuginea and 
tunica vaginalis (outermost). The tunica albuginea extends inwards, dividing each 
testis in to a number o f compartments or lobules. Each lobule contains one to three 
highly coiled seminiferous tubules, which are lined with Sertoli cells and 
spermatogenic cells at various stages of development (tubular compartment). The 
seminiferous tubules are surrounded by interstitial tissue composed o f loose 
connective tissue containing mast cells, fibroblasts, macrophages, nerve fibres, lymph 
vessels, blood vessels and clusters of Leydig cells (interstitial compartment). A layer 
of peritubular tissue composed of extracellular matrix, fibroblasts and myoid cells 
forms the border of the interstitial space. -
1.2.2 Testicular Cell Types
The endocrine and reproductive functions of the testis involve three major cell types: 
Leydig cells that secrete testosterone, Sertoli cells that support spermatogenesis and 
the male germ cells. The roles o f each cell type are discussed in the following section.
Leydig Cell
Leydig cells appear as clusters of plump cells that reside in the interstitial space 
between adjacent seminiferous tubules. Closer examination reveals numerous 
mitochondria, abundant smooth endoplasmic reticulum, a well-developed Golgi 
complex, variable numbers o f lipid droplets and a network of peroxisomes. Leydig 
cells are often found intimately associated with blood and lymph vessels, which 
facilitates the rapid exchange of materials with the systemic circulation (Fawcett et al., 
1973).
'  ■ ■ ■
Leydig cells are the principal site of androgen biosynthesis (mainly testosterone), 
which underlies their central role in the paracrine control of spermatogenesis and 
endocrine control o f structures such as the accessory sex organs, bone and skeletal 
muscle (Christensen & Mason, 1965; Hall et al., 1969). The androgèn-dependence o f 
these structures is illustrated following androgen withdrawal, which leads to rapid 
germ cell depletion and atrophy of the accessory sex organs in rats (Bartlett et al..
1986). In the adult testis, the Leydig cell is also the major site for aromatisation of 
testosterone to form oestradiol (Tsai-Morris et al., 1985).
In the mammalian testis, at least two distinct generations o f Leydig cells exist: fetal 
and adult Leydig cells (reviewed by Habert et al., 2001). The first generation develops 
during fetal life and these cells are responsible for masculinisation of the male 
reproductive system. The second population of Leydig cells predominate in the adult 
testis and produce the testosterone required for the onset of spermatogenesis and 
maintainance o f reproductive function. Both generations o f Leydig cells appear to be 
formed by differentiation from mesenchymal-like stem cells (Hardy et al., 1989). In 
the adult rat, Leydig cells comprise approximately 2.7% of the testicular volume (Mori 
& Christensen, 1980). Under normal conditions Leydig cells rarely divide and this 
cell population remains relatively stable throughout adult life (Teerds et al., 1989a).
Sertoli Cell
The Sertoli cells are found embedded between the germ cells and play a crucial role in 
the regulation of spermatogenesis. They provide nutritional, metabolic and structural 
support to the developing germ cells. The Sertoli cells secrete tubular fluid, which 
transports newly formed sperm cells to the epididymis and contains a number of 
important proteins such as transferrin, plasminogen activator and androgen binding 
protein (ABP). ABP sequesters testosterone and maintains the high intratesticular 
hormone levels required for spermatogenesis (Zirkin et al., 1989). The unique tight 
junctions between adjacent Sertoli cells form the blood-testis barrier, which separates 
the interstitial and tubular compartments. This barrier aids regulation o f the chemical 
environment of the tubule and affords some protection o f the developing germ cells 
from potentially mutagenic substances. The Sertoli cell also appears to play an 
important role in intratesticular communication through secretion of a variety of 
proteins and peptides (e.g. TGF-P and IGF-1) (reviewed by Gnessi et al., 1997; Saez,
1994) (s e e l.2.3.2).
Germ Cell
Spermatogenesis is the highly synchronised and complex process through which 
primitive germ cells divide and mature to form specialised spermatozoa. There are 
essentially three different germ cell types: spermatogonia, spermatocytes and 
spermatids. The spermatogonia are the primitive germ cells, which divide and 
differentiate to form mature sperm cells and continuously replenish the stem cell 
population (Huckins, 1971). Spermatogenesis occurs within the seminiferous tubules, 
where the spermatogonia are closely associated with the basement membrane and the 
developing germ cells progressively migrate towards the lumen of the tubule 
(reviewed by Foote & Bemdtson, 1992). This process occurs throughout adult life 
and takes approximately 56 days in the rat (Leblond & Clermont, 1952).
1.2.3 Regulation of Testicular Function
1.2.3.1 Endocrine Regulation
The functions o f the testis are primarily regulated by the hypothalamic-pituitary-testis 
axis (HPT axis) which maintains the dynamic equilibrium of circulating testosterone 
levels using a closed negative feedback loop (Figure 1.4). Overall control is at the 
level o f the hypothalamus which releases pulses o f gonadotropin-releasing hormone 
(GnRH) at a critical frequency and amplitude. GnRH stimulates the anterior pituitary 
gland to release luteinising hormone (LH) and follicle-stimulating hormone (FSH), 
which act on specific target cells within the testis.
LH
LH acts exclusively on the Leydig cells and is the primary regulator o f testosterone 
biosynthesis and secretion (Menon et al., 1967; Purvis & Hansson, 1978). Binding of 
LH to a specific plasma membrane receptor activates a cAMP-dependent protein 
kinase pathway leading to an acute stimulation o f testosterone production (Cooke et 
al., 1976). LH also exerts a long-term trophic effect on the Leydig cell and is the 
major factor required to maintain the fully differentiated structure and function o f this 
cell population (reviewed by Saez, 1994). This long-term effect of LH is dependent 
upon RNA and protein synthesis (reviewed by Saez, 1994). Hypophysectomy or 
suppression of LH is associated with Leydig cell atrophy, diminished volume of the
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Figure 1.4: Regulation of the testis by the hypothalamic - anterior pituitary - 
testis axis
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smooth endoplasmic reticulum, reduced steroid secretory capacity and a decrease in 
LH receptor numbers (Russell et a l, 1992; Keeney et a l, 1988).
Testosterone completes a negative feedback loop to regulate further LH secretion from 
the pituitary gland. Testosterone acts mainly at the level of the hypothalamus, but also 
has a weak inhibitory effect on the pituitary gland (Roselli & Resko, 1990). 
Oestradiol, produced by the aromatization of testosterone in tissues such as the brain 
and testis, also participates in this negative feedback loop acting mainly at the level of 
the pituitary gland (Nishihara & Takahashi, 1983; Roselli & Resko, 1990). These 
regulatory pathways allow the Leydig cells to adapt to the fluctuating demands of the 
body for steroid hormones. In addition, stimulation of the Leydig cell by LH has been 
reported to evoke adaptive changes (e.g. downregulation o f LH receptor numbers and 
uncoupling o f the receptor from adenylate cyclase), which tend to reduce cell 
responsiveness to further stimulation (Wang et al., 1991; Saez et al., 1978a,b). 
However, steroidogenic desensitisation appears to represent a pharmacological 
response, which is probably not involved in the regulation o f Leydig cell 
steroidogenesis in vivo. Studies have demonstrated that treatment o f rats with 
LH/hCG causes downregulation of testicular LH receptors, but steroidogenic 
desensitisation is only observed following a single large, non-physiological dose of 
LH/hCG (Saez et al., 1978a,b; Zipf et al., 1978b). Indeed, repeated treatment o f rats 
with low levels of LH enhances LH-stimulated steroidogenesis in vivo, despite 
downregulation of LH receptor numbers (Zipf et al., 1978b).
FSH
FSH acts primarily on the Sertoli cells, but also has a mitogenic effect on the 
spermatogonia (reviewed by Bardin et al., 1994; Griswold, 1993). Binding of FSH to 
a plasma membrane receptor activates a cAMP-dependent protein kinase pathway 
leading to changes in protein synthesis and cellular function. Little is known about the 
precise hormonal roles o f FSH in adult males, but it appears to be essential for the 
initiation and maintenance of normal spermatogenesis (Matsumoto et al., 1986). A 
close interrelationship exists between FSH, testosterone and the Sertoli cell. In the 
immature testis, FSH triggers seminiferous tubule growth, initiates spermatogenesis 
and stimulates the secretion o f Sertoli cell products such as tubular fluid and ABP 
(reviewed by Sharpe, 1994). In the adult testis, most o f these functions appear to be
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more responsive to testosterone (Dym et a l, 1979; Ahmad et al., 1975). FSH may 
also act, via the Sertoli cell population, to regulate Leydig cell structure and function 
through the production of various paracrine factors (see 1.2.3.2).
FSH stimulates the Sertoli cell to release of the non-steroidal factor inhibin, which 
completes a negative feedback loop to regulate further FSH secretion from the 
pituitary gland (Bicsak et al, 1987; Franchimont et al., 1975). Inhibin has no effect on 
pituitary LH secretion (Franchimont et al., 1975). Gonadal sex steroids have minimal 
effects on FSH secretion, although oestrogens have an inhibitory influence (Gay & 
Dever, 1971). Severe damage to the seminiferous tubules or germ cell population is 
associated with elevated circulating FSH levels, probably due to reduced secretion of 
inhibin from the Sertoli cells (Zylber-Haran et al., 1982).
Prolactin
The anterior pituitary gland also secretes prolactin, which appears to play an important 
role in the regulation of gonadal function. Secretion of prolactin is influenced by 
multiple factors including dopamine (inhibits release) and thyrotropin-releasing 
hormone (TRH) (stimulates release) (Hill-Samli & MacLeod, 1974; MacLeod & 
Lehmeyer, 1974).
Prolactin has no well-defined physiological role in males but adequate levels appear to 
be essential for normal testicular function (reviewed by Bartke, 1980). Prolactin itself 
has little influence on the male reproductive tract, but it potentiates the effects of LH 
(Welsh et al., 1986; Bartke et al., 1978; Hafiez et al., 1972). Prolactin appears to be 
required for the maintenance o f LH receptor numbers, which increases the sensitivity 
of the Leydig cells to gonadotropin stimulation (Welsh et al., 1986; Bartke et al., 
1978; Zipf et al., 1978a). This hormone also appears to influence testosterone 
biosynthesis through effects on the availability of androgen precursors (Welsh et al., 
1986). In addition to the direct effects on the testis, prolactin appears to exert indirect 
effects on testicular function through modulation of gonadotropin secretion from the 
pituitary gland (McNeilly et al., 1978). Prolactin suppresses LH and FSH secretion, 
which may be due to decreased pituitary responsiveness to GnRH or reduced secretion 
of GnRH from the hypothalamus (Winters & Loriaux, 1978; Smith & Bartke, 1987; 
Cheung, 1983). Prolactin appears to be essential for normal testicular function but
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pathological increases in circulating hormone levels can have a deleterious effect. In 
humans and rodents, hyperprolactinaemia is associated with a hypogonadism 
characterised by testicular atrophy, decreased testosterone production and infertility 
(Carter et al., 1978; Sharpe & McNeilly, 1979; Bartke et al., 1977; Fang et al., 1974).
1.2.3.2 Paracrine Regulation
The HPT axis provides the overall control o f testis function but a number of 
intratesticular regulatory factors have also been identified. These may constitute a 
more sensitive local control system to enable rapid “fine-tuning” o f testicular cellular 
function with changing requirements. Many of these factors are expressed and 
secreted in a highly regulated manner, suggesting potential roles in the regulation of 
testicular development and function. Locally secreted factors may mediate regulatory 
pathways between the interstitial and tubular compartments. Numerous potential 
paracrine factors have been detected in the mammalian testis but in general their 
precise roles remain poorly understood (reviewed by Habert et al., 2001; Gnessi et al., 
1997; Saez, 1994). For the majority, effects on testicular cells have been observed in 
vitro and their physiological significance is unknown. Paracrine regulation o f the 
Leydig and Sertoli cell populations is discussed in the following sections.
Leydig Cell
Leydig cell structure and function is primarily regulated by pituitary LH, but may also 
be influenced by paracrine factors. Leydig cells appear to regulate their own activity 
through gap junctions linking adjacent cells and secretion of autocrine factors such as 
testosterone and oestradiol, which have inhibitory effects on steroidogenesis (Risley et 
al., 1992; Damey et al., 1996). Sertoli cells, peritubular cells, germ cells and . 
macrophages secrete numerous regulatory factors, which appear to act upon the 
Leydig cell (reviewed by Habert et al., 2001; Gnessi et al., 1997; Saez, 1994). 
Table 1.1 summarises the effects o f various paracrine factors on Leydig cell number 
and function and two well-documented examples are discussed in more detail below.
IGF-1, derived from the circulation or produced locally, may influence Leydig cell 
proliferation, differentiation and function (Gelber et al., 1992; Khan et al., 1992). 
During puberty, circulating IGF-1 levels rise concomitantly with the period o f rapid 
Leydig cell proliferation in rats (reviewed by Daughaday & Rotwein, 1989). IGF-1
14
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exerts a stimulatory effect on testosterone synthesis and a modest mitogenic effect on 
cultured Leydig cells (Gelber et al., 1992; Khan et al., 1992). The most convincing 
evidence supporting a testicular role for IGF-1 has come from studies with IGF-1 gene 
knockout mice, which show reductions in testicular size, Leydig cell number and 
volume, testosterone biosynthesis and circulating testosterone levels (Baker et al., 
1996). This suggests that IGF-1 may play a crucial role in the regulation o f Leydig 
cell proliferation and differentiation.
Platelet-derived growth factor (PDGF), which is produced by the Sertoli cells, 
enhances the LH-stimulated steroidogenic response in adult Leydig cells (Risbridger,
1993). PDGF gene knockout mice develop marked testicular abnormalities. These 
animals have normal testis at birth, but subsequently show progressive reductions in 
testicular size and a marked absence of adult Leydig cells (Gnessi et al., 2000). These 
studies suggest that PDGF may play a crucial role in the commitment o f Leydig cell 
precursors to proliferate and differentiate to form the adult Leydig cell population.
Sertoli Cell
Sertoli cells are a major site for the testicular synthesis and secretion o f paracrine 
factors but are also a target for the effects of certain regulatory molecules. The Leydig 
cells produce factors such as testosterone and |3-endorphin, which influence the 
secretion of several of Sertoli cell products (Fabbri et al., 1985; Skinner & Fritz, 
1985). p-Endorphin has inhibitory effects on the Sertoli cell, including inhibition of 
ABP production and cell proliferation, and may have a local role in antagonism o f the 
stimulatory effects of FSH on this cell population (Fabbri et al., 1985; Orth, 1986). 
The peritubular myoid cells produce a nonmitogenic paracrine factor termed PModS, 
which stimulates Sertoli cell functions such as ABP and transferrin secretion (Norton 
& Skinner, 1989; Skinner & Fritz, 1985). There is evidence that androgens may 
regulate the secretion o f PModS from the peritubular cells (Skinner & Fritz, 1985). 
Sertoli cell morphology and secretory activity also appears to vary with the stage of 
the seminiferous epithelium, suggesting that the germ cells may release factors to 
modulate Sertoli cell function (reviewed by Sharpe, 1994). Elimination o f specific 
germ cell types from the testis is associated with stage-dependent changes in inhibin 
secretion from this cell population (reviewed by Weinbauer & Wessels, 1999).
16
1.3 Xenobiotic-Induced Leydig Cell Tumours
1.3.1 Introduction
Mammalian reproduction is a complex and highly regulated process, which provides 
many potential sites for toxicological disruption. There are a vast number of 
publications describing adverse effects o f chemicals on the male reproductive system, 
including drugs, pesticides, industrial chemicals and environmental contaminants 
(reviewed by Creasey, 1998). For many of these agents, their primary target site and 
biochemical mechanism of toxicity are unknown.
The testes are the most significant site of xenobiotic-induced damage that affects 
fertility. Testicular toxicants can be divided in to two broad classes based on their 
mode of action. The first class of compounds directly interfere with the cells involved 
in spermatogenesis (i.e. germ and Sertoli cells), often due to some inherent chemical 
reactivity. This class includes agents that damage cellular macromolecules (DNA, 
RNA or proteins), which may have cytotoxic or genotoxic consequences for the cell 
(e.g. cyclophosphamide, daunorubicin). The second class o f compounds indirectly 
affect spermatogenesis through disturbance of endocrine or paracrine regulatory 
pathways (e.g. ethanol, ethane dimethane sulphbnate). v Morphological responses 
observed in testicular cells following a toxic insult include degeneration, necrosis, 
inflammation, hyperplasia and neoplasia.
In general, testicular tumours are rarely observed in laboratory animals with the 
exception of Leydig cell tumours (LCTs), which frequently occur in rats. Rat LCTs 
occur spontaneously and are readily induced by a diverse range o f  xenobiotics. The 
spontaneous incidence of LCTs is age-related and varies considerably depending on 
the strain, most notably the incidence in two-year-old Fischer 344 rats is 
approximately 76% (Mitsumori & Elwell, 1988) (Table 1.2). The underlying causes 
o f the high incidence in this strain are currently unknown, but it might be related to a 
progressive hormonal imbalance (Amador et al., 1985). The spontaneous incidence o f 
LCTs is considerably lower in all strains of mice (Mitsumori & Elwell, 1988; Lang,
1995).
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Table 1.2: Incidence o f spontaneous Leydig cell tumours in strains o f rats commonly 
used in safety assessment studies at 24 months old.
Strain Incidence %
Wistar 87 / 1249 7
Sprague-Dawley 16/349 4.6
F344 39,253/51,230 76.6
Crl:CD®BR 37/721 5.1
■ F344/DuCij 537/569 94.4
(Data derived from Cook et al., 1999)
1.3.2 Pathology of Leydig Cell Tum ours
The morphologic appearance o f the proliferative changes in the Leydig cells that result 
in the generation o f LCTs appears to be the same in both spontaneous and chemically- 
induced tumours (McConnell et al., 1992). This usually begins with focal hyperplasia, 
which may progress to form benign tumours (adenomas). In rare cases, adenomas 
undergo malignant transformation to form carcinomas. No consistent criteria have 
been identified to differentiate between Leydig cell hyperplasia and adenomas 
therefore this distinction is often based primarily on the size of the lesion. Guidelines 
released by The Society o f Toxicologic Pathologists propose that an adenoma be 
defined as a lesion that is larger than the diameter o f three seminiferous tubules 
(McConnell et al, 1992). In rodents, it may take up to two years for xenobiotic- 
induced LCTs to develop and generally there are no distinctive early (i.e. following 
one to two weeks o f compound exposure) indications of Leydig cell proliferation 
(reviewed by Clegg et al., 1997).
1.3.3 Role of LH in Leydig Cell Tumorigenesis
It is well established that LH has a major role in the control o f Leydig cell function but 
this hormone may also regulate Leydig cell proliferation. There is considerable 
evidence to support a causal relationship between elevated circulating LH levels and 
the development of LCTs. Leydig cells rarely divide but prolonged administration of
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LH to rats, mice and monkeys can induce Leydig cell proliferation (Christensen & 
Peacock, 1980; Pfeiffer & Hooker, 1943; Simpson & Van Wagenen, 1954; Teerds et 
al., 1989b). Chatini et al (1990) reported that spontaneously occurring LCTs in 
Fischer 344 rats are associated with high circulating LH levels and testosterone 
supplementation prevented LCT development. Elevation o f circulating LH levels has 
been reported in animals treated with a diverse range of Leydig cell tumourigens, 
suggesting a common mechanism of tumour induction (reviewed by Cook et al., 
1999). In rats, prolonged elevation o f serum gonadotropins is correlated to the 
increased incidence o f LCTs (Brown et al., 1979; Chatini et al., 1990; Yamada et al., 
1994b). The evidence described herein suggests that any condition capable of 
producing a chronic elevation o f circulating LH levels may have the potential to 
induce Leydig cell hyperplasia and tumours. It is currently unclear whether chronic 
elevation o f LH levels alone is a sufficient stimulus to cause Leydig cells to divide or 
whether other factors are involved.
Very little is known about the mechanism through which LH may induce LCTs, but it 
might involve the activation o f proto-oncogenes (reviewed by Saez, 1994). Studies 
using cultured pig Leydig cells and MA-10 tumour cells have confirmed that 
LH/human chorionic gonadotropin (hCG) exposure induces a rapid and transient 
increase in c-fos and c-jun mRNA levels (Hall et al., 1991; Czerwiec et al., 1989). 
The role these transcription factors in the long-term trophic effects of LH are currently 
unknown.
1.3.4 Role of Paracrine Factors in Leydig Cell Tumorigenesis
There is substantial evidence to support a role for LH in Leydig cell tumorigenesis, 
but other findings indicate that testicular paracrine factors might also be involved. 
Cook et al (1999) postulated that paracrine factors are likely to play a role in the 
aetiology of LCTs in rats, either as a primary factor or as a consequence o f other 
changes (e.g. gonadotropin levels or spermatogenesis). Studies have demonstrated 
that local regulatory factors can influence Leydig cell proliferation, therefore changes 
in the balanced secretion of inhibitory and stimulatory factors might predispose the 
testis to uncontrolled cell division. The paracrine pathways that may be involved are 
currently unknown.
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1.3.5 Mechanisms of Induction of Leydig Cell Tumours
An extensive and diverse range of pharmaceutical preparations have been reported to 
increase the incidence o f Leydig cell hyperplasia and tumours during rodent toxicity 
and carcinogenicity studies (reviewed by Cook et al, 1999) (Table 1.3). Figure 1.5 
illustrates five mechanisms through which chemicals can disrupt the HPT axis and 
produce LCTs. The common point is that all of these compounds increase circulating 
LH levels. The following section uses a mechanistic approach to classify some o f the 
nongenotoxic compounds that induce Leydig cell hyperplasia and adenomas.
Testosterone Biosynthesis Inhibitors. Testosterone biosynthesis inhibitors reduce 
serum testosterone levels and increase serum LH levels in rats (Fort et al., 1995; 
Hamada & Futamura, 1998). Most testosterone biosynthesis inhibitors belong to the 
imidazole, benzimidazole, dicarboximide or dimethylpyridine classes. Imidazole and 
benzimidazoles inhibit cytochrome P450-catalysed steps in the testosterone 
biosynthetic pathway by binding to the protoporphyrin iron of the enzyme (Vanden 
Bossche, 1985; Feldman, 1986).
Lacidipine is a calcium channel antagonist that inhibits testosterone biosynthesis, 
increases plasma LH levels and produces LCTs in rats but not mice (Hamada & 
Futamura, 1998). This compound reduces basal and LH-stimulated testosterone 
production in isolated Leydig cells from rats, mice and monkeys (Hamada & 
Futamura, 1998). Lacidipine increased 5-bromodeoxyuridine (BrdU) incorporation in 
LH-stimulated rat Leydig cells, but not in Leydig cells from mice or monkeys 
(Hamada & Futamura, 1998). These findings are consistent with data from 
carcinogenicity studies in rats and mice and suggest that elevated LH levels may be 
responsible for LCT induction in rats. Other examples o f testosterone biosynthesis 
inhibitors known to produce LCTs in rats include felodipine (Oradell, 1995a); 
cimetidine (Leslie et al., 1981) and metronidazole (Rustia & Shubik, 1979).
Androgen receptor antagonists. These compounds bind to the androgen receptor to 
reduce the negative feedback signal of gonadal steroids at the hypothalamus and 
pituitary gland (Simard et al., 1986). This leads to hypersecretion o f LH and a 
consequent increase in circulating testosterone levels (Cook et al., 1993; Viguier-
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Figure 1.5: Five mechanisms through which xenobiotics can disrupt the HPT axis to 
induce Leydig cell hyperplasia and tumours.
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Table 1.3: Examples of nongenotoxic pharmaceutical compounds that produce Leydig 
cell hyperplasia and adenomas in rats
Compound Clinical Indication Leydig Cell 
Response
Buserelin Prostate and breast carcinoma Hyperplasia
Carbamazepine Anticonvulsant/ analgesic Adenoma
Cimetidine Reduction of gastric acid secretion Adenoma
Finasteride Benign prostatic hyperplasia Hyperplasia
Flutamide Prostate carcinoma Adenoma
Gemfibrozil Hyperlipidaemia Adenoma
Isradipine -Antihypertensive Adenoma
Leuprolide Endometriosis Adenoma
Mesulergine Hyperprolactinaemia Adenoma
Norprolac Hyperprolactinaemia Adenoma
Metronidazole Antibacterial Adenoma
Indomethacin Anti-inflammatory Adenoma
Bicalutamide Prostate carcinoma Adenoma
Lansoprazole Reduction o f gastric acid secretion Adenoma
Guanadrel Antihypertensive Adenoma
Lacidipine Antihypertensive Adenoma
Vinclozolin Fungicide Adenoma
Procymidone Fungicide Adenoma
Oxlolinic acid Antimicrobial Adenoma
Felbamate Anticonvulsant Adenoma
Oxazepam Anxiolytic Adenoma
(Derived from Cook et al., 1999)
Martinez et al., 1983a,b). F lu t^ id e  is a potent non-steroidal antiandrogen that 
induces Leydig cell adenomas in rats following one year o f treatment (Oradell, 
1995b). This is associated with elevated circulating LH and testosterone levels and 
reductions in prostate and seminal vesicle weights (Viguier-Martinez et al, 1983a,b). 
Other examples of compounds with anti-androgenic activity that produce LCTs in rats
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include cimetidine (Brimblecombe & Leslie, 1984), linuron (Cook et al., 1993) and 
bicalutamide (reviewed by Iswaran et al, 1997).
5a~reductase inhibitors. 5a-reductase inhibitors, such as finasteride, block the 
conversion of testosterone to the more potent androgen, dihydrotestosterone (DHT) 
(Prahalada et al, 1994; Oradell, 1995c). This reduces the net androgenic feedback 
signal to the hypothalamus and pituitary gland leading to a compensatory increase in 
LH secretion (Prahalada et al., 1994). Chronic treatment (83 weeks) o f mice with 
finasteride has been reported to increase the incidence of Leydig cell hyperplasia and 
adenomas (Prahalada et al., 1994). In short term studies (5 to 14 weeks), a positive 
correlation was observed between the increased incidence o f Leydig cell hyperplasia 
and the increase in serum LH levels in finasteride-treated mice (Prahalada et al.,
1994).
Aromatase inhibitors. Aromatase inhibitors, such as formestane and letrozole, block 
the conversion of testosterone to oestradiol resulting in a decrease in serum oestradiol 
levels and a consequent increase in LH secretion (Junker-Walker & Nogues, 1994). In 
subchronic studies (3 months), formestane and letrozole produced Leydig cell 
hyperplasia in beagle dogs but not rats (Junker-Walker & Nogues, 1994). It was 
postulated that these species differences might have been due to the more prominent 
role of oestradiol in the feedback regulation of LH secretion in dogs compared to 
rodents (Junker-Walker & Nogues, 1994).
Dopamine agonists. Dopamine agonists or agents that enhance dopamine levels 
reduce serum prolactin levels. This may lead to downregulation o f Leydig cell LH 
receptors resulting in a partial inhibition of testosterone biosynthesis (Prentice at al,
1992). This would provoke a compensatory increase in LH secretion. Alternatively, 
dopamine agonists may increase serum LH levels through direct effects on the 
hypothalamus or pituitary gland (Yamada et al., 1994b).
Oxolininc acid is an antimicrobial agent that increases the incidence of Leydig cell 
hyperplasia and tumours in rats (Yamada et al., 1994a). Dietary exposure to oxolinic 
acid is associated with reduced serum prolactin levels and a significant increase in LH
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secretion (Yamada et al., 1994b). Co-treatment of rats with the dopamine receptor 
(D2) antagonist, haloperidol, completely blocked the oxolinic acid-induced increase in 
LH levels (Yamada et al., 1994b). These findings suggest that oxolinic acid may 
induce LCTs through facilitation of the hypothalamic dopaminergic system leading to 
an increase in LH secretion. Other examples of dopamine agonists known to produce 
LCTs in rats include mesulergine (Dirami et al., 1996) and norprolac (Roberts et al.,
1993).
GnRH agonists. GnRH agonists, such as buserelin, histrelin and leuprolide, induce 
LCTs in rats by binding to Leydig cell GnRH receptors (Donaubauer et al., 1987; 
Oradell, 1995d; Oradell, 1995e; Hunter et al., 1982). Low doses o f GnRH agonists 
have similar effects to LH and may stimulate the Leydig cell directly or by enhancing 
LH secretion from the pituitary gland (Hunter et al., 1982). This mode o f tumour 
induction appears to be a specific to rats because mice, monkey and human Leydig 
cells do not express GnRH receptors (Wang et al., 1983; Mann et al., 1989; Clayton & 
Huhtaniemi, 1982).
Oestrogen agonists. Oestrogen agonists, such as diethylstilbestrol (DES) and ethinyl 
estradiol, appear to induce LCTs in certain strains o f mice through their ability to 
elevate circulating LH levels (Baroni et al., 1966; Huseby, 1976; Yasuda et al., 1988). 
In mice, oestrogens increase pituitary LH secretion and also have a direct carcinogenic 
effect on the Leydig cells (Huseby, 1980). Oestrogen agonists may also induce LCTs 
by increasing prolactin levels, which would stimulate LH secretion in mice (Klemcke 
& Bartke., 1981; Chandrashekar et al., 1991). Species differences in susceptibility to 
LCT induction by oestrogen agonists have been illustrated in studies using DES, 
which is a model compound used for the induction of LCTs in mice (Baroni et al., 
1966). In contrast, the hyperprolactinaemia resulting from DES treatment is 
associated with a reduction in the incidence of LCTs in Fischer 344 rats (Bartke et al., 
1985).
The role of oestrogens in the development of LCTs in rats is currently a matter o f 
debate. Oestrogen agoinists do not induce LCTs in rats at dosages that cause testicular 
atrophy, but this condition may interfere with the detection o f the Leydig cell lesions 
(Gibson et al., 1967; reviewed by Biegel et al., 2001). There is some evidence to
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suggest that oestradiol may enhance Leydig cell tumorigenesis in rats. The high 
spontaneous incidence of LCTs in Fischer 344 rats is associated with an age-related 
increase in serum oestradiol levels (Turek & Desjardins, 1979). In contrast, serum 
oestradiol levels show an age-related decrease in CD rats, which have a low 
spontaneous incidence of LCTs (Biegel et al., 2001). Further research is required to 
clarify the role of oestradiol in LCT induction in rats.
Peroxisome proliferators. Peroxisome proliferator is the term used to describe a 
diverse range of compounds that cause peroxisome proliferation, induction of 
peroxisomal enzymes and hepatocellular carcinomas in rats (reviewed by Gibson & 
Lake, 1993). A number of these compounds also induce LCTs, including ammonium 
perfluorooctanoate (C8 ) (Biegel et al., 2001; Sibinski, 1987), clofibrate (Oradell, 
19951) and Wyeth-14,643 (Biegel et al., 2001). These compounds do not appear to 
induce peroxisomes in the Leydig cell, suggesting a distinct mechanism o f  tumour 
induction in the testis (Biegel et al., 1992; Cook et al., 1994; Mori et al., 1980).
The mechanism of LCT induction has been investigated for two peroxisome 
proliferators, C8  and Wyeth 14,643. These compounds increase hepatic aromatase 
activity and produce a sustained increase in circulating oestradiol levels, which is 
correlated with the potency of LCT induction (Biegel et al., 2001; Liu et al., 1996; 
Biegel et al., 1995a). Elevated serum oestradiol levels are associated with increased 
testicular hormone levels, which might modulate testicular growth factor expression to 
produce LCTs (Biegel et al., 1995a; Cook et al., 1992). Consistent with this 
hypothesis, C8  treatment was associated with an increase in testicular transforming 
growth factor alpha (TGFa) levels in rats (Biegel et al., 1995a). In addition, 
peroxisome proliferators directly modify Leydig cell fimction in vitro, reducing basal 
and LH-stimulated testosterone production (Liu et al., 1996).
1.3.6 Human Relevance
The common occurrence of Leydig cell hyperplasia and tumours during rodent 
toxicity studies with new therapeutic agents demands careful assessment o f the risk 
presented to man. The significance of this effect to humans is currently unknown but 
there is evidence to suggest that men might be less susceptible than rodents to this
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drug-induced lesion. First, there are marked species differences in the spontaneous 
incidence of LCTs. In contrast to the common occurrence of LCTs in rodents, the 
age-adjusted human incidence is 0.4 per million and the tumours are usually benign 
(Gilliland & Key, 1995). The magnitude of the difference in tumour incidence may be 
partially exaggerated by the different methods of diagnosis, usually by palpation in 
humans compared to detailed histological examination of the testis in laboratory 
animals. This may tend to underestimate the true incidence in the human population 
because small, impalpable LCTs would not be detected.
Second, physiological differences between rats and humans appear to confer a 
differential sensitivity o f the Leydig cells to elevated circulating LH levels. The 
following factors might help to explain the apparent higher susceptibility o f the rat 
Leydig cell to tumour formation secondary to hormonal imbalance. First, rats express 
a greater number of LH receptors per Leydig cell than humans, which may confer a 
greater sensitivity to circulating LH (Huhtaniemi, 1983). This is consistent with the 
finding that rat and human Leydig cells respond differently to exogenous hCG, 
showing a hyperplastic or hypertrophic response respectively (Christensen & Peacock, 
1980; Heller & Leach, 1971). Second, rat Leydig cells express GnRH receptors, 
which have not been detected on mouse, monkey or human Leydig cells (Hunter et al., 
1982; Wang et al., 1983; Mann et al., 1989; Clayton & Huhtaniemi, 1982). Low 
levels of GnRH may stimulate the Leydig cell directly or indirectly by enhancing LH 
secretion from the pituitary gland (Hunter et al., 1982). Third, prolactin is necessary 
for the maintenance o f Leydig cell LH receptor numbers in rats but not humans (Zipf 
et al., 1978a; Walhstrom et al., 1983). Finally, humans express a high affinity sex 
hormone binding globulin (SHBG), which binds circulating testosterone retarding its 
metabolism and clearance (reviewed by Moore & Bulbrook, 1988; Dunn et al., 1981). 
In contrast, rats lack a high affinity circulating SHBG and consequently circulating 
testosterone levels may be perturbed more readily (Tenniswood et al., 1982).
The apparent species differences in Leydig cell responsiveness to LH are supported by 
data from certain human endocrine diseases. One example is androgen insensitivity 
syndrome (AIS) in which the body is unable to recognise androgens due to defective 
androgen receptor function (reviewed by Quigley et al., 1995). Affected individuals 
have elevated oestradiol and LH levels, normal or elevated testosterone and FSH
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levels, and an increased incidence o f  testicular tumours (germ, Sertoli and Leydig cell 
origin). One group reported the frequent occurrence of Leydig cell hyperplasia and a 
tumour incidence o f 2.3% in men with AIS (Rutgers & Scully, 1991). Cook et al 
(1999) contrasted this to the high incidence o f LCTs in rats treated with the androgen 
receptor antagonist, flutamide (approaches 1 0 0 %), and concluded that this provided 
further evidence for the lower sensitivity of humans to induction of LCTs.
Data from epidemiology studies have reported no increase in the incidence o f LCTs in 
humans despite widespread exposure to compounds such as 1,3-butadiene, clofibrate, 
lactose arid nicotine, which all induce LCTs in rats (reviewed by Cook et al., 1999). 
However, Cook et al. (1999) emphasised that relatively insensitive methods were used 
to detect tumours (e.g. palpation, abnormal endocrine profiles) and human exposure is 
generally much lower than the dosages used in rodent bioassays. Similarly, post 
marketing surveillance for therapeutic agents that induce LCTs in rodents 
(e.g. flutamide) have reported no increased incidence of these tumours in man.
In conclusion, most o f the available evidence suggests that human Leydig cells are 
less sensitive than rat cells in their proliferative response to LH, but the possibility of 
LCT induction by therapeutic agents cannot be ruled out. Clegg et al. (1997) 
concluded that the occurrence o f LCTs in rodent bioassays with new therapeutic 
agents is o f concern unless there is sufficient mechanistic data regarding the mode o f 
induction to conclude that it is not relevant to humans. By this principle, induction of 
LCTs by GnRH agonists and dopamine agonists are considered to present no risk to 
men because humans Leydig cells do not express GnRH receptors and prolactin is not 
permissive for LH receptor function in humans (Clegg et al., 1997; Clayton & 
Huhtaniemi, 1982). For the remaining modes of induction there is currently 
insufficient information available to rule out their relevance to humans. Further 
research is therefore required to improve the detection of LCTs in humans, to further 
investigate modes o f induction and to clarify the mechanistic and sensitivity 
differences between species (Clegg et al., 1997).
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1.4 Cytochrome P450 and Testosterone Metabolism
1.4.1 Cytochrome P450
Cytochrome P450 (CYP) enzymes constitute a superfamily of haemoproteins that 
catalyse the biotransformation of a diverse range of endogenous and exogenous 
compounds which include drugs, pesticides, carcinogens, food additives, 
environmental contaminants, steroid hormones, vitamins and fatty acids (reviewed by 
Lewis, 2001).. CYPs function as monooxygenases, which catalyse the general reaction 
shown below:
, Cytochrome P450 ,
. NADPHH"* + O2 + RH ___________  ► NADP^ + H2 O + ROH
where RH is the substrate and ROH is the hydroxylated metabolite. During this 
reaction NADPH H^ supplies two reducing equivalents and molecular oxygen is 
cleaved such that one oxygen atom is inserted in to the substrate while the other is 
reduced to water.
CYPs are found in every biological kingdom, including animals, plants and bacteria 
(Nebert et al., 1989). In mammalian species, CYPs are most abundantly expressed in 
the liver, but have been detected in virtually all tissues studied including the brain, 
lung, kidney, intestine, spleen, pancreas and gonads (reviewed by Lewis, 2001). 
These enzymes are membrane bound and are mainly localised in the endoplasmic 
reticulum, although certain forms are found in the mitochondria.
The CYP superfamily is composed of multiple forms, each showing distinct and 
sometimes overlapping substrate specificities, which are classified in to a number of 
gene families (members share over 40% sequence similarity) (e.g. CYPl to 3) and 
subfamilies (members share over 70% sequence similarity) (e.g. CYP2A to Q). 
Individual members of a subfamily are assigned a number (e.g. CYP2D6). The 
general functions of the different CYP families are shown in Table 1.4.
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Table 1.4: General functions of the cytochrome P450 gene families
CYP Family Function
C Y P1-C Y P3 Drug, xenobiotic and steroid metabolism
CYP4 Fatty acid and prostaglandin metabolism
CYP5 Thromboxane synthesis
CYP7 Cholesterol 7a-hydroxylation
C Y Pll Cholesterol side chain cleavage
CYP17 Steroid 17 a-hydroxylation
CYP19 Aromatisation of steroids
CYP21 Steroid 21-hydroxylase
CYP24 Vitamin D hydroxylation
CYP27 Cholesterol 27-hydroxylase
(Adapted from Gibson & Skett, 2001)
Many CYPs are expressed constitutively (i.e. in the absence o f an external stimulus) 
but certain forms can be reversibly induced following exposure to xenobiotics. 
Induction o f the synthesis of a pre-existing or previously unexpressed enzyme may 
result in qualitative and quantitative changes in hepatic metabolism. Mechanisms 
involved in enzyme induction include transcriptional activation (e.g. CYPl A l, 2B1/2, 
3A), post-transcriptional effects (e.g. stabilisation of CYP1A2 mRNA) and post- 
translational effects (e.g. reduced degradation of the CYP2E1 protein) (reviewed by 
Gibson & Skett, 2001). Conversely, CYP enzyme expression may be suppressed by 
certain xenobiotics (Yeowell et al, 1987; Waxman et al., 1984). Expression o f CYP 
enzymes is also influenced by endogenous factors such as species, age, sex, and 
hormones (reviewed by Gibson & Skett, 2001).
CYPs catalyse key reactions in the biosynthesis and catabolism of steroid hormones, 
and consequently play an important role in steroid hormone homeostasis in 
mammalian systems. The CYP enzymes involved in testosterone biosynthesis are 
markedly different to those associated with catabolic reactions in that they tend to 
possess specific substrate specificities and usually produce a single steroid metabolite 
(reviewed by Zimniak & Waxman, 1993).
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1.4.2 Testosterone Biosynthesis
The majority of testosterone biosynthesis occurs within the Leydig cells of the testis, 
which have been estimated to secrete over 95% of the circulating hormone after 
puberty (Christensen & Mason, 1965; Hall et ah, 1969). Testosterone biosynthesis 
involves a sequence of reactions, the majority being catalysed by CYP enzymes 
(Figure 1.6).
Testosterone is synthesised from the common steroid precursor, cholesterol, which 
may be derived from three sources: intracellular lipid droplets, de novo synthesis from 
acetate or circulating lipoproteins (Hall, 1994). Transfer of cholesterol to the inner 
mitochondrial membrane forms the rate-limiting step in steroid biosynthesis and is 
primarily regulated by LH (Crivello & Jefcoate, 1980; Privalle et al., 1983; Hall et al., 
1979). Several proteins have been postulated to play a role in cholesterol transport, 
including sterol carrier protein 2 (SCP-2), steroidogenesis activating polypeptide 
(SAP) and the peripheral benzodiazepine receptor (PDR) (Yamamoto et al., 1991; 
Pedersen & Brownie, 1987; Papadopoulos, 1998). More recently a protein named 
steroidogenic acute regulatory protein (StAR), which transports cholesterol between 
the outer and inner mitochondrial membranes, has been purified and cloned (Clark et 
al., 1994). StAR is expressed almost exclusively in steroidogenic tissues and its 
presence is correlated with steroid hormone production (Sugawara et al., 1995; Clark 
et al., 1995; Luo et al., 2001). LH regulates transcription of the StAR gene, leading to 
increases in mRNA and protein levels (Clark et al., 1995; Caron et al., 1997; Luo et 
al., 1998; Clark et al., 1994). StAR gene expression is also influenced by aiitocrine 
and paracrine factors such as IGF-1, TGFP and tumour necrosis factor alpha (TNFa) 
(reviewed by Christensen & Strauss, 2000).
Conversion of cholesterol to pregnenolone is catalysed by the mitochondrial side- 
chain cleavage complex, CYP450scc (product of the C Y P llA l  gene), which forms the 
rate-limiting enzymatic step during steroid biosynthesis (reviewed by Simpson, 1979). 
CYPscc expression is confined to steroidogenic tissues and in the testis is localised 
exclusively to the Leydig cells (O’Shaugnessy & Murphy, 1991). Once formed, 
pregnenolone rapidly enters the smooth endoplasmic reticulum where subsequent 
reactions occur. Two parallel pathways produce testosterone from pregnenolone, the
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relative importance of each being species-dependent. In humans the major pathway of 
testosterone biosynthesis is the A5-pathway, whereas the A4-pathway predominates in 
the rat (Weusten et al, 1987). Four principal steroidogenic enzymes are localised in 
the endoplasmic reticulum: 3 |3-hydroxysteroid dehydrogenase (3p-HSD), CYP17A1, 
17p-hydroxysteroid dehydrogenase (17p-HSD) and CYP19A1 (Reviewed by Saez,
1994). CYP17A1 is a bifunctional protein supporting both 17a-hydroxylase and 
C l7-20 lyase activity, which converts progesterone to androstenedione (Nakajin et al., 
1981). In the testis, CYP17A1 expression is confined to the Leydig cells and is 
regulated by LH (O’Shaugnessy & Murphy, 1991).
17p-HSD catalyses the reversible interconversion of androstenedione and testosterone 
(reviewed by Andersson & Moghrabi, 1997). Several distinct 17P-HSD enzymes have 
been identified, which differ in their substrate specificity, cofactor requirements, 
preference for oxidative or reductive reactions and subcellular and tissue distribution 
(reviewed by Peltoketo et al., 1999). This enzyme plays a key role in the formation o f 
active androgen and is present in gonadal and extragonadal tissues (e.g. liver, prostate, 
lung, testis and brain) (Martel et al., 1992).
CYP19A1 catalyses the conversion of androgens to oestrogens, under the influence o f 
LH (Valladares & Payne, 1981). CYP19A1 is primarily located in steroidogenic 
tissues, but activity is also present in adipose tissue, liver and skeletal muscle (Lephart 
& Simpson, 1991; Longcope et al., 1978). CYP19A1 exhibits an age-dependent 
cellular distribution in the testis, with activity predominantly localised to the Sertoli 
cells in immature rats whereas the Leydig cells are the major site of oestradiol 
production in mature animals (Tsai-Morris et al., 1985; Rommerts et al., 1982). 
Oestrogens have an inhibitory effect on 17a-hydroxylase activity in adult rat Leydig 
cells, which may be involved in the autocrine regulation of testosterone biosynthesis 
(Onoda & Hall, 1981; Kalla et al., 1980).
Steroid biosynthesis requires the controlled expression and activity o f the enzymes 
and other proteins involved in this pathway. Testosterone biosynthesis is dependent 
upon LH stimulation, which exerts both acute and chronic effects on the Leydig cell 
(reviewed by Saez, 1994). The acute steroidogenic response occurs within minutes o f
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LH exposure and involves increased translocation of cholesterol to the inner 
mitochondrial membrane (Hall et al., 1979). Chronic trophic stimulation o f the 
Leydig cell is required for optimal expression of steroidogenic enzymes (Wing et al., 
1984; O’Shaughnessy & Payne, 1982; Purvis et al., 1973). LH increases the mRNA, 
protein and activity o f StAR, 3p-HSD, CYPscc and CYP17A1 (Lejeune et al., 1998; 
Keeney & Mason, 1992; Anakwe & Payne, 1987; Payne et al., 1992). Cultured 
Leydig cells show high basal expression of CYPscc, although maximal levels o f 
expression require LH stimulation (Anakwe & Payne, 1987; Payne et al., 1992, 
Anderson & Mendleson, 1985). In contrast, CYP17A1 expression is absolutely 
dependent upon LH stimulation (Anakwe & Payne, 1987; Payne et al., 1992). 
Intratesticular autocrine and paracrine factors may also modulate the expression and 
activity of steroidogenic enzymes (Saez, 1994).
1.4.3 Testosterone Catabolism
1.4.3.1 Introduction
In humans, testosterone becomes loosely bound with plasma albumin or more tightly 
bound with sex hormone binding globulin (SHBG), such that a relatively small 
percentage o f the circulating hormone exists in an unbound form (Dunn et al., 1981). 
In contrast, male rats lack a high affinity circulating SHBG and consequently virtually 
the entire circulating hormone is loosely associated with plasma albumin (Tenniswood 
et al., 1982). This might represent an important physiological difference between the 
species as plasma protein binding may modulate the biological availability o f 
testosterone, thus influencing its effects on target tissues and the rate o f metabolism 
and clearance (Hobbs et al., 1992).
The 5a-reductase enzyme (5a-R) converts a small proportion of the circulating 
testosterone to the more potent androgen, DHT (Moore & Wilson, 1972; Zhou et al.,
1995). This occurs primarily in peripheral tissues, but enzyme activity is also present 
in the Leydig cells of the testis (Normington & Russell, 1992; 0 ’Shaugnessy & 
Murphy, 1991). In rats, two genes encoding 5a-R  have been identified: 5a-R l (major 
form found in the liver) and 5a-R2 (major form expressed in reproductive tissues, 
such as the prostate) (Normington & Russell, 1992). Hepatic 5a-R  activity exhibits 
sex-specific developmental regulation with activity increasing at puberty in females
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only, such that liver microsomes from adult male rats possess low 5a-R  activity 
(Sonderfan & Parkinson, 1988). Testicular 5a-R  activity shows a similar pattern of 
expression with high activity in immature animals, which progressively declines to 
reach the low levels observed in during adulthood (Lacroix et al., 1975).
A number o f pathways contribute to the hepatic biotransformation of circulating 
testosterone to form inactive or less active metabolites, which are excreted in the urine 
or bile. First, testosterone is hydroxylated at a number o f different positions in 
reactions catalysed by CYP enzymes (reviewed by Waxman, 1988). Second, 
testosterone is conjugated with glucuronic acid or sulfate, either directly or following 
hydroxylation, in reactions catalysed by UDP-GT and ST enzymes respectively 
(Matsui et al., 1974). These reactions generally result in the formation o f more polar 
products, facilitating excretion in the urine or bile. Finally, testosterone may be 
dehydrogenated to form androstenedione through pathways catalysed by CYPs and 
17p-HSD (reviewed by Waxman, 1988; Andersson & Moghrabi, 1997). Testosterone 
is metabolised by intact rat parenchymal cells to form the following major 
metabolites: androstenedione (46% total metabolites), 16a-0H T (21.5%), 2a-0H T 
(18.5%) and 6p-0HT (9.5%) (Utesch et al, 1992). Waxman (1992) suggested that the 
physiological importance o f steroid hydroxylation reactions might not only involve 
hormone deactivation. Testosterone metabolites may also possess unique biological 
or endocrine activities, although the physiological functions of the individual 
hydroxylated metabolites are largely unknown. There is however evidence to support 
a role for 7a-hydroxylated androgens in the regulation o f testicular testosterone 
biosynthesis (Inano et al., 1973; Rosness et al., 1977; Mittler, 1985) (see 1.5).
Various CYPs hydroxylate testosterone with a high degree o f regio- and 
stereospecificity (Figure 1.7 & Table 1.5). Certain steroid hydroxylation reactions are 
predominantly catalysed by a single CYP enzyme (e.g. CYP2C11 at the 2a-position) 
whilst others involve multiple forms (e.g. 16a-hydroxylation catalysed by CYP2B1, 
2B2 and 2C11) (Waxman, 1988). The hydroxysteroid metabolite profile can be used 
as a diagnostic marker to monitor the relative concentrations o f individual CYP 
enzymes in hepatic microsomes (Waxman, 1988). For example, testosterone 7a-,
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Table 1.5: Properties of the major rat hepatic cytochromes P450 that catalyse 
testosterone metabolism.
CYP Site(s) of 
Testosterone 
Metabolism
Constitutive/
Inducible
Inducers Gender
Selectivity
% Hepatic 
P450 t
lA l 6p I 3-MC,
PNF
None 1
1A2 6p C 3-MC,
pNF
Female
dominant
<5
2A1 7a*, 6a C PB, 3-MC Female
dominant
12
2A2 15a*, 6p, 7a, 16a c - Male
specific
3.5
2B1 16a, 16P, 17 I PB Male
dominant
<1
2B2 16p, 16a c PB Male
dominant
<1
2C6 2a, 16a, 17 c PB None 2 0 -3 0
2C7 16a c Ethanol Female
dominant
15
2C11 16a*, 2a*, 6p, 17 c - Male
specific
40
2C12 15P* c - Female
specific
27
2C13 6P, 15a, 16a c - Male
specific
23
3A1 6P*, 2P, 15P I PB, PCN Male
dominant
<20
3A2 6P,2P c PB, PCN Male
specific
Unknown
*, Almost all (> 85%) o f the indicated metabolite is' produced by this form; 3-MC, 3- 
methylcholanthrene; PNF, P-naphthoflavone; PB, phénobarbital; PCN, pregnenolone-16a-carbonitrile; 
t , based on immunological quantification of control rat liver. (Adapted from Lewis, 2001 & Lewis, 
1996).
36
16p- and 2a-hydroxylase activities reflect the levels of CYP2A1, 2B1/2 and 2C11 
respectively (Sonderfan et al, 1987).
1.4.3.2 Regulation of Steroid Hormone Hydroxylation
In rodents, numerous studies have demonstrated that the relative rate of steroid 
hormone hydroxylation at each position is influenced by the age, sex and 
monooxygenase induction status of the animal (Waxnian et al, 1988a; Waxman et al., 
1985). This relationship exists because the levels of expression o f individual CYPs 
can be altered dramatically during development, by hormonal status and following 
exposure to xenobiotics (Waxman et al, 1988a; Waxman et al., 1985).
Age- and Sex-Dependent Regulation
Age- and sex-dependent regulation of CYP expression, and the concomitant changes 
in steroid hormone metabolism, maintains the appropriate levels o f circulating 
hormones in male and female animals at various stages of development (reviewed by 
Kedderis & Mugford, 1998). In general, male rats display higher rates of metabolism 
of xenobiotic and steroid substrates compared to females (reviewed by Kedderis & 
Mugford, 1998).
Several CYPs that catalyse testosterone metabolism show sex-specific developmental 
regulation in rats (Table 1.5). CYP2A2 and 2C11 are male specific forms due to 
induction of gene expression in male rats only at puberty (Imaoka et al., 1991; 
Waxman et al., 1988a; Waxman et al., 1985). This underlies the male specific post- 
pubertal rise in testosterone 2a- and 16a-hydroxylase activity (Waxman et al., 1985). 
Similarly, the female specific form, CYP2C12, is induced at puberty in females only 
(Imaoka et al., 1991). CYP2A1 expression is activated in male and female rats at 
birth, but is subsequently suppressed to low levels in males at the onset of puberty 
(Imaoka et al., 1991; Waxman et al., 1985). CYP3A2 is expressed in both sexes at 
low levels after birth but expression is suppressed in females at puberty, in parallel to 
the loss of steroid 6|3-hydroxylase activity (Imaoka et al., 1988; Waxman et al., 1985).
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Sex-dependent expression of CYPs is complex and is regulated, at least in part, by 
androgens. In rats, exposure to critical levels of androgen during the neonatal period 
“imprints” the expression of specific CYP fonris in the adult animal (e.g. CYP2C11 
and 3A2) (Gustafsson et al., 1983; Waxman et al., 1985). During adulthood, the 
presence of circulating androgens may be required to maintain full expression of 
certain CYP forms (e.g. CYP2C11) (Waxman et al., 1985). The ability of androgens 
to regulate CYP expression does not involve a direct effect on the liver, but is related 
to the ability of androgens to modulate growth hormone (GH) secretion from the 
pituitary gland (reviewed by Kedderis & Mugford, 1998). In many species, including 
rats and humans, GH secretory patterns are sexually differentiated during adulthood 
(Winer et al., 1990; reviewed by Jansson et al., 1985b). Secretion o f GH is pulsatile in 
male rats (peaks every 3 to 4 hours with low levels of GH between) whereas females 
show a more continuous secretion (irregular peaks with high inter peak GH levels) 
(reviewed by Jansson et al., 1985b). These sex-dependent GH secretory patterns 
appear to regulate CYP expression. For example, pulsatile secretion of GH stimulates 
the expression of the male specific form, CYP2C11 (Waxman et al., 1991a).
Effects o f  Xenobiotic Exposure
The levels of individual CYPs show marked changes following exposure to 
compounds that induce or suppress their expression, with concomitant effects on 
hepatic steroid metabolism. Monooxygenase enzyme inducers may influence steroid 
metabolism in several ways including: induction of a new hydroxylation pathway 
(e.g.~25 fold induction of CYP2B1-mediated 16|3-hydroxylation by PB), enhancement 
of an existing pathway (e.g. 3-4 fold increase in CYP3A2-mediated 6 p-hydroxylation 
by pregnenolone-16a-carbonitrile (PCN)) or induction of pathways that are usually 
subject to endocrine control (e.g. ~15 fold induction o f CYP3A- mediated 6 p~ 
hydroxylation in female rats upon exposure to PCN) (Waxman el al., 1988a; Waxman 
et al., 1985). Inducers such as PB and dexamethasone increase the total rate o f 
hydroxylated metabolite formation by liver microsomes (Purdon & Lehman- 
McKeeman, 1997; Parkinson et al., 1992; Sonderfan et al., 1987). Administration of 
N-phenylbarbital to humans has no effect on the plasma clearance rate of testosterone 
but induced a change in the pattern o f metabolites excreted in the urine (Southren et 
al., 1969).
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Suppression (up to 70 to 80%) of constitutive hepatic CYPs has been reported 
following treatment o f rats with several classical monooxygenase enzyme inducers 
(Waxman, 1984). Selective repression of hepatic CYP2C11 protein and catalytic 
activity (e.g. 16a- and 2 a-hydroxylase activity) has been demonstrated following 
treatment of male rats with compounds such as 3-methylcholanthrene (3-MC), PB, 
PCN, dexamethasone and p-naphthoflavone (p-NF) (Waxman, 1984; Yeowell et al, 
1987). 3-MC treatment also produces an initial suppression o f CYP3A2 catalytic 
activity (testosterone 6 p-hydroxylation) and protein levels, which is followed by an 
increase in expression above control levels (Jones & Riddick, 1996).
The quantitative and qualitative effects o f  many compounds on the hepatic CYP 
complement have been well characterised. In contrast, the physiological 
consequences of the concomitant changes in steroid hormone metabolism are poorly 
understood. These secondary changes may have an important impact on steroid 
hormone homeostasis within the animal, with potential implications for steroid 
hormone regulated processes, such as spermatogenesis.
1.4.3.3 Testosterone Metabolism by Rat Liver Microsomes
The following section will briefly describe the major CYP forms known to catalyse 
hepatic testosterone hydroxylation reactions in rats (Table 1.5 and Figure 1.7).
CYPIA
C Y PlA l and 1A2 are expressed at low levels in the livers o f male and female rats, but 
are extensively induced following exposure to compounds such as 3-MC, P-NF, 
benzo(a)pyrene, 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD) and other polycyclic 
aromatic hydrocarbons (Thomas et al., 1983).
Purified CYPlA l and 1A2 both show testosterone 6 p-hydroxylase activity in 
reconstituted systems but appear to make a relatively modest contribution to the 
overall rate of 6 p-hydroxylation catalysed by rat liver microsomes (Sonderfan et al., 
1987; Wood et al., 1983). Treatment of immature Long Evans rats with 3-MC 
produces a dramatic increase in hepatic C Y PlA l content (>70% total CYP content), 
however this is associated with a 60% reduction in the rate o f 6 P-hydroxylation
39
(Wood et a l, 1983). Studies employing anti-CYPlA antibodies indicate that CYPIA 
catalyses less than 1 0 % of the microsomal testosterone 6 p-hydroxylase activity of 
intact liver microsomes from untreated and inducer-treated rats (PB, 3-MC and 
Aroclor 1254) (Wood et al, 1983). Purified CY PlA l also supports testosterone 2p- 
hydroxylation, albeit at a very modest rate (Sonderfan et al., 1987).
CYP2A
CYP2A1 and 2A2 share approximately 8 8 % amino acid sequence homology but 
possess markedly different regioselectivities for testosterone hydroxylation and their 
expression is differentially regulated (Matsunaga et al., 1988). CYP2A1 is weakly 
induced by compounds such as PB, p-NF and 3-MC whereas CYP2A2 appears to be 
relatively refractory to induction (Waxman et al., 1985; Nagata et al., 1987; Thomas et 
al., 1981; Matsunaga et al., 1988). In fact, CYP2A2 expression is suppressed (50 to 
80%) following exposure to PB, p-NF, 3-MC and isosafrole (Waxman et al., 1988a; 
Thummel et al., 1988).
CYP2A1 shows narrow regioselectivity and metabolises testosterone to one major 
product, 7a-hydroxytestosterone (7a-0H T) (Waxman et al., 1990; Wood et al, 1983; 
Sonderfan et al, 1987). Incubation of liver microsomes from.untreated and inducer- 
treated rats (e.g. PB, 3-MC and dexamethasone) with anti-CYP2A antibodies 
completely abolishes microsomal testosterone 7a-hydroxylase activity (Levin et al., 
1987; Wood et al., 1983; Waxman et al., 1987). The formation o f 7a-0H T  can 
therefore be used as a diagnostic marker for the expression o f CYP2A1 in liver 
microsomes. Purified CYP2A1 also shows some degree o f testosterone 6 a- 
hydroxylase activity (~5% the rate o f 7a-hydroxylation), which is abolished following 
incubation of liver microsomes with anti-CYP2Al antibody (Sonderfan et al., 1987; 
Wood et al., 1983).
In contrast, CYP2A2 hydroxylates testosterone with little regio- or stereoselectivity to 
produce a number of metabolites (e.g. 6 P-, 7a-, 16a-, 15a- and 15p-0HT) (Jansson et 
al., 1985a; Thummel et al., 1988; Arlotto et al., 1989). The major metabolite formed 
by purified CYP2A2 is 15a-0HT, which accounts for between 40 and 50% of the
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total testosterone metabolism catalysed by this form in reconstituted systems 
(Waxman et ah, 1990; Jansson et a l, 1985a). Polyclonal anti-CYP2A antibodies 
(cross-react with CYP2A1 and 2A2) inhibit approximately 75% of the microsomal 
15a-hydroxylase activity whereas a monoclonal anti-CYP2Al (selective for CYP2A1) 
had little effect on this activity, indicating that CYP2A2 is the major testosterone 15a- 
hydroxylase present in liver microsomes (Waxman et al., 1988a). Formation o f 15a- 
OHT is therefore a useful marker for the levels of CYP2A2 in liver microsomes.
CYP2B
CYP2B1 and 2B2 enzymes share 97% amino acid sequence homology, but show 
differential expression and regulation (Yuan et al., 1983). CYP2B1 and 2B2 are 
expressed at low levels in untreated male rats but are extensively induced following 
exposure to the prototype inducer, PB (Waxman & Azaroff, 1992). PB treatment 
causes marked induction of CYP2B1 (up to 40 fold) and a smaller increase GYP2B2 
levels (Omiecinski, 1986; Waxman & Azaroff, 1992). Other CYP2B inducers include 
DDT, chlordane, dexamethasone and isosafrole (Lubet et al., 1992; Thomas et al., 
1981; Wortelboer et al., 1991; Waxman et al., 1985).
CYP2B1 and 2B2 appear to lack specific stereoselectivity for testosterone 
hydroxylation but oxidation sites are limited to the 16- and 17- positions (Wood et al, 
1983). CYP2B1 catalyses testosterone 16a- and 16p-hydroxylation in addition to 
oxidation at the 17-position to form androstenedione (Wood et al., 1983; Sonderfan et 
al, 1987). These oxidation products are produced in approximately equal amounts 
(Wood et al, 1983; Sonderfan et al., 1987). CYP2B2 metabolises testosterone to form 
the same major metabolites as CYP2B1 but at a much slower rate (-10%  of the 
turnover rate of CYP2B1) (Wood et al., 1983). Studies using anti-CYP2B antibodies 
revealed that CYP2B enzymes catalyse the majority (85 to 95%) o f the steroid 16p- 
hydroxylase activity present in liver microsomes from PB-treated rats (Wood et al.,
1983). Similar levels of inhibition were observed for microsomal testosterone 16a- 
hydroxylase activity and androstenedione formation (Wood et al., 1983). However, all 
o f these reactions were inhibited to a markedly reduced extent (<2 0 % total activity) 
when anti-CYP2B antibodies were incubated with control liver microsomes.
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suggesting that other CYP forms catalyse these reactions in untreated animals (Wood 
et a l, 1983; Thomas et ah, 1981; Waxman et ah, 1987).
CYP2C
CYP2C is a large subfamily of enzymes that support a range of testosterone 
hydroxylase activities (Schenkman et ah, 1989). In general, CYP2C forms are 
constitutively expressed and show sex-specific developmental regulation in the rat 
(Schenkman et ah, 1989; reviewed by Waxman, 1991).
CYP2C11 is abundantly expressed in the liver and catalyses testosterone 16a- and 2a- 
hydroxylation in addition to oxidation at the 17-position to form androstenedione 
(Sonderfan et ah, 1987). Studies employing anti-CYP2Cl 1 antibodies have 
demonstrated that this enzyme supports the majority (>90%) o f the microsomal 
testosterone 2a- and 16a-hydroxylase activity in untreated male rats (Morgan et ah, 
1985; Waxman, 1984; Waxman et ah, 1987). However, treatment o f adult rats with 
PB is associated with a reduction in CYP2C11-catalysed 16a-hydroxylation to 
approximately 30% of this pathway, with the remaining activity being catalysed by 
CYP2B1 (Waxman et al., 1987). The formation of 2a-0H T  is used as a diagnostic 
marker for the expression of CYP2C11 in liver microsomes (Sonderfan et ah, 1987). 
Purified CYP2C11 also hydroxylates testosterone at the 6 p-position, albeit at a very 
modest rate (Sonderfan et ah, 1987). Significant suppression o f hepatic CYP2C11 
expression (up to 70 to 80%) has been reported following treatment o f rats with 
several prototype CYP inducers (e.g. PB, P-NF, PCN, 3-MC) and is associated with a 
reduction of microsomal testosterone 2a-hydroxylase activity (Waxman, 1984; 
Yeowell et al, 1987).
Other members o f the CYP2C subfamily hydroxylate testosterone at several positions 
but with slower turnover rates than CYP2C11 (Table 1.5) (Schenkman et ah, 1989). 
Purified CYP2C6 metabolises testosterone to form the same major products as 
CYP2C11 (androstenedione, 16a- and 2a-0H T) and is induced following exposure to 
PB (~2 to 3 fold) (Schenkman et ah, 1989; Guengerich et ah, 1982; Omiecinski et ah, 
1990b).
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CYP2C7 is a female predominant form, which shows low testosterone 16a- 
hydroxylase activity (Schenkman et al., 1989). CYP2C12 is a female-specific 
testosterone 15P-hydroxylase, which appears refractory to induction by several 
prototype inducers (e.g. PB, PCN, isosafirole) and is suppressed following exposure to 
dexamethasone in rats (Waxman et al., 1985; Wright & Morgan, 1991).
CYP2C13 is a male-specific form, which appears re frac to r to induction by several 
classical inducers (Bandiera et al., 1986). Purified CYP2C13 primarily metabolises 
testosterone at the 6 P-position, but also produces small amounts o f 15a- and 
16a-0H T along with traces of 7a- and 2a-0H T  (McClellan-Green et al., 1987). 
Antibody inhibition studies indicate that CYP2C13 makes a relatively minor 
contribution to the overall rate of testosterone 6 p-hydroxylation catalysed by rat liver 
microsomes (McClellan-Green et al., 1987).
CYP3A
A major pathway o f steroid metabolism in both humans and rats involves 
hydroxylation at the 6 p-position, which is primarily catalysed by CYP3A enzymes 
(Waxman, 1988; Zimniak & Waxman, 1993; Maenpaa et al., 1993). In the rat, five 
CYP3A genes have been identified: CYP3A1, 3A2, 3A9, 3A18 and 3A23 (Nelson et 
al., 1996). CYP3A1 and 3A2 proteins share 89% amino acid sequence similarity and 
both support testosterone 6 p-hydroxylase activity (Gonzalez et al., 1986). Antibody 
inhibition studies have demonstrated that CYP3A2 catalyses over 85% of the total 
testosterone 6 p-hydroxylation in liver microsomes from untreated rats (Waxman et al., 
1985). In contrast, CYP3A1 catalyses over 85% of the microsomal 6 P-hydroxylation 
in dexamethasone-treated rats (Gonzalez et al., 1986). Other CYP forms support 
testosterone 6 p-hydroxylase activity in purified, reconstituted systems (e.g.CYPlAl, 
2 A2 , 2C13) but appear to make a relatively modest contribution to the total rate o f 6 p- 
hydroxylation catalysed by intact liver microsomes (Waxman et al., 1987; Wood et al., 
1983; McClellan-Green et al., 1987). In addition to testosterone 6 p-hydroxylation, 
purified CYP3A1 catalyses 2p- and 15p-hydroxylation and purified CYP3A2 
catalyses 2P-hydroxylation (Sonderfan et al., 1987; Schenkman, 1992). The
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combined production of 2p~, 6 p- and ISp-OHT reflects the combined levels of 
CYP3A1 and 3A2 in rat liver microsomes (Sonderfan et al., 1987).
CYP3A1 is expressed at low levels in liver microsomes from male rats, but is 
extensively induced following exposure to compounds such as dexamethasone, PCN, 
triacetyloleandomycin (TAO), rifampicin and isosafrole (Cooper et al., 1993; Debri et 
al., 1995; Waxman et al., 1985; Gonzalez et al., 1986). CYP3A2 is a constitutive 
enzyme that is induced by many of the compounds known to induce CYP3A1 (e.g. 
PB), albeit to a smaller extent (Cooper et al., 1993).
1.4.4 Testosterone Metabolism by Human Liver Microsomes
Testosterone metabolism catalysed by rat liver microsomes is characterised by 
hydroxylation at multiple sites and involves a number o f CYPs belonging to the 
CYPl, 2 and 3 families (Sonderfan et al., 1987; Schenkman, 1992). In contrast, 
human liver microsomes metabolise testosterone to form one major product, 6p-0HT 
(>7 5 % hydroxylated metabolites formed), and smaller amounts o f androstenedione, 
2p-, 15p, 2a- and 15a-0H T (Waxman et al., 1988b; Maenpaa et al, 1993; Draper et 
al., 1998). Hydroxylation at the 6 p-position is predominantly catalysed by CYP3A 
enzymes, which are abundantly expressed in human liver (-30% total CYP content) 
(Wang & Lu, 1997; Waxman et al., 1988b; Shimada et al., 1994). Hydroxylation of 
testosterone at the 2 P- and 15P- positions is correlated with 6 P-hydroxylase activity 
and specifically inhibited by anti-CYP3A antibodies, suggesting that these reactions 
are also primarily catalysed by CYP3A enzymes in human liver (Waxman et al., 
1988b).
CYP3A4 is the major CYP3A form expressed in human adult liver and is induced 
following exposure to compounds such as rifampicin, phenytoin and dexamethasone 
(Shimada et al., 1994; Pichard et al., 1990). CYP3A5 is structurally and functionally 
related to CYP3A4 and is expressed in 10 to 20% of human livers (Aoyama et al., 
1989). Certain human livers also express CYP3A7, which is otherwise considered to 
be a fetal form (Lacroix et al., 1997).
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Purified CYP3A4 and 3A5 hydroxylate testosterone at the 6 p~position in reconstituted 
systems, but CYP3A4 appears to be the major testosterone 6 p-hydroxylase in human 
liver microsomes (Waxman et al., 1991b; Maenpaa et al, 1993; Wang & Lu., 1997). 
Hydroxylation reactions at the 2p-, 2a- and ISP- positions are also predominantly 
catalysed by CYP3A4 (Maenpaa et al, 1993). In contrast, androstenedione formation 
was not significantly inhibited by midazolam (CYP3A4 substrate) or anti-3 A4 
antibodies, indicating that this reaction is predominantly catalysed by other CYP 
enzymes in human liver (Maenpaa et al, 1993).
CYP2C enzymes are abundantly expressed in human liver (-20%  total hepatic CYP 
content) and certain forms are induced following exposure to compounds such as 
rifampicin (Shimada et al., 1994; Kay et al., 1985). Yamazaki and Shimada (1997) 
used recombinant CYP proteins to demonstrate that CYP2C19 metabolises 
testosterone to the major product androstenedione and the minor metabolites 6 P-, 16p- 
and 2p-0HT. Recombinant CYP2C9 also metabolises testosterone to form the same 
products but with a lower turnover rate (Yamazaki & Shimada, 1997). Incubation of 
human liver microsomes with anti-CYP2C9 (inhibits both CYP2C9 and CYP2C19) 
produced a marked inhibition o f androstenedione formation (Yamazaki & Shimada, 
1997). These findings suggest that CYP2C19, and to a lesser extent CYP2C9, are 
primarily responsible for metabolism of testosterone to form androstenedione in 
human liver microsomes.
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1.5 Testicular Cytochrome P450 Enzymes
1.5.1 Introduction
CYPs are most abundantly expressed in the liver but are also found in a number of 
extrahepatic tissues, including the testis (Menard & Purvis, 1973). In addition to CYP 
enzymes involved in testosterone biosynthesis, CYPl, 2 and 4 family members have 
been detected in rat testis using a variety of techniques (e.g. enzyme assays, nucleic 
acid hybridisation, polymerase chain reaction (PCR), immunological detection) (e.g. 
Walker et al., 1995; Omiecinski, 1986; Seng et al, 1991). Expression of CYP 
enzymes along with epoxide hydrolases (EH) and various transferases (e.g. ST and 
UDP-GTs) indicates that the testis may mediate the local biotransformation of 
endogenous and exogenous compounds (Lee et al, 1980; Magnanti et al., 2000). The 
overall metabolic capacity will be dependent upon the qualitative and quantitative 
composition of the testicular enzyme complement. Expression of testicular CYP 
enzymes is regulated by anterior pituitary hormones (e.g. LH) and gonadal steroids 
(e.g. testosterone) (Waterman & Simpson, 1985; Otto et al., 1992; Lee et al, 1980). In 
general, testicular CYP enzymes appear to be less sensitive to exogenous chemical 
inducers than their hepatic counterparts (Goldstein & Linko, 1984; Omiecinski, 1986).
1.5.2 Testicular Metabolism of Exogenous Compounds
The mammalian testis appears to' be capable of metabolising a range of exogenous 
compounds (Thomas et al., 1987; Georgellis et al., 1987; Flowers et al., 1989). The 
Leydig cells, where a substantial proportion of the enzyme activity is localised, are in 
direct contact with substances entering the testis in the blood or lymph, whereas the 
germ cells are somewhat protected by the blood-testis barrier (Rommerts et al., 1982; 
Mukhtar et al., 1978). CYP enzymes play a crucial role in the detoxification of 
xenobiotics, but also “bioactivate” certain chemicals to form reactive metabolites. The 
contribution of the testis to the overall rate o f xenobiotic metabolism is probably 
relatively small, but local formation of reactive metabolites may be an important 
determinant of the testicular toxicity o f certain compounds.
7,12-dimethyl benz(a)anthracene (DMBA) is a potent carcinogen whose toxicity is 
correlated to the extent of biotransformation it undergoes within the target tissues
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(Otto et al, 1992; Miyata et al., 1999). This compound exerts toxic effects at a number 
o f sites including the testis, where it causes germ cell damage and sterility (Ford & 
Huggins, 1963). DMBA is metabolised by CYPs and microsomal epoxide hydrolases 
to form 3,4-dihydrodiol, which is a precursor for the ultimate carcinogenic and toxic 
metabolite, 3,4-dihydrodiol-1,2 epoxide (Georgellis & Rydstrom, 1989; Georgellis et 
al., 1987; Miyata et al., 1999). In the rat testis, DMBA bioactivation is predominantly 
localised to the Leydig cells and is stimulated by LH (Georgellis & Rydstrom, 1989; 
Lee et al., 1980). The CYP enzyme primarily responsible for the metabolic activation 
o f DMBA in the rodent testis is CYPIBI (Otto et al., 1992; Buters et al., 1999). 
CYP IB 1 mRNA is constitutively expressed in the adrenal ^ d  testis o f untreated rats, 
where it may function as a physiological steroid hydroxylase (Walker et al., 1995). 
The crucial requirement for CYP IB 1 in DMBA carcinogenesis has been confirmed by 
the generation of CYP IB 1-knock out mice (Buters et al., 1999). CYP IB 1 null mice 
failed to show significant metabolism of DMBA and were resistant to the toxic effects 
of this compound (Buters et al., 1999).
The balanced expression of enzymes that catalyse the bioactivation and detoxification 
of DMBA may be an important factor influencing the ultimate toxicity o f this 
compound. Furthermore, certain xenobiotic metabolising enzymes show differential 
expression in the various testicular cell types. For example, CYPs are predominantly 
found in the Leydig cells whereas EH and glutathione transferase activities are mainly 
localised to the seminiferous tubules (Mukhtar et al., 1978). This may influence the 
susceptibility of specific cell populations to the adverse effects o f certain toxicants.
CYP2E1 is responsible for the hepatic bioactivation of numerous environmental 
toxicants and carcinogens, including halogenated hydrocarbons and nitroso 
compounds (Raucy et al., 1993; Kokkinakis et al., 1985). Low levels of CYP2E1 
protein have been detected in testis microsomes from untreated rats by Western 
blotting (Jiang et al., 1998). Futhermore, testicular CYP2E1 protein levels are induced 
following treatment of rats with pyridine (> 2 fold) or isoniazid ( -  3 fold) (Jiang et al., 
1998; Thomas et al., 1987). N-Nitrosodiethylamine (NDMA) is a procarcinogen, 
which requires metabolic activation catalysed by a CYP-dependent NDMA 
demethylase to exert its toxic and carcinogenic effects (Fahmy & Fahmy, 1976).
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Antibody inhibition studies have confinned that déméthylation o f NDMA is 
predominantly catalysed by CYP2E1 in liver and testis microsomes (Thomas et al., 
1987). NDMA demethylase activity is constitutively expressed at low levels in the 
testis, but is induced ( -3 .6  fold) following treatment of rats with isoniazid (Thomas et 
al., 1987). The physiological significance of testicular CYP2E1 is currently unknown 
but it may play a role in the local bioactivation of certain toxicants, which may be 
exacerbated following exposure to chemical inducers.
1.5.3 Testicular Metabolism of Endogenous Compounds
The testis may also play a role in the metabolism of endogenous substances, such as 
testosterone. The liver is the major site of androgen inactivation, but testicular 
microsomes have been shown to catalyse several pathways o f testosterone metabolism 
(Sonderfan et al, 1989; Lacroix et al., 1975). Local formation of androgen 
metabolites, which might have altered biological activities, may underlie important 
physiological roles within the testis. Several pathways o f testicular testosterone 
metabolism appear to show age-related changes in activity (Lacroix et al., 1975; 
Sonderfan et al., 1989). For example, immature testes possess high 5a-R  activity, 
which progressively declines to reach the low levels observed during adulthood 
(Lacroix et al., 1975).
The major pathway of testosterone metabolism catalysed by testicular microsomes 
from adult rats involves oxidation at the 17-position to form androstenedione 
(Sonderfan et al, 1989). Approximately equal amounts o f 6 a - and 7a-0H T  are also 
formed, along with traces o f 6 p- and 16a-0HT (Sonderfan et al, 1989). In contrast to 
7a-0H T, formation of androstenedione and 6a-0H T are not dependent upon NADPH 
or inhibited by carbon monoxide (Sonderfan et al., 1989). 17p-HSD catalyses the 
formation of androstenedione, but the identity of the testicular 6 a-hydroxylase is 
currently unknown (Sonderfan et al., 1989). Antibody inhibition studies revealed that 
testosterone 7a-hydroxylation is catalysed by CYP2A1 in testicular microsomes 
(Sonderfan et al, 1989).
CYP2A1 is expressed in the testis ( -  2 - 5% hepatic levels) where it is predominantly 
localised to the Leydig cells (Sonderfan et al, 1989; Seng et al, 1991). Steroid 7a-
48
hydroxylase activity shows age-dependent expression with low or undetectable 
activity reported in microsomes from immature rats, which increases to form the 
higher levels observed in the adult testis (Sonderfan et a l, 1989; Inano et ah, 1973; 
Seng et ah, 1996; Rosness et ah, 1977). This occurs in parallel to the age-dependent 
increase in testicular CYP2A1 expression (Sonderfan et ah, 1989). Interestingly, 
testicular 7a-hydroxylase activity continues to increase with age until the rate o f  
formation of 7a-0H T approaches the rate of testosterone biosynthesis (Eechaute et al, 
1974).
Testicular microsomes also show 7a-hydroxylase activity towards androstenedione 
and DHT (Sunde et ah, 1982; Inano et ah, 1970). 7a-hydroxylated androgens lack 
androgenic activity but inhibit the activity of several enzymes involved in testosterone 
biosynthesis, including 3p-HSD, 3a-HSD, C Y P llA l and 5a-R  (Inano et ah, 1973; 
Inano & Tamaoki, 1971; Sunde et ah, 1982; Rosness et ah, 1977; Mittler, 1985). 7a- 
hydroxylated metabolites may therefore play a role in the regulation of testosterone 
biosynthesis and factors capable o f modulating CYP2A1 expression could perturb 
androgen homeostasis. Hepatic CYP2A1 expression is weakly induced by compounds 
such as PB and p-NF, but it is currently unclear whether the testicular form is sensitive 
to induction by xenobiotics (Waxman et ah, 1985; Thomas et ah, 1981).
Testicular CYP2A1 expression may be one factor involved in the aetiology of 
spontaneous Leydig cell lesions in rodents. Seng et ah (1996) reported a correlation 
between high testicular CYP2A1 expression and severe Leydig cell hyperplasia in 
Fischer 344 rats. In contrast, Sprague Dawley rats, which exhibit a lower incidence o f 
Leydig cell hyperplasia, possess lower CYP2A1 protein and testicular 7a-hydroxylase 
activity (Seng et al, 1996). Sustained caloric restriction produces a marked reduction 
in the incidence of LCTs in Fischer 344 rats and is associated with reduced expression 
o f CYP2A1 and testicular 7a-hydroxylase activity (Seng et ah, 1996; Thurman et ah, 
1994). These findings suggest that Leydig cell hyperplasia may, at least in part, be a 
consequence of prolonged excessive expression of CYP2A1 or alternatively that 
factors which produce such lesions also induce CYP2A1 (Seng et al, 1996).
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1.5.4 Other Rat Testicular Cytochrome P450 
CYPIA
CYPIA enzymes are responsible for hepatic bioactivation o f numerous carcinogenic 
and mutagenic substances, including polycyclic aromatic hydrocarbons and aromatic 
amines (Guengerich, 1988). Extrahepatic expression o f CYPIA enzymes may 
therefore be an important determinant of the organ specific toxicity of certain 
xenobiotics. Dibasio et al. (1991) reported low levels o f CYP 1 A-associated 
ethoxyresorufin 0-dealkylase (EROD) activity in rat testicular microsomes. Goldstein 
and Linko (1984) reported low levels of C Y PlA l and 1A2 proteins in testis 
microsomes from untreated Sprague Dawley rats using a radioimmunassay (RIA) 
method. 2,3,7,8,-tetrachloro-dibenzo-p-dioxin (TCDD) treatment is associated with 
elevated testicular aryl hydrocarbon hydroxylase activity (2 . 1  fold) and induction of 
C Y PlA l but not CYP1A2 protein levels (quantified by RIA) (Goldstein & Linko,
1984). These results could not be confirmed by Western blotting, as C Y PlA l and 
1 A2 levels were below the limits of detection (Goldstein & Linko, 1984).
Subsequent studies have yielded conflicting information concerning the testicular 
expression of CYPIA, which may be related to strain-related differences in levels of 
expression and the sensitivity o f the techniques used. Omiecinski et al (1990a) 
reproducibly failed to detect CLPiv47mRNA in testis firom Sprague Dawley rats using 
a PCR-based assay. Foster et al. (1986) detected no C Y PlA l immunoreactive protein 
in testis firom untreated and inducer-treated (P-NF, PB or clofibrate) Alp/Apk rats 
(Wistar-derived strain) by immunohistochemistry (IHC). In contrast, Kobayashi et al. 
(1991) localised CYPIA protein to the Leydig cells in Wistar rats using IHC. More 
recently, Roman et al. (1998) reported that testicular C Y PlA l expression is localised 
to spermatid tails in untreated Holtzman rats and TCDD treatment was shown to have 
no effect on the expression of this protein (by IHC). Consistent with previous studies, 
no testicular CY PlA l protein was detected by Western blotting (Roman et al., 1998). 
Interestingly, Western blotting confirmed that the aryl hydrocarbon receptor (AhR) 
and aryl hydrocarbon receptor nuclear translocator (ARNT) proteins are expressed in 
the testis (Roman et al., 1998). Using IHC, ARNT expression was localised to certain 
germ cell stages (e.g. mature spermatocytes and some elongating spermatids), Leydig 
cells and endothelial cells (Roman et al., 1998). The physiological significance of the
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testicular expression of these proteins is currently unknown.
CYP2B
ÇYP2B1 mRNA is expressed constitutively at low levels (~ 6 % levels in PB-induced 
liver) in the testis of untreated Sprague Dawley rats (Omiecinski, 1986; Omiecinski et 
al., 1990b). Treatment o f rats with 3-MC or PB had negligible effects on testicular 
CYP2B1 mRNA levels (Omiecinski, 1986). In contrast, CYP2B2 mRNA was not 
detected in testis from control, 3-MC or PB-treated rats (Omiecinski, 1986). CYP2B- 
specifrc pentoxyresorufin 0-dealkylase (PROD) activity and immunoreactive protein 
(Western blotting) were not detected in testicular microsomes from Fischer 344 and 
Sprague Dawley rats respectively (Dibiasio et al, 1991; Bengtsson et al., 1990). 
Kobayashi et al. (1991) used IHC to show that CYP2B protein is exclusively localised 
to the Leydig cells in Wistar rats. This group also reported a significant temporal 
variation in the number o f Leydig cells showing CYP2B-immunoreactivity, which 
might have important physiological and toxicological implications.
CYP2C
CYP2C11 immunoreactive protein has been detected in testis microsomes from Long 
Evans and Harlan Sprague Dawley rats (Ryan et al., 1993; Seng et al., 1996). In 
contrast, CYP2C11-dependent testosterone 2a-hydroxylase activity and CYP2C 
immunoreactive protein were not detected in testicular microsomes from Fischer 344 
or Sprague Dawley rats (National Centre for Toxicological Research (NTCR) colony), 
suggesting that this form shows strain-specific regulation (Seng et al, 1996).
CYP3A
CYP3A immunoreactive protein was not detected in testicular microsomes from 
Sprague Dawley rats by Western blotting (Bengtsson et al., 1990).
CYP4A
CYP4A1 RNA (RNase protection assay) and immunoreactive protein (Western 
blotting) were not detected in testis from untreated and methylclofenapate-treated 
Alderley Park rats (Bell et al., 1992). Low levels of acyl-coA oxidase RNA (~ 6 % of 
hepatic levels) were detected in testis from untreated animals and were significantly 
induced (1.7 fold) following treatment with methylclofenapate (Bell et al., 1992).
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1.6 Aims and Experimental Approach
1.6.1 Aims
The aim of the current project was to investigate the existence o f a liver-testis axis 
wherein microsomal enzyme inducers enhance the metabolic clearance of testosterone 
causing a compensatory increase in LH secretion. Elevated circulating LH levels may 
be responsible for the induction of LCTs in rats. The ultimate aim o f this work was to 
provide mechanistic biochemical and molecular data to help explain the aetiology of 
Leydig cell hyperplasia and tumour formation to aid human risk assessment.
1.6.2 Experimental Approach
Lansoprazole
Lansoprazole was selected as the model compound for studies designed to investigate 
the existence of a liver-testis axis as it induces hepatic CYPs and chronic exposure 
produces LCTs in rats (Masubuchi et al., 1997a; Atkinson et al., 1990). The following 
section will summarise the relevant background information regarding this compound.
Lansoprazole is a gastric proton pump inhibitor that is frequently prescribed for the 
treatment of conditions such as peptic ulcers, reflux oesophagitis and pathological 
hypersecretory states such as Zollinger-Ellison syndrome (ZES). The chemical 
structure o f lansoprazole contains an asymmetric sulphur atom and this compound is 
administered clinically as a racemic mixture of the (+) and (-) enantiomers (Figure 
1.8). This compound is extensively metabolised in the liver by CYP-dependent 
pathways to form the major plasma metabolites, 5-hydroxylansoprazole (primarily 
catalysed by CYP2C19) and lansoprazole sulphone (primarily catalysed by 
CYP3A4/5) (Pearce et al., 1996). The half-life of lansoprazole in the rat has been 
estimated to be 1 . 8 8  and 2.62 hours for the (+) and (-) enantiomers respectively 
following oral administration (Arimori et al., 1998).
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Figure 1.8: The chemical structure o f lansoprazole
C H g - S ^
2-[[[3-m ethyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]-m ethyl]-sulfinyl]benzim idazole 
* indicates the asymmetric sulphur atom.
Treatment of female Sprague Dawley rats with lansoprazole (300mg/kg/day for 
7 days) is associated with a significant increase in total hepatic CYP content and 
induction o f C Y PlA l, 1A2, 2B1, 2B2, 3A2, 2C6 and 4A1 proteins (Masubuchi et al., 
1997a). In cultured human hepatocytes lansoprazole is a “mixed inducer” o f CYPIA 
and CYP3A, increasing both mRNA and protein levels (Curi-Pedrosa et al., 1994; 
Masubuchi et al., 1998). Lansoprazole induces CYPIA in humans but it is currently 
unclear whether this compound induces CYP3A in vivo (Kokufu et al., 1995; Fuchs et 
al., 1994). The mechanism through which lansoprazole induces CYPIA is unclear as 
high affinity binding of this compound to the Ah receptor has not been demonstrated 
(Curi-Pedrosa et al., 1994).
Lansoprazole has been subject to an extensive series o f toxicity studies, many o f 
which indicate adverse effects on the male reproductive system. In a one-year rat 
study, lansoprazole treatment increased the incidence o f Leydig cell hyperplasia and 
one benign Leydig cell tumour was observed (50 mg/kg/day) (Atkinson et al., 1990). 
In a two-year rat study, an increased incidence o f seminiferous tubule atrophy was 
recorded at 50 mg/kg/day along with an increased incidence of Leydig cell hyperplasia 
and tumours at dosages of 15 mg/kg/day or higher (Unpublished report by Takeda 
Chemical Industries Ltd., A-29-681). In contrast, lansoprazole treatment was not 
associated with Leydig cell hyperplasia or tumours in mice or dogs (Unpublished 
reports by Takeda Chemical Industries Ltd., A-29-680; A-29-439). In subchronic 
mouse studies (3 months) an increased incidence o f seminiferous tubule atrophy and 
epididymal hypospermia were reported at high dosages (1200 and 2400 mg/kg/day) 
(Unpublished report by Takeda Chemical Industries Ltd., A -126-049).
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Lansoprazole was found to be negative in an extensive array of in vitro and in vivo 
genotoxicity studies (e.g. bacterial mutagenicity, Ames test, rat bone marrow 
chromosome aberration test) (reviewed by Fort et al., 1995). Fort et al. (1995) 
performed mechanistic studies to investigate the mode of LCT induction following 
lansoprazole treatment in Sprague Dawley rats. In a four-week study, lansoprazole 
treatment (150 mg/kg/day) was associated with the following effects:
• Significant reduction in serum testosterone levels (maximal decrease o f 50%)
• Significant increase in serum LH levels (6 8 % above control levels)
• Significant decrease in intratesticular testosterone levels (6 6 % of control levels)
• Significant increase in intrapituitary LH levels (61% above control levels)
Providing testosterone supplementation to lansoprazole-treated Fischer 344 rats 
lowered serum LH levels and completely suppressed the induction of LCTs (Fort et 
al., 1995). These findings indicate that reduced negative feedback o f testosterone at 
the hypothalamus and pituitary gland leading to an increase in LH secretion may be 
involved in the induction of LCTs by lansoprazole. Lansoprazole inhibits several 
steps in the testosterone biosynthetic pathway in cultured rat Leydig cells, the most 
sensitive site being transport of cholesterol to the CYPscc enzyme (Fort et al., 1995). 
In addition, increased metabolic clearance of testosterone secondary to induction of 
hepatic CYPs might contribute to the lansoprazole-induced reduction in serum 
testosterone levels. Interestingly, lansoprazole induces hepatic UDP-GT activity, 
increases biliary excretion of thyroid hormone and reduces plasma T4  levels in female 
rats (Masubuchi et al., 1997b). However, in a one-year carcinogenicity study no 
adverse effects on thyroid gland histology were reported in lansoprazole-treated rats 
(> 50mg/kg/day) (Atkinson et al., 1990).
The ability o f lansoprazole to induce LCTs in rats is currently considered to represent 
a species-specific effect. Studies indicate that this compound has no clinically 
significant effects on male hormone levels or gonadal function in humans (Meikle et 
al., 1994; Gaetani et al., 1995).
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General Experimental Approach
To investigate the existence of a liver-testis axis, the effects of lansoprazole treatment 
on the following major areas have been studied:
• endocrine control of the testis
• expression of hepatic and testicular CYPs
• hepatic and testicular testosterone metabolism
In addition, the effects of dosing rats with model inducers of the major CYP families 
(P-NF (CYPIA), PB (CYP2B), PCN (CYP3A) and ciprofibrate (CYP4A)) were 
characterised. There is no evidence that these compounds produce LCTs in rats 
therefore it was interesting to compare and contrast their effects to those of 
lansoprazole.
Detailed information concerning the design o f these experiments can be found in the 
experimental strategy section (2.3).
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Chapter 2
Materials and Methods
2.1 Materials
2.1.1 Chemicals
The suppliers of all reagents used in this thesis are listed below. All chemicals and 
solvents were of the highest grade available and were purchased from Sigma or Fisher 
Chemicals unless otherwise stated.
Chemical
Acetonitrile (HPLC-grade)
Acrylamide (30%, w / v)
Agarose
Ammonium acetate 
Ammonium persulphate 
Androstenedione 
Bisacrylamide (2%, w / v)
P-Naphthoflavone
Bovine serum albumin (Fraction V)
Carbonate/ bicarbonate capsules 
Carboxymethylcellulose 
Chloroform (molecular biology grade)
Cholic acid
Ciprofibrate
dNTP mixture (lOmM)
Dried milk powder (fat free)
ECL™ western blotting kits (Rat C Y PlA l, 1A2, 2B, 
3 A and 4A1)
ECL Plus western blotting detection reagents 
Ethyl acetate (HPLC-grade)
Folin-Ciocalteu’s phenol reagent 
Gel loading solution 
Genomic DNA (rat)
Supplier
Fisher
Ultrapure
Flowgen
BDH
Sigma
Sigma
Ultrapure
Sigma
Sigma
Sigma
Sigma
Sigma
Sigma
Sanofr
Gibco
Tesco
Amersham
Amersham
Fisher
Sigma
Sigma
Clontech
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HPLC standards (6 a-, 6 P-, 15a-, 16a-, l lp - , 2a- and Sigma
2P-hydroxytestosterone)
HPLC standards (7a- and 16p-hydroxytestosterone) Ultrafrne
Isopropanol (molecular biology grade) Sigma
Lansoprazole Sigma
Methanol (HPLC-grade) Fisher
4-MA ( 17P-M A'-Diethylcarbamoyl-4-methyl-4-aza-5a- AstraZeneca
androstan-3-one)
NADPH (nicotinamide adenine dinucleotide phosphate. Melford
reduced form tetrasodium salt)
Nitrocellulose membrane (Hybond C) Amersham
Nuclease-free water Ambion
Phénobarbital Sigma
Phosphate buffered saline tablets (minus Ca^^ and Mg^^ Fisher
Ponceau S concentrate Sigma
Pregnenolone-16a-carbonitrile Sigma
Pyronin Y Sigma
qPCR^'^ Mastermix Eurogentec
Random primers Gibco
RNAqueous™-4PCR kit Ambion
Scintillation fluid (Optiphase ‘Safe’ scintillation cocktail) Perkin Elmer
Sodium dithionite Sigma
Supelcosil LC-18 HPLC Column (3pm particle size) Supelco
Supelguard LC-18 Guard column (5pm particle size) Supelco
Superase-In (20U/pl) Ambion
Superblock buffer in PBS Fisher
Superscript II RNase H- Reverse Transcriptase Kit Gibco
Testosterone Sigma
4-^"^C-Testosterone (50pCi/ml in toluene, 50-60mCi/mmol) Amersham
N,N,N’ ,N ’ -T etramethyethylenediamine (TEMED) Sigma
Tris-Borate-EDTA (TBE) Buffer (10 X) Sigma
Triton-X 100 Sigma
Trizol® Reagent Gibco
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Turbo-TMB Substrate Fisher
Tween 20 and 80 Sigma
Water (HPLC-grade) Sigma
2.1.2 HPLC Solvents
Mobile Phase A: 90: 10 (v / vl Methanol:Acetonitrile 
900ml HPLC-grade Methanol 
100ml HPLC-grade Acetonitrile
Mixed by shaking in a closed container and 0.5% (v / v) glacial acetic acid was added. 
Stored at room temperature for up to 1 month.
lOOmM Ammonium Acetate. pH 4.5 
7.708g Ammonium Acetate
Made up to IL with MilliQ water. Adjusted to pH 4.5 with glacial acetic acid.
Stored at room temperature for up to 3 months.
Mobile Phase B: 30:70 (v / v) Methanol:lOmM Ammonium Acetate. pH 4.5 
300ml HPLC-grade Methanol
700ml 1 OmM Ammonium Acetate (1:10 (v / v) 1 OOmM ammonium acetate in
HPLC-grade water)
Stored at room temperature for up to 1 month with continuous stirring.
2.1.3 Western Blotting Solutions
All solutions were stored at 2 to 5°C for up to 3 months unless otherwise stated.
Loading Buffer •
4.8ml MilliQ water
1.2ml 0.5M Tris-HCL (pH 6 .8 )
0.96ml Glycerol
1.92ml 10% ( w / v )  Sodium Dodecyl Sulphate (SDS)
0.48ml P-Mercaptoethanol 
0.6ml 0.05% (w / v) Pyronin Y
Stored protected from light at room temperature for up to 2 weeks.
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2 X Resolving Gel Buffer, pH 8 . 8  
181.6g Tris 
4g SDS
Made up to IL with MilliQ water. Adjusted to pH 8 . 8  with lOM sodium hydroxide.
2 X Stacking Gel Buffer, pH 6 . 8  
60.6g Tris 
4g SDS
Made up to IL with MilliQ water. Adjusted to pH 6 . 8  with lOM sodium hydroxide.
5 X Running Buffer. pH 8.3 
I5.15g Tris 
72g Glycine 
5g SDS
Made up to IL with MilliQ water.
5 X Running buffer was diluted 1:5 ( v / v )  in MilliQ water prior to use.
5 X Transfer Buffer. pH 8.3
11.9g Tris 
56.25g Glycine
Made up to IL with MilliQ water.
5 X Transfer buffer was diluted as follows prior to use: 160ml 5 x  Transfer buffer, 
640ml MilliQ water and 200ml methanol.
Tris-Buffered Saline with 0.1% ( y  /  y )  Tween (TBS-TweenL pH 7.6 
2.42g Tris
8 g Sodium Chloride
Made up to IL with MilliQ water, adjusted to pH 7.6 (with lOM hydrochloric acid) 
and 1ml Tween 20 added.
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2.1.4 ELISA Solutions
All solutions were stored at 2 to 5°C for up to 1 month unless otherwise stated. 
Carbonate/ bicarbonate Buffer
One carbonate/bicarbonate capsule dissolved in 100ml MilliQ water.
Solubilisation Buffer 
lOg Cholic acid
lOg Sodium Chloride
10ml Triton-X 100 .
Made up to IL with MilliQ water.
Wash Buffer
10 PBS tablets (minus Ca^ "^  and Mg^"^
5ml 10% ( v / v )  Tween 20
Made up to IL with MilliQ water
2.1.5 Agarose Gel Electrophoresis Solutions
10 X Tris-acetate-EDTA (TAEl buffer, pH 7.5 
484g Tris base
200ml 0.5M EDTA (pH 8) ^
114.2ml Glacial acetic acid 
500ml MilliQ water
Made up to lOL with MilliQ water. Adjusted to pH 8.3 with lOM sodium hydroxide. 
10 X TAE buffer was diluted 1:10 (v7 v) in MilliQ water prior to use.
Tris-Borate-EDTA (TBE) Buffer (0.5 X)
10 X TBE buffer (0.89M Tris borate, 0.02M EDTA (pH 8.3)) was purchased from 
Sigma and diluted 1:20 (v / v) in MilliQ water prior to use.
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2.2 Methods
2.2.1 Animal Studies
Five animal studies formed the basis of the experimental approach for this project. 
The aims and experimental design of each study are summarised in the Experimental 
Strategy section (see 2.3).
2.2.1.1 Animal Housing
Male Sprague Dawley rats were purchased from Charles River Laboratories (study 1, 
4 and 5) or Bantin & Kingman Universal (study 2 and 3) and were allowed to 
acclimatise for one week prior to initiation of treatment. Animals had free access to 
food (SDS R & M No.l (Special Diet Services Ltd., UK)) (study 1, 4 and 5) or Rat 
and Mouse Expanded Diet (B & K Universal) (study 2 and 3) and tap water 
throughout the study. For all studies animals were held under controlled temperature 
(21 ± 1°C), humidity (55 ± 15%) and light conditions (12 hour light-dark cycle, lights 
on between 6.00a.m. and 6.00p.m. GMT).
2.2.1.2 Study 1: Effect of Model Inducers on Cytochromes P450, Testosterone
Metabolism and Plasma Hormone Levels
Animal Treatment
Dosing o f animals and collection of samples were conducted by technical staff at 
AstraZeneca. Male Sprâgue Dawley rats (8 to 10 weeks old) were randomly assigned 
to one o f the five treatment groups shown in Table 2.1 (n=5 animals per group). 
Animals were dosed once daily for four consecutive days and each compound was 
administered in a volume of lOml/kg body weight. Control animals were not dosed, 
p-naphthoflavone (PNF) and ciprofibrate were administered by oral gavage (p.o.). 
Phénobarbital (PB) and pregnenolone-16a-carbonitrile (PCN) were administered by 
intraperitoneal injection (i.p.). Doses were selected from the published literature 
(Amacher & Schomaker, 1998; Kocarek & Reddy, 1996; Graham et al, 1996; Hanoika 
et al, 1995).
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Table 2.1: Dosing schedules for compounds administered to rats for the model 
inducers study.
Compound Vehicle Dose
(mg/kg body weight/day)
Control 0
p-naphthofiavone Com oil 100
Phénobarbital Saline, pH 7.0 80
Pregnenolone-16a- 
carbonitrile
Com oil 60
Ciprofibrate 1% carboxymethylcellulose 
(CMC)/0.1% Tween 80
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Collection o f Samples
On day five (9.30 a.m. to 12.00 p.m.), animals were killed by administration o f a lethal 
dose of sodium pentobarbital (60mg/kg body weight) (i.p.). The livers and testes were 
removed immediately and weighed. The tissues were then snap frozen using liquid 
nitrogen and stored at -70°C. Blood samples were taken by cardiac puncture and 
transferred in to lithium heparin tubes. Plasma was prepared by centrifiigation (lOOOg 
for 10 minutes at 4° C) and stored a t -20° C.
2.2.1.3 Study 2: Effect of Lansoprazole on Cytochromes P450, Testosterone 
Metabolism and Plasma Horm one Levels
Animal Treatment
Male Sprague Dawley rats (6 to 8 weeks old) were randomly assigned to the control 
(n=l 1) or experimental group (n=14). Each animal was dosed once daily with vehicle 
(0.5% (w / v) CMC) (5ml/kg body weight) or lansoprazole (150mg/kg body 
weight/day) (5ml/kg body weight) by oral gavage for fourteen days. This dose was 
selected as it has previously been shown to reduce serum testosterone and increase 
serum LH levels in male rats (Fort et al., 1995).
63
Collection o f  Samples
On day 15 (10.00 a.m. to 12.00 p.m.), animals were killed by administration of a lethal 
dose of sodium pentobarbital (60mg/kg body weight) (i.p.) and the livers and testes 
were removed immediately. The livers were weighed and then perfused with ice-cold 
0.9% (w / v) saline. The testes were weighed and then decapsulated. Livers and testes 
were transferred in to sterile tubes containing ice-cold 1.15% (w / v) KCl or SET 
buffer (25OmM sucrose, 5.4mM EDTA, 5OmM Tris, pH 7.4) respectively. Blood 
samples were taken by cardiac puncture and transferred in to lithium heparin tubes. 
Plasma was prepared by centrifugation (lOOOg for 10 minutes at 4°C) and stored at 
-20°C.
2.2.1.4 Study 3: Effect of Lansoprazole on Gene Expression in the Liver and 
Testis
Animal Treatment
Male Sprague Dawley rats (6 to 8 weeks old) were randomly assigned to the control or 
experimental group (n=10 animals per group). Each animal was dosed once daily with 
vehicle (0.5% (w / v) CMC) (5ml/kg body weight) or lansoprazole (150mg/kg body 
weight/day) (5ml/kg body weight) by oral gavage for fourteen days.
Collection o f  Samples
On day 15 (9.45 a.m. to 11.45 a.m.), animals were killed by administration of a lethal 
dose of sodium pentobarbital (60 mg/kg body weight) (i.p.). The livers and testes 
were removed immediately and weighed. For each liver, a part o f the left lobe was 
removed using a sterile scalpel and snap firozen using liquid nitrogen. The remaining 
liver was perfused with ice-cold 0.9% (w / v) saline and then placed in to a sterile tube 
containing ice-cold 1.15% (w / v) KCl.
For half of the animals (i.e. n=5 control and n=5 lansoprazole-treated), both testes 
were snap firozen using liquid nitrogen and stored at -80°C. For the remaining 
animals, both testes were transferred in to sterile tubes containing 5ml ice-cold buffer 
(25OmM sucrose, 5OmM Tris, pH 7.4).
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Blood samples were collected by cardiac puncture and transferred in to lithium 
heparin tubes. Plasma was prepared by centrifugation (lOOOg for 10 minutes at 4°C) 
and stored at -20°C.
2.2.1.5 Study 4: Effect of Lansoprazole on Gene Expression in the Pituitary
Gland
Animal Treatment
Dosing of animals and collection of samples were performed by technical staff at 
AstraZeneca. Male Sprague Dawley rats ( 6  to 8  weeks old) were randomly assigned 
to the control or experimental group (n=5 animals per group). Each animal was dosed 
once daily with vehicle (0.5% (w / v) CMC/ 0.1% (v / v) Tween 80) or lansoprazole 
(150mg/kg body weight/day) (5ml/kg body weight) by oral gavage for fourteen days.
Collection o f  Samples
On day 14 (2.00 p.m. to 3.30 p.m.), approximately four hours after the final dose of 
vehicle or lansoprazole, animals were killed by administration o f a lethal dose of 
sodium pentobarbital (60mg/kg body weight) (i.p.). Pituitary glands were removed 
and immediately placed in to tubes containing 500pl Trizol® Reagent. These samples 
were snap frozen using liquid nitrogen and stored at -80°C. Blood samples were 
collected by cardiac puncture and transferred in to lithium heparin tubes. Plasma was 
prepared by centrifugation (lOOOg for 10 minutes at 4°C) and stored at -20°C.
2.2.1.6 Study 5: Effect of Lansoprazole on the Plasma Clearance of
^"^C-Testosterone
Animal Treatment
Dosing of animals and collection o f samples were performed by technical staff at 
AstraZeneca. Male Sprague Dawley rats ( 6  to 8  weeks old) were randomly assigned 
to the control (n=5) or experimental group (n=4). Each animal was dosed once daily 
with vehicle (0.5% (w / v) CMC/ 0.1% (v / v) Tween 80) or lansoprazole (I50mg/kg 
body weight/day) (5ml/kg body weight) by oral gavage for fourteen days.
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Administration of^'^C-Testosterone
On day 15 (10.45 a.m.), approximately 24 hours after the final dose o f vehicle or 
lansoprazole, each animal was dosed via the right tail vein with 50pCi 4-^ "^ C- 
testosterone (0.254mg testosterone) (0.5ml) in 10:90 (v / v) ethanol: 0.9% (v / v) 
saline. This dose o f ^'^C-testosterone was selected based on the limits of detection of 
the methods used to analyse plasma samples.
Collection o f  Blood Samples
Serial blood samples (250pl) were collected at the following timepoints after the dose 
o f ^"^C-testosterone: 5, 15, 20, 30, 40, 50, 60, 90, 120, 180 and 260 minutes. These 
sampling times were selected based on the half-life of testosterone from the published 
literature (Pirke et al., 1982; Wang & Bulbrook, 1967; Henderson et al., 1980). Blood 
samples were collected from the left tail vein except for the final sample (260 
minutes), which was taken by cardiac puncture following the administration of a lethal 
dose of sodium pentobarbital (60mg/kg body weight) (i.p.). Blood samples were 
transferred in to lithium heparin tubes and plasma was prepared by centrifugation 
(lOOOg for 10 minutes at 4°C). Samples were snap firozen on dry ice and stored at - 
80°C.
2.2.2 Preparation of Microsomes
Model Inducers Study
Livers and testes (with capsules) were thawed and then homogenised in ice-cold 
0.154M KCl/ 5OmM Tris (pH 7.4) using a Polytron PT3100 homogeniser. Testes 
from each treatment group were pooled to give five samples. Cell debris, nuclei and 
mitochondria were removed by centrifugation, for 20 minutes at 9,000g in a RC28S 
centrifuge (4°C). The supernatant was transferred to a clean tube and centrifuged for 
1 hour at 100,000g in a RC28S centrifuge (4°C). The microsomal pellet was 
resuspended in 5OmM potassium phosphate buffer containing 20% (w / v) glycerol 
(pH 7.4) using a volume equivalent to 500pl per gram of original liver weight or 
lOOpl per gram of original testis weight. Samples were stored at -80°C.
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Lansoprazole Studies
Chilled livers and decapsulated testes were homogenised in ice-cold 1.15% (w / v) 
KCl or SET buffer respectively using a Potter-Elvehjem homogeniser. Testes from 
each treatment group were pooled to give two samples. Cell debris, nuclei and 
mitochondria were removed by centrifugation for 20 minutes at 10,000g in a MSE 
High Spin 18 centrifuge (4°C). The supernatant was transferred to a clean tube and 
centrifuged for 1 hour at 100,000g in a Beckman L5-65 centrifuge (4°C). The 
microsomal pellet was resuspended in 15ml ice-cold 5OmM potassium phosphate 
buffer (pH 7.4) containing 20% (w / v) glycerol or 6 ml ice-cold SET buffer containing 
20% (w / v) glycerol for liver and testis microsomes respectively. Samples were 
stored at -80°C.
Preparation o f  Washed Microsomes
An experiment was conducted to determine whether it would be advantageous to 
include a washing step during the preparation of liver and testis microsomes. For this 
experiment a batch of microsomes were prepared using the protocol described for 
lansoprazole studies with the following modifications. Following the second 
centrifugation step the microsomal pellet was resuspended in 1.15% (w / v) KCl or 
SET buffer, for liver and testes samples respectively, and then centrifuged for 1 hour 
at 100,000g in a Beckman L5-65 centrifuge (4°C). The microsomal pellet was 
resuspended in ice-cold 5OmM potassium phosphate buffer (pH 7.4) containing 20% 
(w / v) glycerol (500pl per gram of original liver weight) or ice-cold SET buffer 
containing 2 0 % (w / v) glycerol (150pl per gram of original testis weight) for liver and 
testis microsomes respectively. Samples were stored at -80°C.
2.2.3 Preparation of Testicular Supernatant
Testes from each animal were homogenised in 5ml ice-cold buffer (250mM sucrose, 
5OmM Tris, pH 7.4) using a Potter-Elvehjem homogeniser. Samples were centrifuged 
for 20 minutes at 10,000g in a MSE High Spin 18 centrifuge (4°C). The supernatant 
was transferred to a clean tube and centrifuged for 1 hour at 100,000g in a Beckman 
L5-65 centrifuge (4°C). The supernatant obtained after the second centrifugation step 
was transferred to a clean tube and stored at -20°C.
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2.2.4 Hormone Assays
Technical staff at AstraZeneca performed all assays to measure hormone levels in 
plasma and testicular supernatant.
Total testosterone was measured using a solid phase radioimmunoassay method (Coat- 
A-Count® Total Testosterone) supplied by Diagnostic Products Corporation (DPC). 
This kit employs a testosterone specific antibody immobilised to the wall of a 
polypropylene tube. ^^^I-labelled testosterone competes with testosterone present in 
the test sample for antibody binding sites. Antibody-bound radioactivity is separated. 
from free by decanting the tube and quantified using a gamma counter. A standard 
curve is used to determine the amount of testosterone present in test samples. The 
lower limit of detection o f this kit is 0.14 nmol/L.
Plasma prolactin, LH and FSH were measured using radioimmunoassay methods 
supplied by Amersham (Biotrak kits). These kits are based on the principle previously 
described for the testosterone assay except that the hormone specific antibody is free 
in solution. Separation of free and antibody-bound radioactivity is effected by 
magnetic separation using a secondary antibody that is bound to magnétisable polymer 
particles. The lower limits of detection o f the prolactin, LH and FSH kits are 0.7, 0.8 
and 0.9 ng/ml respectively.
2.2.5 Protein Determination
The protein concentration was determined for liver and testis microsomes using the 
method of Miller (1959). A standard curve was constructed using bovine serum 
albumin diluted in MilliQ water to give final protein concentrations spanning the 0 to 
200pg/ml range (0, 20, 40, 80, 100, 120, 160 and 200pg/ml). Standard samples were 
assayed in triplicate. Liver and testis microsomes were diluted in MilliQ water (1:100 
to 1:500 (v / v) dilution) and assayed in duplicate.
For the assay, 1ml of solution A (1ml 5% (w / v) copper (11) sulphate, 10ml 1% (w / v) 
potassium sodium (+) tartrate and 100ml 0.5M sodium hydroxide containing 10% 
(w / v) sodium carbonate (anhydrous)) was added to 1 ml o f the diluted protein sample. 
The tubes were incubated at room temperature for exactly 10 minutes. Then, 3ml
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solution B (Folin-Ciocalteu’s phenol reagent diluted 1:10 in MilliQ water) was added 
and the tubes were incubated at 50°C for 1 0  minutes. The tubes were cooled and the 
absorbance at 650nm was read on a Kontron Uvicon 932 spectrophotometer.
2.2.6 Microsomal P450 Content Determination
The total cytochrome P450 content of liver microsomes was determined using the 
method of Omura and Sato (1964). Liver microsomes were diluted 1:10 (v / v) in 
5OmM potassium phosphate buffer (pH 7.4) and placed on ice. An excess 
(approximately lOmg) of sodium dithionite was added and the tube was vortexed. The 
contents of each tube were divided between two clean spectrophotometer cuvettes and 
a baseline absorbance measured between 400 and 490nm on a Kontron Uvicon 932 
spectrophotometer. Carbon monoxide was then gently bubbled through one o f the 
cuvettes for approximately 30 seconds. The absorbance of the sample was re­
measured across the 400 to 490nm range. The concentration of cytochrome P450 was 
calculated from the difference in absorbance between 450 and 490nm, employing a 
molar extinction coefficient of 91mM'^cm'\
2.2.7 High Pressure Liquid Chromatography (HPLC)
The following HPLC method (B.Buckle, Personal Communication) was used to 
separate and quantify testosterone and individual metabolites present in incubation 
extracts from the testosterone hydroxylase assay (2 .2 .8 ) and plasma samples from 
study 5 (2.2.1.6).
2.2.7.1 HPLC Apparatus
All analyses were performed using a Hewlett Packard HP 1090 Series HPLC system 
controlled by ChemStation software (Hewlett Packard) linked to a Berthold LB506 
C-1 radioactivity monitor (YG-150 solid detector cell) and a SpectroMonitor 3000 
variable wavelength detector (LDC/Milton Roy). Analytes were detected at 240nm 
and by radiochemical detection. Chromatography was performed on a Supelcosil LC- 
18 reverse-phase silica column (150 x 4.6mm, 3pm particle size) preceded by a 
Supelguard LC-18 guard column (2cm, 5pm particle size). Berthold HPLC software 
(version 1.51) was used for data acquisition and analysis.
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12.1.2 Preparation of HPLC Standards
6 a-, 6 p-, 15a-, 7a-, 16a-, 16p-, l ip - , 2a- and 2p-hydroxytestosterone standards 
(>98% purity) were initially diluted to 2000 nmoles/ml in HPLC-grade methanol. 
Standards were then diluted in initial HPLC solvent conditions (see 2.2.7.3) to give 
stock solutions at concentrations of 1000 nmoles/ml (Inmole/pl injected). For 
testosterone and androstenedione, lOOpM solutions were prepared in initial HPLC 
solvent conditions (O.lnmole/pl injected).
2.2.7.3 Chrom atographic Conditions
Testosterone and individual metabolites were separated using the two step linear 
solvent gradient described in Table 2.2. Mobile phase A consisted of 
methanohacetonitrile (90:10 (v / v)) containing 0.5% (v / v) glacial acetic acid and 
mobile phase B consisted of methanol: 1 OmM ammonium acetate (pH 4.5) 
(30:70 (v / v)) (see 2.1.2). The mobile phases were degassed for 30 minutes using a 
gentle stream of helium and then the colunrn was equilibrated with initial solvent 
conditions for 30 minutes prior to injection o f the first sample. All chromatographic 
separations were performed at room temperature using a flow rate of 0 . 8  ml/minute. 
Testosterone and individual metabolites present in test samples were identified by co­
chromatography with authentic standards injected on to the column with each sample.
Table 2.2: The solvent gradient used to separate testosterone and metabolites
Time
(minutes)
Mobile Phase A 
(%)
Mobile Phase B 
(%,)
0 1 0 90
15 1 0 90
32.5 2 0 80
55 60 40
60 60 . 40
65 1 0 90
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2.2.8 Testosterone Hydroxylase Assay: Microsomal Incubations
The following assay (B.Buckle, Personal Communication) was used to measure the 
rates of testosterone hydroxylation and androstenedione formation catalysed by liver 
and testis microsomes.
2.2.8.1 Preparation of the Substrate
Microsomes were incubated with a mixture of 4-^"^C-testosterone and cold testosterone 
substrate, which was prepared as follows. The required volume of ^"^C-testosterone 
(50pCi/ml in toluene, 57mCi/mmol) was dispensed in to a glass vial, reduced to 
dryness under a gentle stream of nitrogen and reconstituted in methanol to give a final 
concentration o f 200pCi/ml. A 1.215mM solution of cold testosterone was prepared 
by weighing 8.76mg testosterone in to a 25ml volumetric flask. This was dissolved in 
7.5ml methanol and then slowly made up to volume with 5OmM potassium phosphate 
buffer (pH 7.4). This solution was sonicated for approximately 10 minutes to aid 
dissolution. Finally, the ^"^C-testosterone and cold testosterone solutions were mixed 
to give a solution containing 1.65%:98.35% (v / v)  ^"^C-testosterone : cold testosterone. 
200pl of this mixture, containing 239 nmoles cold testosterone and 11.6 nmoles 
^"^C-testosterone (0.66|iCi), was added to each incubation.
2.2.8.2 Incubation Conditions
Liver Microsomes
The incubation components listed in Table 2.3 were dispensed in to 10ml conical 
flasks placed on ice. Incubations were performed in triplicate for each animal. A 
blank incubation, in which NADPH was replaced by an equivalent volume o f 5OmM 
potassium phosphate buffer (pH 7.4), was also prepared for each animal. The 5a- 
reductase inhibitor, 4-MA (17p-MA-Diethylcarbamoyl-4-methyl-4-aza-5a-androstan-
3-one) (IpM), was added to all incubations unless otherwise stated. This 
concentration o f 4-MA was selected as it has been previously shown to completely 
inhibit steroid 5a-reductase enzyme without inhibiting other pathways of testosterone 
oxidation catalysed by rat liver microsomes (Sonderfan & Parkinson, 1988).
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Incubation mixtures were pre-incubated for 5 minutes at 37°C with gentle shaking 
Reactions were initiated by the addition of 200|il ^"^C-testosterone (see 2.2.8.1) to give 
a final substrate concentration and incubation volume of 250.6pM and 1ml 
respectively. Samples were incubated for 5 minutes at 37°C with gentle shaking. 
Reactions were terminated by the addition o f 200pl 3M HCl to each flask. The flask 
contents were mixed well and then placed on ice.
Table 2.3: Components of incubation mixtures for the testosterone hydroxylase assay.
Component Stock Solution Volume / 
incubation (pi)
Final
Concentration
Potassium phosphate 
buffer (pH 7.4)
5 OmM 399 5 OmM ;
EDTA lOmM 1 0 0 ImM
Microsomal Protein 2.5mg/ml 2 0 0 0.5mg/ml
NADPH lOmM 1 0 0 ImM
4-MA ImM 1 IpM
All stock solutions and dilutions o f microsomal protein were prepared in 50mM potassium phosphate 
buffer (pH 7.4) with the exception o f 4-MA which was dissolved in acetone.
Testis Microsomes
Incubations using testis microsomes were performed as previously described for liver 
microsomes except that the, microsomal protein concentration was increased to 
2 mg/ml.
2.2.S.3 Extraction of Testosterone and Metabolites
Testosterone and metabolites were extracted by the addition o f 3ml ice-cold ethyl 
acetate followed by vortexing for one minute. Samples were then centrifuged at 
2000g for 10 minutes at room temperature. The lower aqueous phase was frozen 
using an acetone/dry ice bath and the upper organic phase transferred to a clean test 
tube. This extraction procedure was repeated once, the two organic phases were 
combined and then reduced to dryness under a gentle stream of nitrogen.
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Extracts were reconstituted in lOOpl HPLC-grade methanol and then made up to a 
final volume of 200pl with HPLC-grade water. Testosterone and metabolites present 
in extracts were separated and quantified using the HPLC method described in 2.2.7. 
80pl of each extract was injected on to the column along with 2 0 pl o f a mixture o f 
authentic testosterone standards (see 22 .12).
2.2.5.4 Calculation of the Extraction Efficiency
Aliquots of the ^"^C-testosterone substrate (200pl) and reconstituted incubation extracts 
(20pl) were added to scintillation vials containing 3.5ml scintillation fluid and counted 
for one minute on a Wallac 1410 liquid scintillation counter. Triplicate or duplicate 
samples were counted for the substrate and extracts respectively. The extraction 
efficiency was calculated as follows:
dpm /  extract
% Extraction efficiency = ----------------------- — x  100
dpm /  incubation
.
2.2.5.5 Calculation of Enzyme Activity
The specific activity for the formation of each metabolite was calculated in picomoles 
per minute per milligram of microsomal protein (pmol/min/mg protein) as follows. 
The use o f radiolabelled substrate enabled quantification o f individual testosterone 
metabolites injected on to the HPLC column in incubation extracts. Berthold HPLC 
software calculates a percentage Region of Interest (%ROI) value for each peak, 
which corresponds to the percentage of total radioactive counts measured during a 
chromatographic run that were attributable a particular peak.
The %ROI value for a particular metabolite peak was converted to a specific activity 
using the following calculation: '
Specific _  /o  ROI ^  amount o f  substrate added (nmoles) = nmoles /  5 minute 
activity incubation /  0.5 mg
microsomal protein
The product of this calculation was converted to a specific activity in pmol/min/mg 
microsomal protein.
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If metabolism was detected in blank samples, the specific activity was calculated for 
each metabolite and subtracted from the specific activity calculated for incubations 
containing cofactor.
2.2.9 Optimisation of the Testosterone Hydroxylase Assay
The incubation protocol described in 2.2.8 represents a method that was optimised as 
part o f this project. The following sections describe the experiments conducted during 
the optimisation of this protocol for use with microsomal samples from the current 
project.
2.2.9.1 Incubation Time
An optimisation experiment was performed to define the linear range of metabolite 
formation with respect to the incubation time.
The incubation protocol described in 2.2.8 was used except for the following 
modifications. Initially, each flask contained five times the incubation mixture 
(i.e. 5ml final volume) and Img/ml of microsomal protein. 4-MA was not added to 
incubation mixtures and was replaced by an equivalent volume of 5OmM potassium 
phosphate buffer (pH 7.4). Aliquots (1ml) of the incubation mixture were removed 
from each flask at the following timepoints following addition of the testosterone 
substrate: 1, 5, 7.5, 10 and 20 minutes. Reactions were then terminated by the 
addition of 200pl 3M HCl and extractions performed as previously described. All 
incubations were performed in duplicate. ,
2.2.9.2 Microsomal Protein Concentration
An optimisation experiment was performed to define the linear range of metabolite 
formation with respect to the microsomal protein concentration.
The incubation protocol described in 2.2.8 was used except for the following 
modifications. Microsomes were incubated with testosterone at protein concentrations 
of 0.1, 0.5, 0.75, 1, 1.5, 2 and 4 mg/ml. 4-MA was not added to incubation mixtures 
and was replaced by an equivalent volume of 5OmM potassium phosphate buffer
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(pH 7.4). Reactions were terminated by addition o f 200pl 3M HCl and extractions 
performed as previously described. All incubations were performed in triplicate.
2.2.9.3 Stability of Incubation Extracts
A study was performed to determine whether incubation extracts and testosterone 
standards were sufficiently stable at room temperature to allow the use of a non- 
refiigerated autosampler.
Incubations and extractions were performed as described in 2.2.8. 4-MA was not 
added to incubation mixtures and was replaced by an equivalent volume of 5OmM 
potassium phosphate buffer (pH 7.4). Incubation extracts were reconstituted in lOOpl 
HPLC-grade methanol then made up to a final volume o f 200pl with HPLC-grade 
water. 80pl o f the extract was injected on to the HPLC column immediately. A 
further 80pl of the extract was injected on to the column following 24 hours at room 
temperature. This process was repeated for a number of incubation extracts and for a 
mixture of testosterone standards. A metabolite was considered to be stable if  the 
amount detected following the second injection (after 24 hours) was no more than 
15% lower (or higher) than the amount detected after the first injection (at 0  hours).
2.2.9.4 Inclusion of 4-MA in Incubation Mixtures
An experiment was performed to investigate the effects o f the 5a-reductase inhibitor,
4-MA, on testosterone metabolism catalysed by liver microsomes.
The incubation protocol described in 2.2.8 was used. For each microsome sample 
studied, triplicate incubations were performed in the presence o f 4-MA (IpM ) and 
single incubation was performed in which 4-MA was replaced by an equivalent 
volume of 5OmM potassium phosphate buffer (pH 7.4).
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2.2.10 Extraction and Quantification of '^‘C-Testosterone in Plasma Samples
The following section describes analysis of plasma concentrations of ^"^C-testosterone 
in samples from study 5 (see 2.2.1.6).
2.2.10.1 Extraction o f ^"*C-Testosterone from Plasma
Plasma samples (50pl) were added to test tubes containing 450pl HPLC-grade water. 
1.5ml ethyl acetate was added to each tube followed by vortexing for two minutes. 
Samples were then centrifuged at 2000g for 10 minutes at room temperature. The 
lower aqueous phase was frozen using an acetone/dry ice bath and the upper organic 
phase transferred to a clean test tube. This extraction procedure was repeated three 
times and the organic phases were combined. Wherever possible, plasma extractions 
were performed in duplicate.
2.2.10.2 HPLC Analysis of Plasma Sample Extracts
To investigate whether any ^"^C-testosterone metabolites were present, selected plasma 
extracts were subjected to HPLC analysis. Samples from one control animal (at every 
timepoint) and one lansoprazole-treated animal (at 5, 20 and 180 minutes) were 
analysed.
The combined organic phases following extraction were reduced to dryness under a 
gentle stream of nitrogen. Extracts were reconstituted in 90pl HPLC-grade methanol 
and then made up to a final volume of 180pl with HPLC-grade water. Samples were 
analysed using the HPLC method described in 2.2.7. 95pl o f each extract was injected 
on to the column along with 5jil o f an authentic testosterone standard (see 2.2.7.2).
To calculate the extraction efficiency, aliquots of the original plasma sample (5 pi) and 
reconstituted extract (20pl) were added to scintillation vials containing 3.5ml 
scintillation fluid and counted for one minute on a Wallac 1410 liquid scintillation 
counter. All samples were counted in duplicate. The extraction efficiency was 
calculated as follows:
% Extraction efficiency = ______ dpm /extract _____  x  100
dpm /  50fÀ plasma sample
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2.2.10.3 Quantification of ^ '‘C-Testosterone in Plasma Sample Extracts
Aliquots o f the combined organic phases (500pl) and post extraction aqueous phase 
(200pl) were added to scintillation vials containing 3.5ml scintillation fluid and 
counted for one minute on a Wallac 1410 liquid scintillation counter. The organic 
phase was counted in triplicate. Due to sample volume limitations, a single 
determination was performed for each post extraction aqueous phase.
The extraction recovery was calculated as follows. Aliquots of the original plasma 
sample (5pi) were added to scintillation vials containing 3.5ml scintillation fluid and 
counted for one minute on a Wallac 1410 liquid scintillation counter. The following 
calculation was used:
% Extraction recovery = dpm /  organic phase + dpm /  aqueous phase ^  jg g
dpm /  50jj1 plasma sample
2.2.10.4 Calculation of Kinetic Parameters
Plasma '^C-testosterone concentration-time curves were analysed by non- 
compartmental analysis (i.v. bolus model) using WinNonlin software (Version 3.2) 
(Pharsight Corporation, Mountain View, U.S.A .). The area under the plasma 
concentration-time curve (AUC) from the time of dosing to the last measured 
concentration (AUCiast) was calculated using the linear trapezoidal rule. The terminal 
elimination fate constant (Xz) is the slope of the terminal phase o f the plasma 
concentration-time profile on a semi-logarithmic scale, which was determined by 
linear regression of at least three data points in the terminal phase. AUCmf, the area 
under the plasma concentration-time curve from the time of dosing extrapolated to 
infinity, was calculated using the equation below:
AUCirf =  AUC,as, + — EIï L
where, C^st is the plasma concentration at the last measured timepoint.
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Comparison of the AUCiast and AUCinf values for each animal revealed that the 
AUCiast value provided a more accurate estimate of the AUC for this data set. This 
was due to the fact that the 1 % value is derived from linear regression using the last few 
data points, which were subject to greater variability due to the low levels of 
^"^C-testosterone present in these samples. The Xz value is used to calculate the 
extrapolated portion o f the AUCmf and therefore resulted in inaccurate estimations of 
this parameter. All kinetic parameters calculated for this data set were therefore based 
on non-extrapolated area values.
The plasma clearance (CL) o f ^"^C-testosterone was calculated using the equation 
below:
Dose
CL =
AUCiast
The volume of distribution at steady state (Vgg) was estimated using the equation 
below:
Vss =  M R Tiast*CL
where, MRTiast (mean residence time from the time o f dosing to the last measured 
concentration) was calculated using the equation below:
M R T , . .  .
v\LK4wt
where, AUMCiast was the area under the moment curve from the time o f dosing to the 
last measured concentration, which was calculated using the linear trapezoidal rule.
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2.2.11 Western Blotting
Western blotting was used to study the relative levels of CYPIA, 2B, 3A and 4A 
proteins in microsome samples from different experimental groups. Rat cytochrome 
P450 ECL™ Western blotting kits (Amersham) were used for all experiments. Each 
kit contained ECL molecular weight markers, positive control rat liver microsomes, 
anti-rat cytochrome P450 primary antibody, a species-specific Ig-biotinylated 
secondary antibody and streptavidin-horseradish peroxidase (HRP) conjugate. The 
anti-rat cytochrome P450 primary antibodies were polyclonal and showed cross 
reactivity with CYP forms belonging to the same subfamily (e.g. anti-CYP2B 
recognises CYP2B1 and 2B2 proteins) (except anti-CYPlA2 which did not cross react 
with C Y PlA l) but not members of other subfamilies (Amersham data sheets). Bound 
antibodies were visualised using ECL™ Plus Western blotting detection reagents. 
This detection system is based on streptavidin-HRP catalysed oxidation o f the 
Lumigen PS-3 acridan substrate to form acridinium ester intermediates. Reaction of 
these intermediates with peroxide produces a high intensity chemiluminescence. 
Which is captured on film. The following protocol is based on the method supplied by 
the manufacturer.
2.2.11.1 Preparation of Samples
Liver microsomes were diluted to a final protein concentration o f 1 to 2 mg/ml in 
5OmM potassium phosphate buffer (pH 7.4). Testis microsomes were not diluted. 
Samples were then mixed with an equal volume of loading buffer (see 2.1.3), heated to 
95-100°C for 5 minutes and then placed on ice.
2.2.11.2 SDS-Polyacrylamlde Gel Electrophoresis (SDS-PAGE)
Proteins were separated by SDS-P AGE using a Bio-Rad Mini-PROTEAN II dual gel 
system. A 12% resolving gel was prepared by mixing the following reagents together 
is this order: 3.55ml MilliQ water, 4.5ml 2 x resolving gel buffer (see 2.1.3), 7.5ml 
30% (w / v) acrylamide, 2.95ml 2% (w / v) bisacrylamide, 18pl N,N,N’,N’- 
tetramethyethylenediamine (TEMED) and 0.18ml 10% (w / v) ammonium 
persulphate. The gel was cast and 1ml MilliQ water was gently layered on top. The 
gel was allowed to set at room temperature for approximately 1 hour and then the 
layer of water was carefully removed using filter paper.
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A 4% stacking gel was prepared by mixing the following reagents together in this 
order: 6.9ml MilliQ water, 2.5ml 2 x stacking gel buffer (see 2.1.3), 1ml 30% (w / v) 
acrylamide, 0.4ml 2% (w / v) bisacrylamide, lOpl TEMED and 50pl 10% (w / v) 
ammonium persulphate. The stacking gel was layered on top o f the resolving gel and 
a comb was inserted to create ten wells. The stacking gel was allowed to set at room 
temperature for approximately 3 hours.
The gel was placed in to an electrophoresis tank containing 1 x running buffer (see 
2.1.3). Two lanes on each gel were reserved for the molecular weight markers and 
positive control, which were reconstituted and loaded as described in the appropriate 
kit. Microsomal protein samples (5-lOpl per lane) were loaded in to the remaining six 
lanes o f the gel. Electrophoresis was performed at room temperature at 40mA for 1.5 
to 2  hours until the loading dye was approximately 1 cm from the bottom of the gel.
2.2.11.3 Transfer of Proteins to Nitrocellulose Membrane
Following electrophoresis, proteins were transferred on to nitrocellulose membranes 
as follows. The nitrocellulose membrane, blotting paper and scotchbrite fibre pads 
were equilibrated with 1 x transfer buffer (see 2.1.3) for 10 minutes. The gel and 
nitrocellulose membrane were assembled in the transfer cassette in the following 
order: scotchbrite pad, 2  sheets of filter paper, gel, nitrocellulose membrane, 2  sheets 
o f filter paper, scotchbrite pad. The transfer cassette was placed in , to an 
electrophoresis tank containing 1 x transfer buffer. Transfer was conducted overnight 
at 100mA at room temperature.
2.2.11.4 Immunodetection
Following protein transfer, the membranes were placed in to 50ml tubes, which were 
placed on a roller throughout the immunodetection procedure. The following steps 
were carried out at room temperature. First, membranes were blocked for 1 hour 
using 5% (w / v) fat free dried milk powder diluted in TBS-Tween (see 2.1.3). The 
membranes were then washed once for fifteen minutes and twice for five minutes in 
fresh changes of TBS-Tween. Next, membranes were incubated for 1 hour with anti­
cytochrome P450 primary antibody diluted 1:1000 (v / v) in diluent (1% (w / v) fat 
free dried milk powder in TBS-Tween). The membranes were washed in TBS-Tween
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(as previously described) and then incubated for one hour with species-specific Ig- 
biotinylated secondary antibody diluted 1:2000 (v / v) in diluent. The membranes 
were washed in TBS-Tween (as previously described) and then incubated for 30 
minutes with streptavidin-HRP conjugate diluted 1:2000 (v / v) in diluent. The 
membranes were then washed once for fifteen minutes and four times for five minutes 
in fresh changes of TBS-Tween. The membranes were then removed from the tubes 
and placed in to plastic petri dishes, protein side uppermost. Membranes were covered 
with ECL Plus detection reagents (mixed as described in the manual) and incubated 
for 5 minutes. Membranes were drained to remove excess detection reagents and then 
exposed to film (Polaroid 667) in a mini camera.
2.2.11.5 Staining of membranes with Ponceau S
Ponceau S staining was carried out to confirm even protein loading and to evaluate 
protein transfer from the gel to the membrane. Each membrane was immersed in 
Ponceau S working solution (Ponceau S concentrate diluted 1:10 (v / v) in MilliQ 
water) for 1 to 2 minutes and then rinsed with 5% (v / v) acetic acid until the protein 
bands were visible.
2.2.12 ELISA
An enzyme-linked immunosorbant assay (ELISA) was employed as a semi- 
quantitative assay to compare the relative levels o f CYPIA, 2B, 3 A and 4A proteins in 
microsome samples firom different experimental groups. Primary antibodies (goat 
anti-rat cytochrome P450 primary antibodies), secondary antibody (rabbit anti-goat 
IgG-horseradish peroxidase) and positive control rat liver microsomes were purchased 
firom Gentest. The anti-rat cytochrome P450 primary antibodies were polyclonal and 
showed cross reactivity with GYP forms belonging to the same subfamily (e.g. anti- 
CY PlA l recognises C Y PlA l and 1A2 proteins) (Gentest data sheets). During the 
optimisation of this method the binding specificity of each antibody was confirmed by 
Western blotting (see chapter 3). Bound antibodies were detected using streptavidin- 
HRP catalysed oxidation of 3,3’,5,5’ tetramethylbenzidine (TMB). Addition of acid 
to the oxidised TMB forms a yellow colour, which is measured at 450nm. The assay 
was performed using a Standard Operating Procedure (SOP) obtained from 
AstraZeneca.
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A standard curve was constructed using liver microsomes from 3-methylcholanthrene 
(CYPIA), phénobarbital (CYP2B and 3A) or cloflbrate-treated rats (CYP4A). These 
microsomes contain a predetermined amount of the appropriate cytochrome P450 
protein. Standard microsomes were diluted in solubilisation buffer (see 2.1.4) to give, 
final microsomal protein concentrations spanning the 0.195 to 100p,g/ml range (0.195, 
0.39, 0.78, 1.56, 3.125, 6.25, 12.5, 25, 50 and lOOpg/ml). Test samples were diluted 
in solubilisation buffer to a final microsomal protein concentration o f 0.05mg/ml.
The assay was conducted in 96-well Maxisorp ELISA plates (Fisher). lOpl of each 
standard microsome dilution was transferred to the assay plate to give the following 
amounts o f microsomal protein per well: 1.95, 3.9, 7.8, 15.6, 31.3, 62.5, 125, 250, 500 
and lOOOng/well. Standard samples were assayed in triplicate. A blank well, in which 
microsomes were replaced with an equivalent volume o f solubilisation buffer, was 
also prepared. lOpl o f each test sample was transferred to the assay plate (final 
microsomal protein concentration o f 500ng/well) and each sample was assayed in 
duplicate.
For the assay, 190pl of carbonate/ bicarbonate buffer (see 2.1.4) was added to each 
well followed by incubation of the plate at 37°C for one hour. The microsomes were 
removed and the plate was washed four times with fresh changes o f wash buffer 
(200pl) (see 2.1.4) using an automated 96-well plate washer (Dynatech Laboratories). 
lOOpl o f diluted primary antibody (1:4000 (v / v) in Superblock buffer (a proprietary 
protein formulation in phosphate buffered saline (pH 7.4)) (Fisher)) was added to each 
well, followed by incubation of the plate at 37°C for one hour. The primary antibody 
was removed and four wash cycles performed as previously described. lOOpl o f 
diluted secondary antibody (1:7500 (v / v) in Superblock buffer) was added to each 
well, followed by incubation o f the plate at 37°C for one hour. The secondary 
antibody was removed and four wash cycles performed as previously described. 
lOOpl o f Turbo-TMB substrate (a proprietary formulation containing TMB and 
stabilised hydrogen peroxide (Fisher)) was added to each well and the plate was 
incubated at room temperature for 10 to 30 minutes to allow colour development. 
lOOpl o f sulphuric acid (IM) was added to each well and the absorbance at 450nm 
measured using a Victor 2 microplate reader (Wallac).
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The concentration of cytochrome P450 proteins in test samples was interpolated from 
the appropriate standard curve using Origin software (logistic fit). Mean values were 
calculated for the control and drug-treated groups. Fold induction was calculated by 
dividing the mean of the drug-treated group by the mean of the control group.
2.2.13 Optimisation of the ELISA Assay
The ELISA method described in 2.2.12 was the result of the optimisation experiments 
described below.
2.2.13.1 Specificity of the anti-CYP Primary Antibodies
The binding specificity of the anti-CYP primary antibodies used for the ELISA assay 
was evaluated by Western blotting using liver microsomes firom control and inducer- 
treated animals (from study 1). The general protocol described in 2.2.11 was used 
except for the following modifications to the immunodetection procedure. The 
primary antibodies (goat anti-rat cytochrome P450 primary antibodies) were diluted 
1:500 (v / v) and the secondary antibody (rabbit anti-goat IgG-horseradish peroxidase) 
was diluted 1:50,000 (v / v). The secondary antibody was conjugated to HRP 
therefore the step in which the membranes were incubated with streptavidin-HRP was 
omitted. Finally, the membranes were developed with ECL detection reagents (mixed 
as described in the manual) and then exposed to film.
2.2.13.2 Linear Range of Microsomal Protein Concentrations
The linear range o f the assay was determined with respect to the amount of 
microsomal protein added to each well. Standard curves were constructed by serial 
dilution o f liver microsomes (from study 1 or purchased from Gentest) in 
solubilisation buffer and each sample was assayed in triplicate as described in 2 .2 . 1 2 .
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2.2.14 Preparation of Samples for Real-time PCR (TaqMan™)
For all nucleic acid work, gloves were worn throughout and all glass and plasticware 
were sterilised by autoclaving at 121°C for 20 minutes at 15 Ib/m^.
2.2.14.1 Total RNA Extraction
Total RNA was isolated from tissue samples using Trizol® Reagent, according to the 
technical manual provided by the manufacturer (Gibco). Trizol® Reagent is a 
monophasic solution of phenol and guanidine isothiocyanate which disrupts and 
dissolves cellular components whilst maintaining the integrity of the RNA. RNA is 
separated from DNA, proteins and other contaminants by adding chloroform followed 
by centrifugation. RNA remains exclusively in the aqueous phase and is recovered by 
precipitation with isopropanol.
Liver and Testis
The following steps were performed at room temperature unless otherwise stated. 
Frozen tissue samples (« 80mg) were ground under dry ice using a mortar and pestle 
and then homogenised in 1ml Trizol® Reagent using a glass-Teflon® hand held 
homogeniser. Samples were incubated for 5 minutes to allow the complete 
dissociation of nucleoprotein complexes. 200pl of chloroform was added and the 
tubes were shaken vigorously for 15 seconds. Samples were incubated for 3 minutes 
and then centrifuged at 12,000g for 15 minutes (4°C). The upper aqueous phase, 
containing the RNA, was transferred to a clean tube. Samples were incubated for 
10 minutes with 500pl o f isopropanol and then centrifuged for 10 minutes at 12,000g 
(4°C). The supernatant was discarded and the RNA pellet was washed by mixing each 
sample with 1ml of 75% (v / v) ethanol followed by centrifugation at 7,500g for 
5 minutes. The supernatant was discarded and the RNA pellet allowed to air dry. The 
pellet was resuspended in 40pl nuclease-free water.
Pituitary Glànds
Total RNA was isolated from pituitary glands as previously described for liver and 
testis samples except for the following modifications. Pituitary glands, in 500pl 
Trizol® Reagent (see 2.2.1.5), were removed from the -80°C freezer and thawed on
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ice. The tissue was disrupted using a Polytron PT3100 homogeniser. The volumes of 
chloroform and isopropanol added were reduced to lOOpl and 250pl respectively to 
correct for the smaller volume of Trizol® Reagent used at the start.
2.2.14.2 Purification of RNA (Ambion RNAqueous’^ -4PCR Kit)
Total RNA was purified using materials and solutions firom the kit supplied by 
Ambion, according to the technical manual provided. This kit uses silica-based filters 
which selectively bind RNA allowing DNA, protein and other contaminants to be 
removed using a series o f washing steps. The pure RNA is then eluted from the filter 
and treated with DNase 1 to remove any residual DNA contamination.
Liver and Testis Samples
The following steps were performed at room temperature unless otherwise stated. 
RNA isolated using Trizol® Reagent was added to 1ml o f the Lysis/Binding Solution 
from the kit. An equal volume of 64% ethanol was added, samples were mixed 
thoroughly and then transferred on to the filter cartridges. Samples were moved 
through the filter by centrifugation at 12,000g for 1 minute. The RNA was washed 
once with 700pl o f Wash Solution 1 and then twice with 500pl o f Wash Solution 2. 
For each washing step, the Wash Solution was added to the filter cartridge and then 
moved through the filter by centrifugation as previously described. The RNA was 
eluted firom the filter in two steps using a total volume o f 80pl o f hot Elution Solution 
(O.lmM EDTA) (100°C). Samples were then incubated at 37°C for 30 minutes with 
Ip l DNase 1. The reaction was terminated by adding 9pl of DNase Inactivation 
Reagent, which was then removed by centrifugation at 10,000g for 1 minute. The 
purified RNA was transferred to a clean tube and stored at -20°C.
Pituitary Gland Samples
RNA isolated from pituitary gland samples was purified as previously described for 
liver and testis samples except for the following modifications. The RNA was added 
to 200pl o f the Lysis/Binding Solution and was eluted from the filter using 50pl hot 
Elution Solution.
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2.2.14.3 Determination of Total RNA Yield and Quality
Liver and Testis Samples
The concentration and purity of RNA samples were measured using a Genequant™ II 
spectrophotometer (Pharmacia Biotech). An aliquot o f each sample was diluted 1:35 
in nuclease-free water and the absorbance was measured at 260nm and 280nm. 
Nuclease-free water was used as a blank. The concentration of RNA was determined 
from the absorbance at 260nm. The ratio of A 2 6 0  to A2 8 0  values provides a measure of 
RNA purity. Pure RNA has an A2 6 0  • A2 8 0  ratio between 1.8 and 2.1.
The overall quality of RNA. samples was assessed by denaturing gel electrophoresis. 
A 1% (w / v) agarose gel was prepared by dissolving 0.5g agarose in 50ml 1 x Tris- 
acetate (TAB) buffer (see 2.1.5) by heating in a microwave oven. Ethidium bromide 
(0.2pg/ml) was added and the gel was allowed to cool to approximately 50°C. The 
agarose was poured in to a gel casting tray containing a comb to create loading wells 
and was allowed to set. The gel was then transferred in to an electrophoresis tank 
containing 1 x TAE buffer. RNA samples were mixed with Gel Loading Solution 
(0.05% (w / v) bromophenol blue, 40% (w / v) sucrose, 0.1% (w / v) SDS, O.IM 
EDTA (pH 8) (Sigma)) (4pl: Ip l RNA (v / v)) and then loaded on to the gel. 
Electrophoresis was conducted at lOOV until the loading dye had migrated 
approximately three quarters o f the length of the gel. The gel was visualised using a 
UV transilluminator. Total RNA should give two.fairly sharp bands, corresponding to 
28S and 18S ribosomal RNA. The intensity o f the 28S band should be approximately 
twice that o f the 18S band for intact RNA.
Pituitary Gland Samples
The concentration and quality of RNA isolated from pituitary gland samples was 
■ assessed by denaturing gel electrophoresis using an RNA standard curve. A 1% (w / 
v) agarose gel was prepared as previously described for liver and testes samples except 
that 0.5 X Tris-borate (TBE) buffer (see 2.1.5) was used in place of 1 x TAE buffer.
A standard curve was constructed using material (brain RNA) for which the total RNA 
content had been accurately quantified. This sample was diluted in nuclease-free
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water and 2pi Gel Loading Solution to give solutions with the following RNA 
concentrations: 0.01, 0.025, 0.05, 0.1 and 0.2 pg/pl. Pituitary gland samples were 
mixed with 2pl Gel Loading Solution and 6pl nuclease-free water. All samples were 
incubated for 5 minutes at 70°C using a dry heat block and then placed on ice for 5 
minutes. lOpl of each sample was loaded on to the gel. Electrophoresis was 
conducted at 140V until the loading dye had migrated approximately three quarters of 
the length of the gel. The gel was visualised using an Image Master VDS 
(Amersham). The concentration o f RNA isolated from pituitary gland samples was 
estimated by comparing the band intensity in each sample to those o f standard curve 
samples.
2.2.14.4 First-Strand cDNA Synthesis
First strand cDNA synthesis was carried for each total RNA sample using a 
Superscript II Reverse Transcriptase (RT) kit, according to the technical manual 
provided by manufacturer (Gibco). This kit contained Superscript II RNase H" reverse 
transcriptase (RT) (200U/pl), 5 x First-Strand buffer (375mM KCl, 15mM MgClz, 
250mM Tris-HCl (pH 8.3)) and O.IM dithiothreitol (DTT). Reactions contained 3pg 
total RNA for liver and testis samples or Ipg total RNA for pituitary gland samples. 
The reaction was primed using random hexamers, therefore all RNA species in a 
population will act as templates for first-strand synthesis.
For the reaction, 200ng random primers were added to each aliquot o f RNA and 
nuclease-free water was added to a final volume of 11 pi. The tubes were heated to 
70°C for 10 minutes using a dry heat block and then immediately placed on ice. The 
following reaction components were added to each tube: 8pi 5 x First-Strand buffer, 
2pi O.IM DTT, Ipl lOmM dNTP mix and Ipl Superase-In (20 U/pl). Superase-In is 
an RNase inhibitor, which was added to prevent degradation of the RNA template 
during cDNA synthesis. The tubes were mixed gently and then heated to 25°C for 10 
minutes immediately followed by 42°C for 2 minutes.
Ip l of Superscript II RT (RT+) or nuclease-free water (RT-) was added to each tube. 
Inclusion of a reaction containing no RT enzyme (RT-) for each sample in addition to
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the standard reaction (RT+) allowed the identification of any genomic DNA 
contamination. Following addition of the RT enzyme, the tubes were heated to 42°C 
for 50 minutes followed by 70°C for 15 minutes and then immediately placed on ice 
for 2 minutes. cDNA samples were stored at -20°C.
2.2.15 Real-time PCR (TaqMan™) Analysis of Candidate Genes
TaqMan™ was used to study the effects of lansoprazole treatment on mRNA levels for 
selected candidate genes in liver, testis and pituitary samples. A number of genes of 
relevance to our hypothesis were selected for quantitation
2.2.15.1 Background
Real-time PCR (TaqMan) is a powerful method that enables measurement o f the 
abundance of a target sequence in a biological sample quantitatively (Holland et al, 
1991; Lee et al., 1993; Livak et al., 1995). This technique measures the accumulation 
of a PCR product in real-time and differs from a standard PCR reaction in the addition 
of a single reagent, the fluorogenic probe designed to anneal to the target sequence. 
The probe generates a signal that accumulates during PCR cycling in a manner 
proportional to the concentration of amplification products (Holland et al., 1991; Lee 
et al., 1993).
Principle o f  the assay
A diagrammatic representation o f a typical TaqMan reaction is shown in Figure 2.1. 
This technique uses a specific, non-extendable oligonucleotide probe, which anneals 
to a portion of the target sequence located between the two primer binding sites. The 
probe is labelled with a 5’-reporter dye (e.g. 6 -carboxy-fluorescein (FAM)) and a 3’- 
quencher dye (e.g. 6 -carboxy-tetramethyl-rhodamine (TAMRA)). When the probe is 
intact, the proximity o f the quencher dye absorbs the fluorescent emission from the 
reporter dye (Livak et al., 1995).
During PCR cycling, the probe anneals to the template and is then cleaved by the 5’ to 
3’ exonuclease activity of Taq DNA polymerase (Holland et al., 1991). This separates 
the reporter dye from the probe, resulting in an increase in reporter fluorescence
Figure 2.1: Diagrammatic Representation of the steps in a typical TaqMan reaction
Step 1: DNA dénaturation 3’ 5’
5 ’ -------------   3 ’
3 ’
Step 2: Probe annealing y  ------------------------ ----------------------- --
5’ -------------------   3 ’
Forward primer
Step 3: Primer annealing y    y
and extension __________________________________
Reverse primer
Step 4: 5’ exonuclease 5’
cleavage o f  probe 3’ 5 ’
I
O
Step 5: Continuing y
polymerisation y         ^
(&) Reporter dye 
Quencher dye
Adapted from Lie & Petropoulos (1998)
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without affecting emission of the quencher dye (Heid et al., 1996). This process 
occurs during each PCR cycle and the increase in reporter fluorescence is directly 
proportional to the amount of PCR product accumulated (Heid et al., 1996). 
Fluorescence emission is monitored in real-time during the PCR amplification using a 
sequence detector, which combines a 96-well thermal cycler, a laser for excitation of 
the fluorescent dyes and a system for data collection and analysis.
Data Analysis
The sequence detector software automatically creates an exponential amplification 
plot for each sample by plotting the normalised reporter (R„), a value which reflects 
the amount of annealed probe that has been cleaved, against the cycle number. The 
quencher dye emission intensity varies only minimally during PCR cycling and is used 
to normalise reporter dye emission (Heid et al., 1996). The cycle at which reporter 
fluorescence rises above baseline is known as the threshold cycle or C?. The Ct value 
is inversely proportional to the starting template copy number (Heid et al, 1996).
The Ct value o f a test sample is used to determine the initial target copy number by 
interpolation from a standard curve amplified in the same PCR run. Levels of 
expression of a target sequence can be compared across experimental samples by 
expressing the data relative to an endogenous control gene, which is expressed at a 
constant level in all samples. Normalisation of data in this way compensates for 
factors such as intersample variation in efficiency of the reverse transcriptase reaction 
and inaccuracies in estimation of the concentration and quality o f total RNA samples. 
A constitutively expressed “housekeeping” gene, such as p-actin, GAPDH or 18S 
ribosomal RNA (rRNA), is often used as an endogenous control.
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2.2.15.2 Prim er and Probe Design
Rat sequences for target genes were obtained from the NIH gene database 
(http:/www.ncbi.nlm.nih.gov/). TaqMan primers and probes were designed for each 
gene using Primer Express"^*  ^ software (Version 1) (Applied Biosystems) according to 
the guidelines sununarised in Table 2.4. The nucleotide sequences o f primers and 
probes used for this study are shown in Table 2.5. Probes designed for target genes 
were labelled with the reporter dye FAM (5’ end) and the quencher dye TAMRA (3’ 
end). Primers and probes for target genes were purchased from Oswel DNA Services 
(University of Southampton). Primers and probes for 18S rRNA were purchased as a 
kit (Applied Biosystems). The probe was labelled with the reporter dye VIC (5’ end) 
and the quencher dye TAMRA (3’ end).
Table 2.4: Guildelines for the design of TaqMan primers and probes
Prim ers Probe
20 -  80% GC content
Length 9 -  40 bases
Tm 58 -60°C Tm 10°C higher than primer Tm
<2°C difference in Tm between the two 
primers
No G on 5’ end
Maximum of 2 G or C bases within the 
5 nucleotides at the 5’ end
<4 contiguous G’s
3’ end of the primer as close as possible 
to the probe without overlapping it
Select the strand that gives the probe 
more G’s than C’s
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2.2.15.3 TaqMan Reaction
PCR reactions were performed in optical 96-well reaction plates (Applied 
Biosystems). Expression of 18S rRNA was used as an endogenous control to 
normalise data. Each plate was divided in to two halves: the left-hand side was used 
for the target gene and the right-hand side for 18S rRNA. Each side o f the plate 
contained a standard curve, buffer blanks (containing no DNA) and RT+ and RT- 
cDNA for each test sample. Each reaction was performed in duplicate.
A standard curve was constructed by serial dilution o f rat genomic DNA (1:10, 1:100, 
1:400 and 1:1000 (v / v)). Five standard curve points were used and were designated 
arbitrary values o f 0.1, 0.25, 1, 10 and 100. The standard curve was used to compare 
the relative levels o f expression o f the target gene between samples, therefore it was 
not necessary to determine the exact amount o f genomic DNA present in each 
standard sample. cDNA samples were diluted 1:1000 (v / v) for 18S rRNA and 1:2 to 
1:100 (v / v) for the target gene. All dilutions were made using nuclease-ffee water.
Each PCR reaction contained the following components: 12.5pl qPCR™ Mastermix 
(proprietary mixture containing dNTPs, Hot Goldstar DNA polymerase, 5mM MgCl], 
Uracil-N-glycosylase, stabilisers and ROX passive reference dye) (Eurogentec), 
300nM forward primer, 300nM reverse primer, lOOnM probe, Ipl template (genomic 
DNA dilution or cDNA sample) and nuclease-fi-ee water to a final volume o f 25pl. - A 
mastermix, containing all reaction components except for the template, was prepared 
for each primer and probe set on each plate. 24pl of mastermix was added to each 
well followed by Ip l of template (genomic DNA dilution or cDNA sample). The 
plate was sealed with an optical adhesive cover (Applied Biosystems) and then 
centrifuged briefly. Real-time PCR analysis was performed with an ABI Prism II 
7700, Sequence Detector (Applied Biosystems), using the universal cycling conditions 
shown in Table 2.6.
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Table 2.6: The universal thermal cycling conditions used for TaqMan PCR reactions
Times and Tem peratures
Initial Steps Each of 40 cycles
Melt Anneal/Extend
HOLD HOLD CYCLE
2  minutes 1 0  minutes 15 seconds 1 minute
50°C 95°C 95°C 60°C
2.2.15.4 D ata Analysis
At the end of the PCR reaction, the sequence detector plots an exponential 
amplification plot for each well. The default baseline setting was adjusted to 
accommodate the earliest amplification plot and then the threshold was set just above 
the baseline. For each test sample, the initial copy number o f the target gene or 18S 
rRNA was interpolated from the appropriate standard curve using the Ct value. The 
copy number of the target gene was then divided by the copy number of 18S rRNA to 
give a normalised target value. Fold changes were calculated by dividing the mean 
normalised target value in the drug-treated group by that in the control group.
2.2.16 Statistical Analysis
Unless otherwise stated, all statistical analysis was performed using a Student’s t-test 
(two-tailed).
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2.3 Experimental Strategy
The overall aim of this project was to investigate the existence o f a liver-testis axis 
wherein microsomal enzyme inducers enhance the metabolic clearance of testosterone 
resulting in a drop in circulating hormone levels. The consequent increase in serum 
LH levels may be responsible for the appearance of Leydig cell tumours (LCTs). This 
hypothesis was addressed by designing a series o f animal studies, which are 
summarised in the following experimental plan.
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Study 1: Effect of Model Inducers on Cytochromes P450, Testosterone
Metabolism and Plasma Hormone Levels
Aims:
The aim of this study was to characterise the effects of dosing rats with model 
inducers of the major GYP families (P-naphthoflavone (p-NT), phénobarbital (PB), 
pregnenolone-16a-carbonitrile (PCN) and ciprofibrate) on hepatic and testicular 
testosterone metabolism and the endocrine control of the testis.
Experimental plan:
• Protein assay
• Total cytochrome P450
• Testosterone hydroxylase 
assay ,
• Western blotting
Liver PlasmaTestes
Microsome
preparation
Microsome
preparation
Male Sprague- 
Dawley rats
Collection of 
samples
Treatment with a 
model inducer 
for 4 days
Protein assay Radioimmunoassay:
Testosterone hydroxylase Testosterone, LH
assay FSE and prolactin
General methods sections of relevance to this study: 2.2.1.1, 2.2.1.2, 2.2.2, 2.2.4, 2.2.5, 2.2.6,
2.2.7, 2.2.8 and 2.2.11.
96
Study 2: Effect of Lansoprazole on Cytochromes P450, Testosterone Metabolism
and Plasma Hormone Levels
Aims:
Lansoprazole induces hepatic cytochromes P450 and produces Leydig cell tumours in 
rats (Atkinson et al., 1990; Masubuchi et al., 1997). The aim o f this study was to 
investigate the effects o f lansoprazole treatment on GYP expression (CYPIA, 2B, 3A 
and 4A) in the liver and testis, hepatic and testicular testosterone metabolism and the 
endocrine control o f the testis. Effects of lansoprazole were compared to the model 
inducers to help identify any changes in CYP-dependent testosterone metabolism that 
may be important in the induction o f LCTs.
• Protein assay
• Total cytochrome P450
• Testosterone hydroxylase 
assay
• Western blotting
• ELISA
Experimental plan:
Liver PlasmaTestes
Microsome
preparation
Microsome
preparation
Male Sprague- 
Dawley rats
Collection of 
samples
Treatment with 
lansoprazole for 
14 days
Protein assay 
Testosterone hydroxylase 
assay
Western blotting
Radioimmunoassay: 
Testosterone, LH 
FSH and prolactin
General methods sections o f  relevance to this study: 2 .2 .1 .1 ,2 .2 .1 .3 , 2 .2 .2 , 2 .2 .4 , 2 .2 .5 , 2.2.6, 
2.2.7, 2.2.8, 2.2.11 and 2.2.12
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Study 3: Effect of Lansoprazole on Gene Expression in the Liver and Testis 
Aims:
This study was designed to further characterise the effects o f lansoprazole on the liver 
and testis with the following objectives:
- further characterise effects on CYP expression in the liver and testis (CYP2À and 
CYP2C)
- investigate effects on the expression of selected genes o f relevance to our 
hypothesis (e.g. steroidogenic enzymes, LH-regulated protein)
- further investigate effects on the HPT axis by measuring intratesticular 
testosterone levels
• Protein assay
• Total cytochrome P450
• ELISA
TaqMan analysis of 
gene expression
Experimental plan:
Radioimmunoassay: 
Testosterone, LH 
FSH and prolactin
Plasma
TestesLiver
Microsome
preparation
Supernatant
preparation
Snap frozen tissue
Male Sprague- 
Dawley rats
Collection of 
samples
RNA extraction & 
cDNA synthesis
Treatment with 
lansoprazole for
' Radioimmunoassay: 
Testosterone
General methods sections o f  relevance to this study: 2.2.1.1, 2 .2 .1 .4 , 2.2.2, 2 .2 .3 , 2 .2 .4 ,2 .2 .5 , 
2.2.6, 2.2.12, 2.2.14 and 2.2.15
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Study 4: Effect of Lansoprazole on Gene Expression in the Pituitary Gland 
Aim:
The aim of this study was to further investigate the effects o f lansoprazole treatment 
on the endocrine control o f the testis by measuring plasma hormone levels and LH  and 
prolactin mRNA levels in the pituitary gland.
TaqMan analysis of 
gene expression
Experimental plan:
Pituitary gland Plasma
Snap frozen tissue
Collection of 
samples
Male Sprague- 
Dawley rats
RNA extraction & 
cDNA synthesis
Treatment with 
lansoprazole for 
14 days
Radioimmunoassay: 
Testosterone, LH 
FSH and prolactin
General methods sections of relevance to this study: 2.2.1.1, 2.2.1.5, 2.2.4, 2.2.14 and 2.2.15
99
Study 5: Effect of Lansoprazole on the Plasma Clearance of ^^C-Testosterone
Aim:
The aim of this study was to investigate the effect o f lansoprazole treatment on the 
plasma clearance of ^"^C-testosterone in vivo.
Experimental plan:
Collection o f serial 
blood samples
Extraction of C- 
testosterone
Male Sprague- 
Dawley rats
Administration of 
^"^C-testosterone
Treatment with 
lansoprazole for 14 
days
HPLC analysis ' Quantitation o f  ^ "^ C- 
testosterone by liquid 
scintillation counting
General methods sections of relevance to this study: 2.2.1.1, 2.2.1.6, 2.2.7 and 2.2.10
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Chapter 3
Method Optimisation
3.1 Introduction
This chapter will describe experiments that were performed in order to optimise and 
validate two of the techniques that were subsequently used as part o f this project, 
namely the HPLC-based testosterone hydroxylase assay and the ELISA assay.
3.2 HPLC-based testosterone hydroxylase assay
3.2.1 Introduction
Testosterone hydroxylase assays have been widely used to monitor the levels o f 
expression of hepatic cytochromes P450. This technique is based upon the fact that 
individual cytochromes P450 form characteristic and unique patterns o f hydroxylated 
metabolites when incubated with steroids such as testosterone (Waxman, 1988). 
Certain hydroxylation reactions are catalysed by a single CYP form and can be used as 
a diagnostic probe to monitor the levels of expression of that enzyme in rat liver 
microsomes (e.g. 2 a-hydroxylation catalysed by CYP2C11) (Morgan et al., 1985; 
Waxman, 1984; Waxman et al., 1987). Other hydroxylation reactions are catalysed by 
multiple CYP forms (e.g. 16a-hydroxylation catalysed by CYP2B1/2 and CYP2C11) 
(Wood et al., 1983; Waxman et al., 1987). These properties enable the simultaneous 
analysis o f the levels o f expression of multiple cytochromes P450 by measuring 
changes in testosterone hydroxylation.
For the current project, a HPLC-based testosterone hydroxylase assay was employed 
to study the effects o f chemical inducers on CYP-dependent testosterone metabolism 
in the liver and testis. This assay involves incubation of microsomal samples with 
radiolabelled testosterone followed by separation and quantification o f metabolites 
using a reversed-phase HPLC system. Metabolites are quantified by radiochemical 
detection and the identity of each peak is confirmed by co-chromatography with 
authentic testosterone standards injected on to the column with each sample. The 
following section will describe experiments performed to optimise this assay for use 
with microsomal samples firom the current project.
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3.2.2 High pressure liquid chromatography (HPLC)
3.2.2.1 Separation of authentic testosterone metabolites
Figure 3.1 shows a representative separation o f a mixture of authentic testosterone 
standards using the solvent cycle described in 2.2.7.3. The retention times of the 
standards during this experiment are summarised in Table 3.1. The retention times of 
testosterone standards were found to vary over repeated chromatographic runs but 
crucially the position o f each metabolite on the chromatogram relative to the other 
metabolites remained constant. Such shifts in retention times were not entirely 
unexpected and are probably due to variations in the ambient temperature, as a column 
oven was not used. This finding was of little consequence because identification of 
metabolites is based on co-chromatography with authentic standards injected on to the 
column with each sample.
Figure 3.1: A representative chromatogram showing the separation o f a mixture of 
authentic testosterone metabolites by HPLC
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Standard solutions were prepared as described in 2.2.7.2. Approximately 1.8 nmoles o f each 
hydroxylated metabolite and 0.18 nmoles of testosterone (Testos.) and androstenedione (And.) were 
injected on to the column. Elution o f analytes was monitored by optical absorbance at 240nm.
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Another characteristic of the chromatogram shown in Figure 3.1 is the gradual rise in 
baseline absorbance during the chromatographic run. This is due to the increasing 
proportion of organic solvent (mainly acetonitrile) which also absorbs at 240nm 
wavelength. This does not interfere with peak integration and quantification as this is 
based upon measurement of radiolabelled metabolites whilst the optical absorbance 
trace is used solely as a means o f peak identification.
Good resolution was achieved for all of the metabolites examined except for l i p -  and 
2a-0H T, which were only partially separated using the current HPLC system. Further 
optimisation o f the solvent cycle was not necessary because lip-O H T was not 
detected in any o f the incubation extracts firom the current project. This finding is 
consistent with the published literature, which states that lip -O H T  is not formed 
metabolically by rat liver microsomes (Sonderfan et al, 1987).
Table 3.1 : Chromatographic retention times for testosterone and metabolites
Retention Time
(mins)
Standard Componnd Chemical Name
20.06 6a-0H T 4-Androsten-6a, 17p-diol-3-dione
22.30 15P-0HT 4-Androsten-15p, 17p-diol-3-dione
28.54 6P-0HT 4-Androsten-6p, 17P-diol-3-dione
30.18 15a-0HT 4-Androsten-l 5 a , 17p-diol-3-dione
31.42 7a-0H T 4-Androsten-7a, 17p-diol-3-dione
38.54 16a-0HT 4-Androsten-16a, 17p-diol-3-dione
40.48 16P-0HT 4-Androsten-l 6 p, 17p-diol-3-dione
44.42 lip-O H T 4-Androsten-l Ip , 17p-diol-3-dione
45.18 2a-0H T 4-Androsten-2a, 17p-diol-3-dione
46.12, 2P-0HT 4-Androsten-2p, 17p-diol-3-dione
50.42 Androstenedione 4-Androsten-3,17-dione
53.12 Testosterone 4-Androsten-17p-ol-3-one
Standard solutions were prepared as described in 1 2 .1 2 . Approximately 1.8 nmoles o f each 
hydroxylated metabolite and 0.18 nmoles of testosterone and androstenedione were injected on to the 
column. Elution o f analytes was monitored by optical absorbance at 240nm.
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3.2.2.2 Linear range of radiochemical detection
A study was performed to confirm that the radioactivity detector produced a linear 
response with respect to the amount of radioactivity injected on to the HPLC column. 
Serial dilutions of ^"^C-testosterone were prepared containing amounts of radioactivity 
spanning the range expected to be present in incubation extracts (i.e. 1 0 0  to 600,000 
dpm/lOOpl injected). Each sample was injected on to the HPLC column in triplicate 
and was also quantified by liquid scintillation counting (LSC). The results are shown 
in Figure 3.2.
This study demonstrates that the radioactivity detector displays linear detection 
between 1 0 0  and 600,000 dpm on column, which spans the range o f activities 
typically analysed in incubation extracts. The limit o f detection was approximately 
9 pmoles equivalent on colunm.
Figure 3.2: The linear range of detection of the HPLC radioactivity detector
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Serial dilutions of '“^ C-testosterone were prepared and lOOpl aliquots o f each dilution were counted by 
HPLC and LSC. Each point represents the mean value of triplicate determinations. Linear regression 
was performed and the value is shown on the graph.
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3.2.3 M icrosomal incubations using liver microsomes
3.2.3.1 Timecourse
A study was performed to determine the linear range o f metabolite formation with 
respect to incubation time for rat liver microsomes. Liver microsomes from control 
and lansoprazole-treated animals were incubated with testosterone for various 
incubation periods as described in 2.2.9.1. A representative time course o f formation 
for three metabolites is shown in Figure 3.3. The linear ranges for all metabolites 
studied are shown in Table 3.2.
Table 3.2: Linear range of metabolite formation by rat liver rhicrosomes with respect 
to incubation time
Treatm ent group M etabolite L inear range
(mins)
Control
6P-0HT O-.IO 0.99
16a-0HT 0 -7 .5 0.98
2a-0H T 0 - 1 0 &98
7a-0H T 0 - 1 0 0.99
2P-0HT 5 - 2 0 0.98
Lansoprazole
6a-0H T 0 - 1 0 0.99
6P-0HT 0 - 1 0 0.99
16a-0HT 0  - 1 0 0.97
2a-0H T 0  - 1 0 O j#
7a-0H T 0 - 1 0 0.99
2P-0HT 5 - 2 0 0.99
Liver microsomes from control and lansoprazole-treated animals (from Study 2) were incubated with 
testosterone as described in 2.2.9,1. Each incubation was performed in duplicate. Linear regression 
analysis was performed and values were calculated.
Metabolite formation was proportional to incubation time up to 10 minutes for 6 a-, 
6 P-, 7a- and 2a-0H T  and up to at least 7.5 minutes for 16a-0HT. 2P-0HT was not
106
Figure 3.3: The formation of three testosterone metabolites as a function of the 
incubation time by rat liver microsomes
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Liver mlCTOSomes from a lansoprazole-treated animal (from Study 2) were incubated with testosterone 
as described in 2.2.9.I. Each data point represents the average value from duplicate incubations.
Figure 3.4: The formation o f three testosterone metabolites as a function o f the 
microsomal protein concentration
25
20
15
10
5
0
0.5 1.5 2 2.5 3
M icrosomal protein concen tration  (mg/ml)
3.5 4.5
-6b-OHT
-16a-OHT
-2a-OHT
Liver microsomes from a control animal (from Study 2) were incubated with testosterone as described 
in 2.2.9.2. Each data point represents the average value from duplicate incubations.
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detected at the one minute timepoint but metabolite formation was linear between 5 
and 20 minutes. 15a-0HT and 16p-0HT were not consistently detected in incubation 
extracts from this study therefore it was not possible to draw firm conclusions for 
these metabolites. Based on these findings, a standard incubation time of five minutes 
was selected.
3.2.3.2 Protein Study
A study was performed to determine the linear range of metabolite formation with 
respect to the microsomal protein concentration for rat liver microsomes. 
Testosterone was incubated with liver microsomes from control and lansoprazole- 
treated animals at increasing microsomal protein concentrations as described in 
2.2.9.2. The effect o f the microsomal protein concentration on the formation o f three 
metabolites is shown in Figure 3.4. The linear ranges for all metabolites studied are 
shown in Table 3.3.
Table 3.3: Results of linear regression analysis o f data from the protein study
Treatm ent group M etabolite L inear range
(mg/ml)
R '
Control
6P-0HT 0 - 2 0.99
16a-0HT 0 - 2 0.99
2a-0H T 0 - 2 0.99
7a-0H T 0 - 2 0.98
2P-0HT 0 .7 5 -1 .5  - 0.96''
Lansoprazole
6P-0HT 0 - 2 0.95
16a-0HT 0 - 2 0.97
2a-0H T 0 - 2 0.97
7a-0H T 0 - 2 0.97
2P-0HT 0.5 -1.5 0.96
Liver microsomes from control and lansoprazole-treated rats (from Study 2) were incubated with 
testosterone as described in 2.2.9.2. Each incubation was performed in duplicate. Linear regression 
analysis was performed and values were calculated. #, indicates an value where only three data 
points were used for linear regression analysis.
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Metabolite formation was proportional to the protein concentration up 2 mg/ml for 
6 P-, 16a-, 2a- and 7a-0H T. 2P-0HT was not detected in incubation extracts at lower 
microsomal protein concentrations (below 0.5 mg/ml), but metabolite formation was 
linear up to 1.5 mg/ml. 15a-0HT and 16P-0HT were not consistently detected in 
incubation extracts from this study therefore it was not possible to draw firm 
conclusions for these metabolites. Based on these findings, a standard microsomal 
protein concentration of 0.5 mg/ml was selected.
3.2.3.3 Effect of 4-MA on microsomal testosterone metabolism
In addition to cytochromes P450, rat liver microsomes also contain other enzymes that 
are capable o f metabolising testosterone, such as the 5a-R. The 5a-R  inhibitor, 
4-MA, is often added to incubation mixtures to prevent extensive conversion of 
testosterone and its metabolites to 5a-reduced forms (Sonderfan & Parkinson, 1988). 
A study was performed to investigate the effect o f 4-MA on testosterone metabolism 
by rat liver microsomes. Liver microsomes from control and lansoprazole-treated 
animals were incubated with testosterone in the presence or absence of 4-MA (IpM) 
as described in 2.2.9.4. This concentration of 4-MA was selected as it has previously 
been shown to completely inhibit steroid 5a-reductase activity without inhibiting other 
pathways of testosterone oxidation catalysed by liver microsomes (Sonderfan & 
Parkinson, 1988). Inclusion of 4-MA in incubation mixtures had no marked effects on 
testosterone metabolism by rat liver microsomes as shown in Figure 3.5. 4-MA might 
have produced slight increases in the accumulation o f some hydroxylated testosterone 
metabolites but it was not possible to assess the statistical significance o f this effect as 
single incubations were performed in the absence of 4-MA. In the absence o f any 
adverse effects of 4-MA on testosterone metabolism it was decided to include 4-MA 
(IpM ) routinely in all incubation mixtures.
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3.2.3 A  Stability of incubation extracts
A study was performed to determine whether incubation extracts and authentic 
testosterone standards were sufficiently stable at room temperature to allow the use of 
a non-reffigerated autosampler. Aliquots of reconstituted incubation extracts and 
mixtures o f authentic testosterone standards were injected at 0  hours and then 
following 24 hours incubation at room temperature. An example o f the data obtained 
from stability studies with incubation extracts is shown in Figure 3.6. Mixtures of 
authentic testosterone standards and metabolites present in incubation extracts were 
found to be stable at room temperature for at least 24 hours.
3.2.4 Microsomal incubations using testis microsomes
Studies were performed to determine the linear range o f metabolite formation with 
respect to the incubation time and the microsomal protein concentration for testis 
microsomes. Unfortunately, due to the low levels of testosterone hydroxylase activity 
present in testis microsomes these experiments failed to yield any useful data. 
Consequently, the incubation conditions for testis microsomes were based upon the 
optimisation experiments previously described for liver microsomes. A standard 
incubation time of 5 minutes was selected as this was previously used for liver 
microsomes and it was sufficient for the formation o f detectable levels o f all o f the 
metabolites formed by testis microsomes. A standard microsomal protein 
concentration of 2 mg/ml was used because this concentration was at the top o f the 
linear range for liver microsomes therefore it would be expected to be within the linear 
range for testis microsomes, which contain less cytochrome P450 per milligram of 
protein. The use of a higher protein concentration would also increase the absolute 
amount o f metabolites formed and thereby facilitate their detection and accurate 
quantification. This protein concentration has also been used by other groups 
measuring testosterone hydroxylase activity in testis microsomes from rats (Sonderfan 
et al., 1989).
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3.2.5 Discussion
The HPLC system has been shown to be capable of resolving at least eleven potential 
metabolites of testosterone, which are expected to include all o f the major and the 
majority of the minor pathways of testosterone metabolism catalysed by liver 
microsomes. The linear response o f the radioactivity detector has been demonstrated 
across the range o f activities typically analysed in incubation extracts. In addition, 
studies have confirmed that authentic testosterone standards and metabolites present in 
incubation extracts are sufficiently stable to allow the use of a non-refirigerated 
autosampler, enabling a marked increase in sample throughput for the assay.
The microsomal incubation procedure has been optimised with respect to incubation 
time and microsomal protein concentration for liver microsomal samples. The 
substrate concentration used in this assay (250pM) would be expected to be saturating 
with respect to the cytochromes P450 involved in testosterone metabolism based on 
the published Km value for testosterone metabolism by rat liver microsomes (26pM) 
(Kuntzman et al., 1965). This substrate concentration is used by the majority of 
testosterone hydroxylase assays from the published literature (Reinerink et al., 1991; 
Sonderfan et al., 1987; Wortelboer et al., 1991; Purdon & Lehman-McKeeman, 1997).
The 5a-R  inhibitor, 4-MA, is often added to incubation mixtures to prevent extensive 
conversion of testosterone and its metabolites to 5a-reduced forms. Studies conducted 
by Sonderfan and Parkinson (1988) indicated that 4-MA increases the accumulation o f 
hydroxylated testosterone metabolites through two mechanisms. Firstly, it inhibits 
5a-reduction of metabolites that are substrates for the 5a-R  enzyme (e.g. 6P-0HT). 
Secondly, it inhibits the formation of 5a-dihydrotestosterone, which acts as a 
competitive inhibitor of CYP-dependent pathways o f testosterone metabolism 
catalysed by rat liver microsomes. In the current study, inclusion of 4-MA in 
incubation mixtures might have resulted in a slight increase in the accumulation of 
some hydroxylated testosterone metabolites, consistent with reports that 5a-R activity 
is low in liver microsomes firom adult male rats (Sonderfan & Parkinson, 1988). In 
the absence of any adverse effects o f 4-MA on testosterone metabolism it was decided 
to include 4-MA (IpM ) routinely in all incubation mixtures. This concentration has 
previously been shown to completely inhibit 5a-R activity without inhibiting other
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pathways o f testosterone oxidation catalysed by liver microsomes (Sonderfan & 
Parkinson, 1988).
In conclusion, a HPLC-based testosterone hydroxylase assay has been set up and 
optimised for use with microsomal samples from our laboratory. This method uses 
optical absorbance and radiochemical detection to identify and quantify metabolites 
respectively, which has a number of advantages. Firstly, use of the optical absorbance 
trace solely as a means of metabolite identification allowed a mixture o f authentic 
testosterone standards to be injected with each sample. Overlaying the optical 
absorbance and radioactivity traces makes metabolite identification rapid and accurate 
and avoids potential problems associated with inter-run variability in metabolite 
retention times. Secondly, the use of radiolabelled substrate allows the construction of 
a mass balance relating the loss of counts as testosterone is metabolised to the 
appearance of counts as each metabolite is formed (Arlotto et al., 1991). Finally, the 
use o f radiolabelled substrate enables the calculation o f extraction efficiency without 
the need for an internal standard. Recovery o f radioactivity using the current 
extraction procedure is typically within the range o f 85 to 95%. Samples with 
extraction efficiencies o f less than 70% were excluded from the analysis.
3.3 ELISA
All optimisation experiments fo r  the ELISA assay were conducted by Alex Bell at 
AstraZeneca (Loughborough).
3.3.1 Introduction
An enzyme-linked immunosorbant assay (ELISA) was employed as a semi- 
quantitative assay to compare the relative levels o f CYPIA, 2B, 3 A and 4A proteins in 
liver microsomes from different experimental groups. For the assay, 96-well plates 
are coated with solubilised microsomal samples and CYP proteins are detected using 
the principle o f the antigen-antibody interaction. The plates were incubated with an 
anti-CYP primary antibody followed by a secondary antibody conjugated to 
streptavidin-HRP. The extent of antibody binding can then be quantified using the 
HRP catalysed oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) to form a coloured 
product, which is measured at 450nm using a spectrophotometer. The following
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section will describe experiments that were conducted during the optimisation of this 
assay for use with liver microsomes.
3.3.2 Specificity of the anti-CYP primary antibodies
The binding specificity of the anti-CYP primary antibodies used for the ELISA assay 
was evaluated by Western blotting using liver microsomes from control and inducer- 
treated animals (from study 1). These experiments confirmed that the anti-CYPlAl 
did not cross react with CYP2B, 3A or 4A proteins in liver microsomes from control 
or inducer-treated animals (Figure 3.7). Similarly, anti-CYP3A2 and anti-CYP4Al 
did not cross react with CYP proteins belonging to other CYP subfamilies (data not 
shown). Anti-CYP2B1 showed some cross reactivity with CYP proteins from other 
subfamilies in liver microsomes from control and inducer-treated animals (data not 
shown). This was probably due to the high concentration of primary antibody used for 
Western blotting (1:500) whereas a much higher dilution (1:4000) is used for the 
ELISA assay. Each of these antibodies is known to cross react with other CYP 
proteins belonging to the same subfamily (e.g. anti-CYP2Bl cross reacts with 
CYP2B2) (Gentest data sheets).
3.3.3 Linear range of microsomal protein concentrations
The linear range o f the assay was determined with respect to the amount of 
microsomal protein added to each well. Standard curves were constructed by serial 
dilution of liver microsomes and the range over which the microsomal protein 
concentration showed a linear relationship with the absorbance at 450nm was 
identified. , '
A representative standard curve from this study is shown in Figure 3.8. The linear 
range of the assay was found to be between approximately 0 . 1  and Ipg o f microsomal 
protein per well for each of the antibodies used. At microsomal protein concentrations 
higher than Ipg per well the assay was saturated such that the increase in absorbance 
at 450nm no longer showed a linear relationship with the protein concentration (Figure 
3.8). Based on these results, a microsomal protein concentration of 0.5 pg per well 
was used for all experiments.
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Figure 3.7: Western blot of rat liver microsomes developed with anti-CYP 1 A l 
(Gentest)
Lane 1 2  3 4  5 6  7 8
5|ag microsomal protein was loaded in each lane.
Lane 1, C Y PlA l positive control liver microsomes from |3-NF-treated rats (Amersham) 
Lane 2, CYP1A2 positive control liver microsomes from isosaffole-treated rats (Amersham) 
Lane 3, CYPIA positive control liver microsomes from 3-MC-treated rats (Gentest)
Lane 4, Liver microsomes from a P-NF treated animal 
Lane 5, Liver microsomes from a PB-treated animal 
Lane 6, Liver microsomes from a PCN-treated animal 
Lane 7, Liver microsomes from a ciprofibrate-treated animal 
Lane 8, Liver microsomes from a control animal
Figure 3.8: CYPIA ELISA standard curves constructed using liver microsomes from 
control and inducer-treated animals
1.6
•>*«• artmja 1 ( * batn-NPf
artroM tuiilfaaWt 
-K - CvF 1A sJardsfd c«vo
5.4
1.S -
06
06 -
04
02
10 100 lOiW
In^ng pm lain}
IWOO
Liver m icrosom es were assayed for C Y P IA  protein levels as described in 2 .2 .12 . The C Y P IA  standard 
curve was constructed using liver m icrosom es from 3-M C-treated rats (Gentest). Each data point 
represents the mean ± SD from  replicate determinations (n=3 for each protein concentrations).
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3.3.4 Discussion
The ELISA assay has been optimised and will be used to quantify the levels of CYP 
proteins present in liver microsomes generated as part o f this project. Western 
blotting experiments indicated that the anti-CYP antibodies would not be expected to 
cross react with CYP proteins belonging to other subfamilies at the dilutions used in 
the ELISA assay. However, these results can only be considered as a guide due to 
potential differences in antibody-antigen interactions between the denatured protein 
samples used for Western blotting and the solubilised proteins used for the ELISA. 
The ELISA assay has also been optimised to ensure to that the amount o f microsomal 
protein added to each well is within the linear range o f the assay. Overall, this assay 
has been shown to be a reproducible, sensitive and relatively rapid method for the 
quantification of CYPIA, 2B, 3 A and 4A proteins in rat liver microsomes.
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Chapter 4
Effect of model inducers on cytochromes P450, testosterone 
metabolism and plasma hormone levels
4.1 Introduction
This study was designed to characterise the effects of dosing rats with model inducers 
o f the major CYP families (P-NP-CYPIA, PB-CYP2B, PCN-CYP3A and ciprofibrate 
-CYP4A) on microsomal testosterone metabolism and the endocrine control of the 
testis. The quantitative and qualitative effects of these compounds on the hepatic CYP 
complement have previously been well characterised, however the physiological 
implications o f concomitant changes in steroid hormone metabolism are poorly 
understood (Guengerich et al., 1982; Waxman et al., 1985; Wortelboer et al., 1991; 
Parkinson et al., 1992; Makowska et al., 1990; Zangar et al., 1996). The four model 
compounds selected for the current study all induce hepatic CYPs but there is no 
evidence that they produce Leydig cell hyperplasia or tumours in rats. It was therefore 
useful to compare and contrast the effects of these compounds on CYP-dependent 
pathways o f testosterone metabolism to those of CYP inducers known to produce 
LCTs (e.g. lansoprazole). The overall aim of this study was to provide an insight in to 
the pathways that might be involved in xenobiotic-induced LCT formation in rats.
The main objective was to characterise the effects of these four compounds on hepatic 
CYP-dependent testosterone metabolism and plasma hormone levels (testosterone, 
LH, FSH and prolactin). In addition, experiments were performed to determine 
whether these compounds also influenced testicular CYP-dependent testosterone 
metabolism. Such changes could have important local effects on the testis because 
hydroxylated testosterone metabolites might possess unique biological or endocrine 
activities that could underlie important physiological functions (e.g. 7a-hydroxylated 
androgens may regulate testosterone biosynthesis (see section 1.5)).
4.2 Study design
Male Sprague Dawley rats were dosed once daily with P-NP (100 mg/kg/day) (p.o.), 
PB (80 mg/kg/day) (i.p.), PCN (60 mg/kg/day) (i.p.) or ciprofibrate (10 mg/kg/day) 
(p.o.) for four days. The dosages were selected as they have previously been shown to 
cause induction of the appropriate CYP enzymes in rats (Amacher & Schomaker, 
1998; Kocarek & Reddy, 1996; Graham et al, 1996; Hanoika et al, 1995). On day 
five, blood samples were collected and liver and testis microsomes were prepared. 
More detailed experimental details concerning animal treatment, sample collection 
and the analytical methods used for this study can be found in ehapter 2 .
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4.3 Results
4.3.1 Body, liver and testes weights
Final body weights and relative liver and testes weights for control and xenobiotic- 
treated animals are shown in Table 4.1.
Table 4.1: Effect of xenobiotic pretreatment on relative liver and testes weights
Treatm ent
group
Final body 
weight 
(g)
Relative liver 
weight
(g /lOOg body weight)
Relative testes 
weight
(g /lOOg body weight)
Control 416.0+10.5 3.89 ±0.29 0.86 ± 0.05
P-NF 416.4 ± 4.6 3.95 ± 0.29 0.87 ± 0.08
PB 415.0 ±10.8 4.65 ±0.26** 0.84 ± 0.06
PCN 418.2 ±10.5 4.32 ± 0.45 0.90 ± 0.06
Ciprofibrate 409.0 ± 6.7 5.27 ±0.23*** 0.89 ±0.08
Results are expressed as mean ± SD for each group of animals (n=5 animals per group). Values from 
each xenobiotic-treated group were compared to the control group using a Student’s t-test where 
asterisks (*) represent: * *  P<0.01, *** P<0.001.
There were no statistically significant differences in initial (data not shown) or final 
body weights between control and drug-treated groups. Consistent with the changes 
in relative liver weights, significant increases in absolute liver weights (data not 
shown) were observed in PB- and ciprofibrate-treated animals (P<0.01 and P<0.001 
respectively) whereas no significant changes were observed in P-NF or PCN-treated 
groups. There were no significant changes in absolute (data not shown) or relative 
testis weights in any o f the xenobiotic-treated groups.
4.3.2 Plasma horm one levels
Blood samples were collected (~24 hours after the final dose) and assayed for plasma 
testosterone, LH, FSH and prolactin levels by radioimmunoassay (Figures 4.1 to 4.4). 
No statistically significant changes in plasma testosterone, LH, FSH or prolactin levels 
were observed in any o f the xenobiotic-treated groups.
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Figure 4.1: Plasma testosterone levels in control, p-NF, PB, PCN and ciprofibrate-
treated animals
30
25
20
^ 10
Control B-NF PB
Treatment Group
PCN Qprofibrate
Results are expressed as mean ± SEM for each group (n=5 animals per group).
Figure 4.2: Plasma luteinising hormone (LH) levels in control, p-NF, PB, PCN and 
ciprofibrate-treated animals
Control B-NF PB
TreeÉment Q"oup
PCN Qprofibrate
Results are expressed as mean ± SEM for each group (n=5 animals per group).
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Figure 4.3: Plasma follicle-stimulating hormone (FSH) levels in control,
p-NF, PB, PCN and ciprofibrate-treated animais
PB
Treatment Group
C ipro fib ra te
Results are expressed as mean ± SEM for each group (n=5 animals per group).
Figure 4.4: Plasma prolactin levels in control, p-NF, PB, PCN and ciprofibrate- 
treated animals
PB
Treatment Group
C ipro filxa te
Results are expressed as mean ± SEM for each group (n=5 animals per group).
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4.3.3 Protein content of liver and testis microsomes
The protein content o f liver and testis microsomes prepared from control and 
xenobiotic-treated animals are shown in Table 4.2. Due to the fact that testis samples 
were pooled, it was not possible to assess the statistical significance o f any differences 
in microsomal protein yields between the treatment groups.
Table 4.2: Effect of xenobiotic pretreatment on the protein yields o f liver and testis 
microsomes
Treatm ent
group
Liver protein yield
(mg/g liver)
Testicular protein yield
(mg/g testis)
Control 21.31 ±0.67 3.99
P-NF 21.39 ±0.99 4.05
PB 21.45 ± 1.19 3.96
PCN 2 2 . 2 2  ± 1 . 0 1 3.83
Ciprofibrate 23.99 ±0.92 *** 4.04
Results are expressed as mean ± SD from individual liver microsomal preparations (n=5 animals per 
group). Values from each xenobiotic-treated group were compared to the control group using a 
Student’s t-test where asterisks (*) represent; * * * P<0.001. Protein yields are shown for pooled testis 
microsomes from each group of animals.
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4.3.4 Total CYP content of liver microsomes
The specific CYP content of liver microsomes from control and xenobiotic-treated 
animals are shown in Table 4.3. Due to low levels of expression in the testis it was 
not possible to measure the total CYP content of testis microsomes firom this study.
Table 4.3: Effect of xenobiotic pretreatment on the total cytochrome P450 content of 
liver microsomes
Treatm ent group M icrosomal CYP content
(nmoles/mg microsomal protein)
Control 0.47 ± 0.06
P-NF 0.72 ± 0 .1 8 *
PB 1.02 ±0.15 ***
PCN 0.90 ±0.08***
Ciprofibrate 0.56 ± 0.06
Results are expressed as mean ± SD from individual microsomal preparations (n=5 animals per group). 
Values for each xenobiotic-treated group were compared to the control group using a Student’s t-test 
where asterisks (*) represent: * P<0.05, *** P<0.001.
4.3.5 M icrosomal testosterone metabolism
Testosterone metabolism by liver and pooled testis microsomes firom control and 
xenobiotic-treated rats was determined using the optimised HPLC-based testosterone 
hydroxylase described in Chapter 3.
4.3.5.1 Testosterone metabolism by liver microsomes
Control profile
A representative HPLC profile o f the metabolites formed following incubation of 
testosterone with liver microsomes from a control animal is shown in Figure 4.5. 
Control liver microsomes metabolised testosterone to form up to fourteen peaks, nine 
of which were identified by co-chromatography with authentic standards (namely
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androstenedione, 6 a-, 6 P-, 7a-, 16a-, 16p-, 2a-, 2P- and 15a-0HT). Five 
unidentified peaks were present in all control samples, three of which eluted after 
testosterone. The identity of these peaks is currently unknown and they will be 
referred to using the letters shown in Figure 4.5 throughout this thesis.
The major oxidation products identified in control incubations were androstenedione, 
16a- and 2a-0H T. Smaller amounts of 6 p-, 7a-, 6 a- and 2P-0HT were also formed. 
Traces of 16p- and 15a-0H T were detected in a small number o f control incubation 
extracts.
Figure 4.5: Representative chromatographic separation of testosterone metabolites 
formed following incubation of '"^C-testosterone with liver microsomes 
from a control animal.
cprn
6p
6a
7a
16a
Testes.
2a X
And
2 p
B
1 0 2 0 30 40 Time (mins)
Liver microsomes from a control animal were incubated with C-testosterone as described in 2.2.8. 
80gl of the reconstituted incubation extract was injected on to the HPLC column and analytes were 
quantified by radiochemical detection. Metabolites were identified by co-chromatography with 
authentic standards (detected by optical absorbance at 240nm, not shown), for example 6a corresponds 
to 6a-0HT, Testos., testosterone; And., androstenedione. Unidentified peaks are indicated by capital 
letters.
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Metabolism in blank samples
A blank incubation containing all o f the reaction components except for NADPH was 
prepared for each microsomal sample to verify that this cofactor was required for 
metabolism. Measurable amounts of 6a-0H T, 6p-0HT, peak Y and androstenedione 
were detected in blank incubation extracts (Figure 4.6). 6a-0H T  and peak Y were 
formed in equal amounts in incubations conducted in the absence and presence of 
NADPH, as shown in Figure 4.7. In contrast, the rates o f formation of 6p-0HT and 
androstenedione were higher in incubations containing NADPH compared to blanks.
Figure 4.6: Representative chromatographic separation o f testosterone metabolites 
detected following incubation of ^ "^C-testosterone with liver microsomes 
in the absence of NADPH
Testos.
S3.
cpm
6p Y
. And.
i
1 0 20 30 40 50 Time (mins)
Liver microsomes from a control animal were incubated with '^^C-testosterone in the absence of  
NADPH as described in 2.2.8. SOpl of the reconstituted incubation extract was injected on to the HPLC 
column and analytes were quantified by radiochemical detection. Metabolites were identified by co­
chromatography with authentic standards (detected by optical absorbance at 240nm, not shown), for 
example 6a corresponds to 6a-0H T, Testos., testosterone; And., androstenedione. Unidentified peaks 
are indicated by capital letters.
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Figure 4.7: The effects of omission of NADPH from incubation mixtures on
testosterone metabohsm by rat liver microsomes from a control animal.
□ (+) NADPH 
O {-) NADPH
6  a lp h a -O H T A nd.
Metabolite
Liver microsomes were incubated with testosterone in the presence or absence of NADPH as described in 2.2.8. The rate of 
formation of each metabolite in the blank incubation (no NADPH) is expressed as a percentage of that in the standard incubation 
(with NADPH) (displayed as 100%). Standard incubations were performed in triplicate and each bar represents the mean ±  SEM. 
A single incubation was performed for the blank.
Figure 4.8: Comparison of the levels of metabohtes detected in blank incubations 
with standard or washed liver microsomes
□  S tan d a rd  
m ic ro so rre s
W a sh e d
m icrosom es
e a lp h a O H T
Liver microsomes from a control animal were prepared using the procedure described in 2.2.2, with (washed microsomes) or 
without (standard microsomes) the inclusion of an additional “washing” step. Microsomes were incubated with 'Y-testosterone 
in absence of NADPH. Each bar represents the average value from duplicate incubations.
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Initially experiments were performed to investigate the possibility that these peaks 
were detected in blank samples due to the presence of residual endogenous NADPH in 
the microsomal sample. “Washed” liver microsomes were prepared by including an 
extra resuspension and centrifugation step that would presumably remove any residual 
cofactor from the sample. The same metabolite peaks were present in blank 
incubations with washed microsomes, confirming that these peaks were not present 
due to residual cofactor (Figure 4.8).
Subsequently, it was observed that following injection o f ^"^C-testosterone on to the 
HPLC colunrn at similar concentrations to those routinely analysed in incubation 
extracts, peaks other than testosterone were present on the chromatogram (data not 
shown). Peaks corresponding to 6P-0HT and androstenedione were identified by co­
chromatography with authentic standards. In addition, a peak corresponding to peak 
Y was identified based on the position of this peak on the chromatogram relative to 
the authentic standards. Traces of 6p-0HT and androstenedione were detected in the 
^"^C-testosterone substrate at levels that did not account for the entire peaks detected in 
the blank samples. In contrast, the amount of peak Y detected in the ^"^C-testosterone 
substrate fully accounted for the peak detected in blank samples. These findings 
indicate that peak Y was not formed metabolically during the incubation period but 
was present as a contaminant in the ^"^C-testosterone. This peak probably represents 
an impurity or breakdown product of testosterone. At present the pathways 
responsible for the formation of 6a-0H T, 6P-0HT and androstenedione in the 
absence o f exogenous NADPH are unknown.
For the current project, the primary interest was CYP-dependent pathways of 
testosterone metabolism, which require the presence of NADPH. The presence of 
peaks in blank samples was therefore corrected for by subtracting the amount o f each 
metabolite detected in the blank sample from the amount detected in the 
corresponding standard incubation (containing NADPH) prior to the calculation of 
enzyme activity. Following the subtraction of blanks, no 6a-0H T  or peak Y were 
detected.
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Effects o f inducers on hepatic testosterone metabolism
The effects of treating rats with the four model CYP inducers on microsomal 
testosterone metabolism are shown in Figures 4.9 to 4.12. In addition to the pathways 
shown in Figures 4.10 and 4.11, PB and PCN induced the formation of unidentified 
metabolites that were not present in incubation extracts firom control microsomes, as 
shown in Figure 4.13. PB and PCN induced the formation of the same metabolites. 
These metabolites were present at low levels and were poorly resolved by the current 
HPLC system and therefore were not quantified.
Figure 4.13: Chromatographic separation o f testosterone metabolites formed
following incubation of ^ "^C-testosterone with liver microsomes firom a 
PB-treated animal.
o.
cpm
6a
15P
16a
16P 2P
10 2 0 30 40 50 Time (mins)
Liver microsomes from a PB-treated animal were incubated with testosterone as described in 2.2.8. 
80gl of the reconstituted incubation extract was injected on to the HPLC column and analytes were 
quantified by radiochemical detection. Metabolites were identified by co-chromatography with 
authentic standards (detected by optical absorbance at 240nm, not shown), for example 6a corresponds 
to 6a-0HT, Testos., testosterone; And., androstenedione. Unidentified peaks that were not present in 
control incubations are shown in circles.
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4.3.S.2 Testosterone metabolism by testis microsomes
Control profile
A representative HPLC profile o f metabolites formed following incubation^ of 
testosterone with pooled testis microsomes from the control group is shown in Figure 
4.14. Incubation extracts from testis microsomes contained the major metabolites 
androstenedione and 6P-0HT, along with traces 6a-0H T, 7a-0H T  and peak Y.
Figure 4.14 : Chromatographic separation of testosterone metabolites formed
following incubation o f  ^ "^C-testosterone with pooled testis microsomes 
jfrom control animals.
cpni
6a
Testos.
And.
18 40 50 Time (mins)
Pooled testes microsomes were incubated with testosterone as described in 2.2.8. 80pl o f the 
reconstituted incubation extract was injected on to the HPLC column and analytes were quantified by 
radiochemical detection. Metabolites were identified by co-chromatography with authentic standards 
(detected by optical absorbance at 240nm, not shown), for example 6a corresponds to 6a-0HT, 
Testos., testosterone; And., androstenedione. Unidentified peaks are indicated by capital letters.
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Metabolism in blank samples
As previously described for incubations with liver microsomes, measurable amounts 
o f 6a-0H T, 6p-0HT, peak Y and androstenedione were present in blank incubations 
with testis microsomes. This was corrected for by subtracting the amount of each 
metabolite detected in the blank sample from the amount detected in the 
corresponding standard incubation (containing NADPH) prior to the calculation of 
enzyme activity. Following subtraction of blanks, no 6a-0H T  or peak Y were 
detected. Due to the low levels of metabolism in the testis, only traces of testosterone 
6 p-hydroxylase activity remained following blank subtraction. In contrast, 
androstenedione was the major metabolite produced by testis microsomes and 
adequate levels o f this metabolite remained following blank subtraction.
Effects o f  inducers on testicular testosterone metabolism
The effects o f treating rats with the four model CYP inducers on testosterone 
metabolism catalysed by pooled testis microsomes are shown in Figure 4.15.
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4.3.6 Western blotting
Western blotting experiments were performed with liver microsomes from control and 
xenobiotic-treated animals as described in 2.2.11. Each CYP protein was localised 
using the appropriate anti-CYP primary antibody and was identified based on the 
literature molecular weight and co-migration with the positive control sample.
Figure 4.16 shows a representative Western blot from this study and the results of all 
Western blotting experiments are summarised in Table 4.4. CYP1A2 and 3A proteins 
were detected in liver microsomes from control animals, whereas CYP2B and 4A 
proteins were not detected. The effects of ciprofrbrate on CYP3A protein levels were 
inconclusive because the lanes on the gel appeared to have merged.
Figure 4.16: Western blot of rat liver microsomes developed with anti-CYP 1A2 
primary antibody
Lane 1
58100
39800
5)Lig microsomal protein was loaded in to each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from isosafrole-treated rats
Lanes 3, Liver microsomes from a control animal
Lanes 4-8, Liver microsomes from five individual P-NF-treated animals
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Table 4.4: Effect of xenobiotic pretreatment on CYP proteins levels in rat liver 
microsomes
Treatm ent
group
CYP1A2 CYP2B CYP3A CYP4A1
p-NF + - - —
PB - + + -
PCN - + + —
Ciprofrbrate - - ? +
+, induction of the isoform was observed; - ,  no induction was observed; ?, results were inconclusive. 
Western blotting for CYP4A1 was performed by Alex Bell at AstraZeneca, Loughborough.
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4.4 Discussion
4.4.1 Effects on hepatic CYPs and testosterone metabolism
4.4.1.1 Testosterone metabolism by control liver microsomes
The optimised HPLC-based testosterone hydroxylase assay described in Chapter 3 
produced good resolution of metabolites present in incubation extracts, the majority 
being identified by co-chromatography with authentic standards. The profile of 
metabolites detected in incubation extracts firom control liver microsomes is consistent 
with previously published data for male Sprague Dawley rats (Purdon & Lehman- 
McKeeman, 1997; Parkinson et al., 1992). The absolute rates of testosterone 
hydroxylation catalysed by liver microsomes in the current study tended to be lower 
than values reported in the published literature, particularly with respect to 
testosterone 6 P-hydroxylation. Such differences might be due to differences in animal 
age and environmental factors (e.g. housing conditions, diet).
In the current study, androstenedione and up to eight hydroxytestosterone metabolites 
(6 a-, 6 p-, 15a-, 7a-, 16a-, 16p-, 2a-, and 2p-0HT) were detected in control 
incubation extracts. In addition to these metabolites, some groups have detected traces 
o f ISp-OHT and 16-ketosterone in control incubations (Purdon & Lehman- 
McKeeman; Parkinson et al., 1992). The generally lower testosterone hydroxylase 
activity of liver microsomes fi*om the current study may have resulted in levels of 
these metabolites that were below the limits of detection of our assay.
Four unidentified peaks were detected in control incubation extracts that were not 
present in blank incubations (Figure 4.5). Firstly, an unidentified peak was detected 
that eluted between androstenedione and testosterone (peak X). Based on the 
published literature this peak might correspond to 17p-hydroxy-4,6-androstadiene-3- 
one (A^-T), which has previously been shown to elute from a C l 8  HPLC column 
between androstenedione and testosterone (Levin et al., 1987). Nagata et al. (1986) 
characterised this metabolite, which is formed by dehydrogenation o f testosterone to 
form a double bond between the C - 6  and C-7 positions. Nagata et al. (1986) provided 
evidence that conversion of testosterone to A^-T by rat liver microsomes is mediated 
by CYP-dependent pathways, possibly involving a CYP3A form. Consistent with our
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current findings for peak X, the formation of A^-T was previously shown to be 
enhanced in liver microsomes from PB- and PCN-treated rats (Nagata et ah, 1986). In 
the current study, peak X showed negligible absorbance at 240nm, which is consistent 
with the fact that A^-T has a maximum absorbance at 284nm (Nagata et ah, 1986).
Secondly, three unidentified peaks (peaks A, B and C) were present that eluted from 
the HPLC column after testosterone. The formation of these metabolites was 
negligible in the absence o f exogenous NADPH. The elution pattern o f these 
metabolites along with the fact that they were not detected on the UV-absorbance trace 
(monitored at 240nm) suggests that these peaks might correspond to reduced 
derivatives of testosterone. Reduced, metabolites known to be formed by rat liver 
microsomes include dihydrotestosterone (DHT) (catalysed by 5a-R), 3a-diol 
(catalysed by 3a-hydroxysteroid dehydrogenase (HSD)) and 3p-diol (catalysed by 3P- 
HSD) (Edwards et al, 1992). However, 4-MA was added to all incubations at a 
concentration that would be expected to completely inhibit the activity o f the 5a-R 
enzyme therefore DHT would not be expected to be present in these samples 
(Sonderfan & Parkinson, 1988). The identity of these three metabolites is currently 
unknown. One approach that could be used to confirm the identity of these peaks 
would be to collect each peak using a fraction collector and then analyse each fraction 
by mass spectrometry or NMR spectroscopy.
4.4.1.2 Effects of model inducers on hepatic testosterone metabolism
/3-Naphthoflavone (P-NF)
Treatment o f rats with p-NF had no significant effect on liver weight or microsomal 
protein content but produced a significant increase in the specific microsomal CYP 
content (1.5 fold), consistent with the published literature (Amacher & Schomaker, 
1998; Guengerich et al., 1982). Western blotting confirmed that P-NF treatment- 
produced a marked induction of CYP1A2 protein with no effects on CYP2B, 3A or 
4A1 protein levels. These findings are consistent with the published literature 
(Guengerich et al., 1982; Waxman et al., 1985; Wortelboer et al., 1991). Although not 
investigated in the current study, treatment of rats with p-NF has been reported to 
suppress hepatic CYP2C11 (-63%  of control) and 2C6 ( - 6 6 % of control) protein
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levels and to have no effect or cause a small induction of CYP2A1 protein 
(Guengerich et a l, 1982; Waxman et al., 1985).
p-NF produced a marked reduction in the formation of androstenedione, 2a- and 16a- 
OHT, indicating suppression of CYP2C11 (and possibly CYP2C6) protein levels 
(Waxman, 1984). p-NF also caused a significant reduction in the formation of two 
unidentified metabolites, peaks A and B. No statistically significant effects were 
observed on the remaining pathways of testosterone metabolism, consistent with the 
lack of effect of this compound on CYP2B or 3 A protein levels. The overall rate of 
formation of hydroxylated testosterone metabolites was significantly reduced in liver 
microsomes from p-NF-treated animals (78% of control).
The effects of P-NF on microsomal testosterone metabolism observed in the current 
study are generally in good agreement with the published literature, except that some 
groups report increases in 7a-hydroxylase activity and decreases in 6 p-hydroxylase 
activity (Lee & Park, 1989; Tredger et al., 1984; Wortelboer et al.,-1991). Such 
differences between the current data and the published literature is probably related to 
differences in strain, age, dosing regimen (e.g. dose, route, duration) and 
environmental factors (e.g. housing conditions, diet) which can influence the effects of 
inducers on testosterone metabolism.
Phénobarbital (PB)
Treatment of rats with PB was associated with significant increases in liver weight and 
specific microsomal CYP content (2.2 fold), consistent with the published literature 
(Guengerich et al., 1982; Amacher & Schomaker, 1998; Tredger et al., 1984). This 
compound had no significant effect on the hepatic microsomal protein yield. Western 
blotting confirmed that PB treatment caused a marked induction of CYP2B and a 
smaller increase in CYP3A proteins, consistent with the published literature 
(Guengerich et al., 1982; Waxman et al., 1985; Parkinson et al., 1992). Although not 
investigated in the current study, PB has been reported to induce hepatic CYP2A1 
(~2 fold) and CYP2C6 (-2.5 fold) and decrease CYP2C11 (-50% of control) protein 
levels in male rats (Guengerich et al., 1982; Waxman et al., 1985; Parkinson et al., 
1992).
141
Consistent with the results of Western blotting experiments, PB treatment produced a 
marked induction of microsomal testosterone 16p-hydroxylase activity (CYP2B) 
along with significant increases in 6 p-, ISp- and 2p-hydroxylase activity (CYP3A). 
The significant increase in testosterone 7a-hydroxylase activity and decrease in 2a- 
hydroxylase activity is consistent with the ability o f this compound to induce CYP2A1 
and suppress CYP2C11 respectively. A significant increase in the formation of the 
unidentified metabolite, peak X, was also observed. There was a trend towards an 
increase in the total rate o f hydroxylated testosterone metabolite formation in the PB- 
treated group (1.3 fold), but this did not reach statistical significance.
PB-treatment also induced the formation of metabolites that were not previously 
detected in control incubations (Figure 4.13). These metabolite peaks were present at 
relatively low levels and were poorly resolved using the current HPLC method, 
therefore they were not quantified. Based on their position on the chromatogram and 
comparison with the published literature, the peak(s) eluting between 16p- and 2 a - 
OHT might correspond to la-/p-O H T and/or 18-OHT (Purdon & Lehman- 
McKeeman, 1997). These metabolites are often poorly resolved by HPLC resulting in 
a composite peak and are reportedly induced following PB treatment (Purdon & 
Lehman-McKeeman, 1997). The identity of the second peak that elutes between 2^- 
OHT and androstenedione is currently unknown.
The effects o f PB on microsomal testosterone metabolism observed in the current 
study are generally in good agreement with the published literature, except that some 
other groups have reported increases in 16a-hydroxylase activity and androstenedione 
formation (Parkinson et al., 1992; Lee & Park, 1989). In the current study, there was a 
trend towards an increase in androstenedione formation but this did not reach 
statistical significance.
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Pregnenolone-16a-carbonitrile {PCN)
PCN-treated rats showed a trend towards increased liver weights but this did not reach 
statistical significance. PCN had no effect on the hepatic microsomal protein yield but 
produced a significant increase in the specific microsomal CYP content (1.9 fold), 
consistent with the published literature (Amacher & Schomaker, 1998; Guengerich et 
al., 1982; Hanoika et al., 1995). Western blotting confirmed that PCN treatment 
caused marked induction of CYP3A and a smaller increase in CYP2B protein levels, 
consistent with the published literature (Guengerich et al., 1982; Waxman et al., 
1985). Although not investigated in the current study, PCN has been reported to 
suppress hepatic CYP2A1 (-54% of control), CYP2C11 (-63%  of control) and 
CYP2C6 (-57% of control) protein levels in male rats (Waxman et al., 1985).
Consistent with the results of Western blotting experiments, PCN treatment produced 
a marked induction o f testosterone 6 p-, 15^- and 2p-hydroxylase activities (CYP3A) 
and a smaller induction of 16p-hydroxylase activity (CYP2B) although the latter did 
not reach statistical significance. Significant induction of 15a-hydroxylation was also 
observed, suggesting induction of CYP2A2. There was a trend towards reduced 
formation of androstenedione, 2a- and 16a-0HT, suggesting suppression of 
CYP2C11 (and possibly CYP2C6). PCN treatment also induced the formation o f the 
unidentified peak X and reduced the fomiation of peak A. There was a statistically 
significant increase in the total rate o f hydroxylated testosterone metabolite formation 
in the PCN-treated group (1.6 fold). PCN treatment also induced the formation of 
metabolites that were not previously detected in control incubations as discussed 
above for PB. The effects of PCN treatment on microsomal testosterone metabolism 
observed in the current study are consistent with the published literature (Duffy et al., 
1995; Sonderfan et al., 1987; Tredger et al., 1984).
Ciprofîbrate
Treatment of rats with ciprofibrate produced a marked increase in liver weight and 
hepatic microsomal protein yield, consistent with the published literature (Graham et 
al., 1994; Makowska et al., 1990). In the current study this compound had no 
significant effect on the specific microsomal CYP content. Makowska et al. (1990)
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reported that treatment of male rats with ciprofibrate for 14 days was associated with 
an increase in the specific microsomal CYP content o f liver microsomes at a low dose 
( 2  mg/kg/day) with no significant effect observed at the higher dose ( 2 0  mg/kg/day). •
Western blotting confirmed that ciprofibrate treatment caused marked induction of 
microsomal CYP4A1 levels, which was not found with any o f the other model 
inducers and is consistent with the published literature (Makowska et ah, 1990; Zangar 
et al., 1996). No effect was observed on the expression of CYP1A2 or 2B proteins. 
The effect of ciprofibrate on CYP3A was inconclusive due to technical difficulties 
with this Western blot (the lanes on the gel had merged). Several studies have 
reported reductions in CYPIA mRNA and associated catalytic activities (EROD and 
methoxyresorufin 0-dealkylase (MROD)) following treatment of Sprague Dawley rats 
with ciprofibrate (Makowska et al., 1990; Canivenc-Lavier et al., 1996; Gallagher et 
al., 1995). Similarly, reductions in CYP3A2 (-80%  of control) and CYP2C11 (-20% 
of control) mRNA levels have been reported following short-term (3 days) dietary 
exposure of rats to this compound (Gallagher et al., 1995). Conflicting data has been 
presented concerning the effects of ciprofibrate on CYP2B expression in male Sprague 
Dawley rats. Makowska et al. (1990) reported that treatment of rats with ciprofibrate 
(2 or 20 mg/kg/day) for 14 days was associated with a significant reduction in 
benzphetamine deaUcylation, a marker for CYP2B1/2. In contrast, a subsequent study 
reported significant increases in benzoxylresorufin 0-dealkylation (BROD) with no 
effect on CYP2B mRNA levels following 3 days dietary exposure to ciprofibrate 
(0.025% w/w) (Gallagher et al., 1995). Zangar et al. (1996) reported a significant 
increase in CYP2B mRNA and protein levels following treatment with ciprofibrate for 
5 days (20 mg/kg/day i.p.). These differences between studies are probably related to 
differences in animal age, dosing regimen (e.g. dose, route, duration) and 
environmental factors (e.g. housing conditions, diet) along, with the different end­
points measured (mRNA, protein, enzyme activity).
In contrast to the other three compounds, the effects o f ciprofibrate on microsomal 
testosterone metabolism have not been well characterised. The most prominent effect 
of ciprofibrate observed in the current study was induction of CYP4A1, which is 
mainly involved in fatty acid metabolism. The major effect o f ciprofibrate on
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microsomal testosterone metabolism was the marked reduction in the formation of 
androstenedione, 16a- and 2a-0H T, suggesting repression o f CYP2C forms. 
Ciprofibrate also produced a significant increase in testosterone 6|3-hydroxylase 
activity (CYP3A) and a decrease in the formation of the unidentified metabolite, 
peak A. Ciprofibrate treatment was associated with a significant reduction in the total 
rate of hydroxytestosterone metabolite formation (6 6 % of control).
4.4.2 Effects on testicular CYPs and testosterone metabolism
4.4.2.1 Organ weights
Treatment o f rats with the four model compounds had no significant effect on testis 
weights. Fahim et al. (1970) and Levin et al. (1974) also reported no significant 
changes in testis weights following treatment o f adult male rats with PB for 60 days 
(50 mg/kg/day i.p.) or 4 weeks (0.05% or 0.1 % in the diet) respectively.
4.4.2.2 Testosterone metabolism
Measurement o f  testosterone metabolism by testis microsomes
Due to the low levels o f CYP expression in the testis, pooled testis microsomes were 
prepared fi*om each treatment group to enrich the preparation for CYP enzymes. The 
major disadvantage o f this approach is that subtle changes might be lost due to 
interanimal variability in the levels of CYP expression and responses to drug 
treatment.
Testis microsomes showed low levels of testosterone hydroxylase activity, which 
presented a problem for the accurate quantification o f individual testosterone 
metabolites. Two factors determined the limit o f detection o f the current testosterone 
hydroxylase assay. The first factor involves discrimination of radioactive counts 
associated with a metabolite from the background counts (by radiochemical detection). 
The second factor involves discrimination o f metabolites that were formed by 
NADPH-dependent pathways from the peaks that were present in blank samples.
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The following metabolites were detected in incubation extracts from testis 
microsomes: 6a-0H T, 6P-0HT, 7a-0H T, peak Y and androstenedione.
Androstenedione formation was the major pathway catalysed by testis microsomes 
and this metabolite was formed at levels that were at least three times higher than the 
amount detected in the blank incubation, resulting in reliable quantification o f this 
metabolite. In contrast, 6P-0HT was present in incubation extracts at levels that 
provided a good signal to noise ratio with respect to radiochemical detection, but 
following subtraction of the blank only traces of this metabolite remained. This would 
mean that the quantification of 6p-0HT would be less accurate than that of 
androstenedione. Consistent with data from incubations with liver microsomes, 
following blank subtraction no 6a-0H T or peak Y were present in incubation extracts 
from testis microsomes. 7a-0H T  was not detected in blank samples but was present 
in incubation extracts at levels that were close to the limits of detection with respect to 
radiochemical detection, resulting in less accurate quantification o f this metabolite. 
These factors must be considered when interpreting the results from incubations with 
testis microsomes. The sensitivity of the current assay might be improved by 
measuring testosterone metabolism using a testicular fraction enriched with Leydig 
cells (e.g. purified using a percoll gradient). Most of the testicular CYP content is 
localised the Leydig cell population, which comprises less than 3% o f the total testis 
volume (Mori & Christensen, 1980).
The profile of metabolites detected in incubation extracts from control testis 
microsomes was consistent with previously published data for male Sprague Dawley 
rats (Sonderfan et al., 1989). In addition to the metabolites detected in the current 
study, Sonderfan et al. (1989) reported low levels of testosterone 16a-hydroxylase 
activity in testis microsomes. The testicular enzymes responsible for testosterone 7a- 
hydroxylation and androstenedione formation are CYP2A1 and 17p-HSD respectively 
(Sonderfan et al., 1989). In contrast, the testicular enzymes that catalyse the formation 
of 6 p- and 16a-0HT are unknown (Sonderfan et al., 1989).
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Effects o f model inducers on testicular testosterone metabolism
Following treatment of rats with the four model inducers no significant effect was 
observed on testicular testosterone 6p-hydroxylase activity, although reliable 
conclusions cannot be drawn due to the sensitivity problems discussed above. The 
apparent ability of PB and PCN to markedly induce hepatic but not testicular 6P- 
hydroxylase activity suggests that this pathway may exhibit tissue-specific sensitivity 
to the effects of chemical inducers. Indeed, much of the published literature indicates 
that testicular CYP enzymes are less sensitive to exogenous inducers than their hepatic 
counterparts (Goldstein & Linko, 1984; Omiecinski, 1986). Hydroxylation of 
testosterone at the 6p-position is predominantly catalysed by CYP3A forms in the 
liver but it is not known whether enzymes belonging to this subfamily also catalyse 
this pathway in the testis (Waxman et al., 1985; Sonderfan et al., 1989). When 
evaluating the effects o f inducers on the testis, consideration must be given to the 
cellular localisation of the enzyme of interest because the blood-testis barrier regulates 
the entry of substances in to the tubular compartment. However, testicular CYPs are 
predominantly localised to the Leydig cells which reside in the interstitial 
compartment, which is in direct contact with substances entering the testis in the blood 
or lymph (Mukhtar et al., 1978).
Treatment of rats with p-NF or PB had no statistically significant effects on testicular 
testosterone 7a-hydroxylase activity. In contrast, 7a-hydroxylase activity showed a 
small but statistically significant increase in ciprofibrate-treated animals and decrease 
in the PCN-treated group, although firm conclusions cannot be drawn due to the 
sensitivity problems discussed above. These compounds had no significant effects on 
the activity of this pathway catalysed by liver microsomes firom these animals. 
Hydroxylation of testosterone at the 7a-position is a developmentally-regulated 
pathway, which is predominantly catalysed by CYP2A1 in both the liver and testis 
(Levin et al., 1987; Wood et al., 1983; Sonderfan et al., 1989). Evidence has been 
presented supporting a potential role for 7a-hydroxylated androgens in the regulation 
o f testosterone biosynthesis therefore xenobiotic-induced alterations in the local 
formation of these metabolites might have important effects on the testis (Inano et al., 
1973; Seng et al., 1991). In addition, there is evidence to support a potential role for
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high testicular CYP2A1 expression in the aetiology of spontaneous Leydig cell 
hyperplasia in rodents (see 1.5.3) (Seng et al., 1996).
Treatment of rats with all four compounds was associated with significant increases in 
androstenedione formation catalysed by testis microsomes. The conversion of 
testosterone to androstenedione by liver microsomes is catalysed by CYP-dependent 
(CYP2B and CYP2C forms) and CYP-independent (17p-HSD) pathways (Wood et 
al., 1983; Sonderfan et al., 1987; Martel et al., 1992). 17P-HSD has also been 
reported to catalyse this pathway in the testis (Sonderfan et al., 1989). Several distinct 
17P-HSD enzymes have been identified, which differ in their substrate specificity, 
cofactor requirements, preference for oxidative or reductive reactions and tissue 
distribution (reviewed by Peltoketo et al., 1999). The forms that catalyse the oxidation 
of testosterone to form androstenedione preferentially use NAD"  ^as the cofactor. For 
the current study, exogenous NAD(P)^ was not added to microsomal incubations 
therefore 17P-HSD would not be expected to make a significant contribution to the 
formation of androstenedione. The majority o f the androstendione formation was 
dependent upon the addition of exogenous NADPH, suggesting that CYP enzymes 
might catalyse this pathway in testis microsomes. Androgens show higher activity in 
the 17p-hydroxy form therefore the conversion of testosterone to androstenedione is 
predominantly considered to represent a catabolic pathway. Consequently, the ability 
o f the model inducers to enhance the activity of this pathway might reduce the local 
concentration of active androgen in the testis.
4.4.3 Effects on plasm a horm one levels
No statistically significant changes in plasma hormone levels were observed following 
treatment of rats with the four, model inducers. This may reflect the true situation but 
subtle changes might not have been detected due to a number of factors. Firstly, the 
timing of blood samples relative to the last dose drug would be expected to affect the 
magnitude of changes in serum hormone levels observed. In the current study, blood 
samples were collected approximately 24 hours after the final dose, by which time 
plasma hormone levels might have been returning towards the normal range 
depending on the half-life o f the drug.
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Secondly, significant “time of day” variations in circulating hormone levels occur in 
rats. Circulating testosterone levels show a diurnal rhythm with the most pronounced 
peak in hormone levels occurring during the dark periods (-23 3Oh) with a smaller 
peak during the light period (-1300h) (Keating & Tcholakian, 1979). The least 
variations in testosterone concentrations are reportedly observed during the morning 
(Keating & Tcholakian, 1979). Circulating FSH levels show a distinct circadian 
rhythm with relatively stable concentrations between 0130 and 1330h and a 
pronounced peak between 1630 and 2130h (Kalra & Kalra, 1977). Clearly, the timing 
of blood samples would influence the levels of testosterone and FSH measured, 
therefore for the current study (and all other studies conducted as part o f this project) 
blood samples were collected between 1000 and 1200h to minimise these effects. In 
addition, circulating LH levels measured at a single timepoint show a high degree of 
variability due to the pulsatile pattern o f LH secretion from the pituitary gland (Ellis & 
Desjardins, 1982).
Finally, circulating hormone levels show marked interanimal variability in rodents, 
which often confounds the detection of statistically significant changes following 
xenobiotic exposure. Wilson et al. (1999) postulated that due to this problem, subtle 
disturbances of steroid hormone homeostasis might remain undetected until more 
profound irreversible effects are manifested. A high degree of intragroup variability in 
plasma hormone levels was apparent in the current study, particularly with respect to 
plasma testosterone concentrations (Figure 4.1). This variability along with the small 
sample sizes used, might have obscured the detection o f statistically significant 
changes in plasma hormone levels.
There is a lack of information in the published literature concerning the effects o f the 
four inducers on steroid homeostasis in rats. Consistent with the current findings, 
Yeowell et al. (1987) reported no significant changes in serum testosterone levels in 
adult male Sprague Dawley rats following treatment with PB (80 mg/kg/day i.p.) for 
one, three or five consecutive days. This study was similar to the current study in that 
the blood samples were collected 24 hours after the final dose of PB.
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4.4.4 Conclusions
The effects of dosing rats with the four model inducers on hepatic CYP-dependent 
testosterone metabolism have been characterised and the current findings are generally 
in good agreement with the published literature. Each model compound exerted 
differential effects on the pathways of testosterone oxidation catalysed by liver 
microsomes, inducing the activity of certain pathways whilst suppressing or having no 
effect on other pathways. Interestingly, all four compounds caused suppression of 
testosterone 2a-hydroxylase activity, albeit to different extents. This pathway is 
catalysed by CYP2C11, which is the major constitutive CYP ( -  40% total hepatic 
CYP) found in male rat liver (Guengerich et al., 1982). Yeowell et al. (1987) reported 
that the reduction in hepatic CYP2C11 levels observed following treatment of rats 
with PB or 3-methylcholanthrene was due to a decrease in protein synthesis. The 
physiological functions of constitutive CYP forms have not been fully elucidated. 
Waxman (1984) postulated that CYP2C11 probably makes a substantial contribution 
to the overall rate of testosterone oxidation in rat liver but might also be responsible 
for the formation of specific hydroxylated metabolites with important physiological 
functions. Changes in CYP2C11 expression following xenobiotic exposure might 
therefore have important physiological implications for the animal.
Each model inducer altered the total rate of hydroxylated testosterone metabolite 
formation catalysed by liver microsomes, but no significant impact was observed on 
circulating testosterone levels. This might be due to compensatory changes in the 
activity o f other pathways o f testosterone metabolism (e.g. reductive pathways, ST 
and UDP-GT), resulting in no effect o f these compounds on the overall rate o f 
testosterone clearance in vivo. Consistent with this hypothesis, treatment o f humans 
with Y-phenylbarbital produces a significant increase (> 60%) in the urinary excretion 
of polar testosterone metabolites but has no significant effect on the plasma clearance 
of testosterone (Bammel et al., 1992). Alternatively, initial effects of these 
compounds on circulating testosterone levels may be rapidly compensated for through 
changes in the rate of testosterone biosynthesis and/or secretion from the testis. Such 
homeostatic regulation might be sufficient to maintain normal circulating hormone 
levels despite the xenobiotic-induced changes in the rate o f metabolic clearance of 
testosterone. Indeed, Stripp et al. (1974) reported that treatment o f rats with PB had
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no effect on seminal vesicle weight suggesting that the ability o f this compound to 
increase hepatic testosterone hydroxylation could be counterbalanced by changes in 
androgen biosynthesis and/or other pathways o f testosterone metabolism.
The effects of the model inducers on the pathways o f testicular CYP-dependent 
testosterone metabolism have been studied, although the low levels o f testosterone 
hydroxylase activity present in this tissue confounded the accurate quantification of 
testosterone metabolites. The magnitude o f the changes in testicular testosterone 
hydroxylase activity observed in the current study would not be expected to have a 
significant impact on the overall rate of androgen clearance from the body, but might 
have important local implications for androgen homeostasis within the testis.
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Chapter 5
Effect of lansoprazole on cytochromes P450, testosterone metabolism
and plasma hormone levels
5.1 Introduction
Lansoprazole was selected as the model compound for studies designed to investigate 
the existence of a liver-testis axis as it induces hepatic CYPs involved in testosterone 
metabolism and chronic exposure produces LCTs in rats (Masubuchi et ah, 1997a; 
Atkinson et al., 1990). This chapter describes initial work to characterise the effects of 
dosing male rats with lansoprazole on CYP expression, microsomal testosterone 
metabolism and the endocrine control of the testis. The main objective of this study 
was to investigate the effects of lansoprazole on hepatic CYP-dependent testosterone 
metabolism and plasma hormone levels. In addition, experiments were performed to 
determine whether this compound also influenced testicular CYP-dependent 
testosterone metabolism, which might play a role in LCT induction.
5.2 Study design
Male Sprague Dawley rats were dosed once daily with lansoprazole (150mg/kg/day) 
or vehicle (0.5% (w / v) CMC) by oral gavage for 14 days. This dose was selected as 
it has previously been shown to reduce serum testosterone levels and increase 
circulating LH levels in male rats (Fort et al., 1995). On day 15, blood samples were 
collected and liver and testis microsomes were prepared. More detailed experimental 
details concerning animal treatment, sample collection and the analytical methods 
used for this study can be found in chapter 2 .
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5.3 Results
5.3.1 Body, liver and testes weights
Final body weights and relative liver and testes weights for control and lansoprazole- 
treated animals are shown in Table 5.1.
Table 5.1 : Effect o f lansoprazole treatment on relative liver and testes weights
Control Lansoprazole-treated
Final body weight (g) 353.6 ±17.5 328.9 ±16.0 **
Relative liver weight
(g/lOOg body weight)
4.14 ±0.24 4.53 ± 0.42 *
Relative testes weight
(g/lOOg body weight)
0 . 8 6  ±0.06 0.94 ± 0 .0 7 *
Results are expressed as mean ± SD for control (n=l 1) and lansoprazole-treated (n=14) animals. 
Statistical analysis was performed using a Student’s t-test where asterisks (*) represent: * P<0.05, 
**P<0.01.
There were no statistically significant differences in initial body weights between 
experimental groups (data not shown) but final body weights o f lansoprazole-treated 
animals were significantly lower than the control group (P<0.01). During the 14 day 
dosing period, body weight gain was significantly lower (P<0.01) in drug-treated 
animals compared to controls from day 4 of dosing onwards (data not shown). There 
were no significant differences in absolute organ weights (data not shown) between 
the experimental groups, but significant increases in relative liver and testes weights 
were observed in lansoprazole-treated animals compared to the control group 
(P<0.05).
5.3.2 Plasma hormone levels
Blood samples were collected (-18 to 20 hours after the final dose) and assayed for 
plasma testosterone, LH, FSH and prolactin levels by radioimmunoassay (Figures 5.1 
and 5.2). Lansoprazole treatment was associated with a significant reduction in 
plasma testosterone levels compared to control group (P<0.05). No statistically 
significant changes in plasma FSH, LH or prolactin levels were observed.
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Figure 5.1: Plasma testosterone levels in control and lansoprazole-treated rats
Cortrol(n=11) Lansopra2Dle4r60ted (rfe14)
Each bar represents the mean ± SEM from control (n=l 1) or lansoprazole-treated (n=14) animals. 
Statistical analysis was performed using a Student’s t-test where an asterisk (*) represents; * P<0.05.
Figure 5.2: Plasma prolactin, follicle-stimulating hormone and luteinising hormone 
levels in control and lansoprazole-treated rats
E3 C ontro l
L a n so p r a z o le - tr e a te d
Hormone
Each bar represents the mean ± SEM from control (n=l 1) or lansoprazole-treated (n=14) animals.
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5.3.3 Protein content of liver and testis microsomes
The protein content of liver and testis microsomes prepared from control and 
lansoprazole-treated animals are shown in Table 5.2.
Table 5.2: Effect of lansoprazole treatment on the protein yields o f liver and testis 
microsomes
Treatm ent group Liver protein yield
(mg/g liver)
Testicular protein yield
(mg/g testis)
Control 16.02 ±3.12 3.53
Lansoprazole 14.53 ±2.47 3.39
Results are expressed as mean ± SD from individual liver microsomal preparations from control (n=l 1) 
and lansoprazole-treated (n=l4) animals. Protein yields are shown for pooled testis microsomes from 
control and lansoprazole-treated groups. ,
There were no statistically significant differences in hepatic protein yields between 
experimental groups. Due to the fact that the testis samples were pooled, it was not 
possible to assess the statistical significance o f any differences in microsomal protein 
yields between experimental groups.;
5.3.4 Total CYP conteiit of liver microsomes
The specific CYP contents o f liver microsomes from control and lansoprazole-treated 
animals are shown in Table 5.3. Due to low levels of expression in the testis it was 
not possible to measure the total CYP content of testis microsomes from this study.
Table 5.3: Effect of lansoprazole treatment on the total cytochrome P450 content of 
liver microsomes
Treatm ent group Microsomal P450 content
(nmol/mg microsomal protein)
Control 1.36 ±0.18 .
Lansoprazole 1.62 ± 0 .18**
Results are expressed as mean ± SD from individual microsomal preparations from control (n=l 1) and 
lansoprazole-treated (n=13) groups. Statistical analysis was performed using a Student’s t-test where 
asterisks (*) represent: ** P<0.01.
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5.3.5 Microsomal testosterone metabolism
Testosterone metabolism by liver and pooled testis microsomes from control and 
lansoprazole-treated rats was determined using the optimised HPLC-based 
testosterone hydroxylase assay described in chapter 3.
5.3.5.1 Testosterone metabolism by liver microsomes
Control profile
Control liver microsomes metabolised testosterone to form up to fourteen peaks, nine 
of which were identified by co-chromatography with authentic standards (namely 
androstenedione, 6 a-, 6(3-, 7a-, 16a-, 16p-, 2a-, 2p- and 15a-0HT). Five 
unidentified peaks (peak X, Y, A, B and C) were detected in all control samples, as 
previously discussed in Chapter 4. The major oxidation products identified in control 
incubations were androstenedione, 2a-, 16a- and 6p-0HT. Smaller amounts o f 7a-, 
2p- and 6a-0H T  were also detected. 16P-0HT was detected in the majority of 
samples and traces of 15a-0H T were detected in a small number o f control incubation 
extracts.
Peaks corresponding to androstenedione, peak Y, 6 a - and 6P-0HT were detected in 
blank incubations, consistent with data from the model inducers study (chapter 4). 
This was corrected for by subtracting the amount o f each metabolite detected in the 
blank sample from the amount detected in the corresponding standard incubation 
(containing NADPH) prior to the calculation o f enzyme activity. Following the 
subtraction of blanks, no 6a-0H T  or peak Y were detected.
Effect o f  lansoprazole treatment on hepatic testosterone metabolism
The effects o f treating rats with lansoprazole on testosterone metabolism by liver 
microsomes are shown in Figure 5.3. Lansoprazole treatment produced a statistically 
significant increase in the activity of several pathways of testosterone metabolism. No 
significant effects were observed on the formation o f any o f the unidentified 
metabolites. Lansoprazole treatment significantly enhanced the total rate o f formation 
of hydroxytestosterone metabolites by liver microsomes (P<0.001).
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5.3.S.2 Testosterone metabolism by testis microsomes
Control profile
Pooled testis microsomes metabolised testosterone to form the major metabolites 
androstenedione and 6p-0HT, along with traces of 6 a-, 7a-, 16a- and 2a-0H T. The 
unidentified peak Y was present in all samples, however previous studies indicate that^ 
this compound probably represents a contaminant that is present in the 
^"^C-testosterone (chapter 4).
Peaks corresponding to androstenedione, peak Y, 6 a - and 6P-0HT were detected in 
blank incubations, consistent with data from the model inducers study (chapter 4). 
This was corrected for by subtracting the amount o f each metabolite detected in the 
blank sample from the amount detected in the corresponding standard incubation 
(containing NADPH) prior to the calculation of enzyme activity. Following the 
subtraction of blanks no 6a-0H T  or peak Y were detected.
Effect o f  lansoprazole on testicular testosterone metabolism
Treatment o f rats with lansoprazole produced no statistically significant effects on the 
pathways of testosterone metabolism catalysed by testis microsomes, as shown in 
Figure 5.4. Testosterone 16a- and 2a-hydfoxylase activities were very low in testis 
microsomes and consequently these metabolites were not detected in all incubation 
extracts. Consequently, it was not possible to draw any conclusions concerning the 
effects of lansoprazole on these pathways.
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Figure 5.4: The effect of treatment of rats with lansoprazole on testosterone 
metabolism by testis microsomes
140
120
100
B60
6beta-OHT 7alpha-0HT 16alpha-0HT
Metabolite
2alpha-0HT And.
E Control
■ Lansoprazole- 
treated
Each bar represents the mean ± SEM from triplicate incubations with pooled testis microsomes from 
control or lansoprazole-treated animals. 16a- and 2a-0H T were not detected in all three incubations 
using microsomes form lansoprazole-treated animals therefore SEM values could not be calculated.
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5.3.6 ELISA
The levels of CYP proteins in liver microsomes from control and lansoprazole-treated 
animals were quantified by ELISA and the results are shown in Table 5.4,
Table 5.4: ELISA quantitation of CYP proteins in liver microsomes from control and 
lansoprazole-treated animals
Anti-CYP CYP content (pmoles/mg protein) Fold change
Control Lansoprazole
CYPIA 5.2 ±1.3 51.8 ±24.6 *** 9.9
CYP2B 31.2 ±3.2 47.5 ± 9.6 *** 1.5
CYP3A 19.6 ±4 .0 27.3 ±8 .0  ** 1.4
CYP4A 1 1 . 2  ± 2 . 0 21.9 ±6.5 *** 2 . 0
Results are expressed as mean ± SD from individual microsomal preparations from control (n=l 1) and 
lansoprazole-treated (n=13) groups. Fold changes were calculated by dividing the mean value in the 
lansoprazole-treated group by the mean value in the control group. Statistical analysis was performed 
using a Student’s t-test where asterisks (*) represent: ** P<0.01, ***P<0.001.
5.3.7 W estern blotting
5.3.7.1 Liver microsomes
The levels o f CYP proteins in liver microsomes from control and lansoprazole-treated 
rats were compared by Western blotting, as described in 2.2.11. Expression of 
CYPIA, 2B and 3A proteins were examined as these forms show testosterone 
hydroxylase activity. The identity of each protein was confirmed based on the 
literature molecular weight and . co-migration with the positive control sample. 
Ponceau S staining of nitrocellulose membranes confirmed even loading of protein on 
to each gel (data not shown). .
CYPIA
C Y PlA l protein was not detected in liver microsomes from control animals but 
induction of this protein was observed in liver microsomes from the lansoprazole-
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Figure 5.5: Western blot o f rat liver microsomes developed with anti-rat CYPl A2
primary antibody.
Lane 1 2 3 4 5 6 7
58100
39800
5|ag microsomal protein was loaded in each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from isosafrole-treated rats
Lanes 3-5, Liver microsomes from three individual control animals
Lanes 6-8, Liver microsomes from three individual lansoprazole-treated animals
Figure 5.6: Western blot of rat liver microsomes developed with anti-rat CYP2B 
primary antibody.
Lane 1
58100
39800
5pg microsomal protein was loaded in each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from phenobarbital-treated rats
Lanes 3-5, Liver microsomes from three individual control animals
Lanes 6-8, Liver microsomes from three individual lansoprazole-treated animals
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treated group (data not shown). Constitutive expression of CYP1A2 protein was 
detected in control liver microsomes and this protein was clearly induced in 
lansoprazole-treated animals (Figure 5.5). The positive control sample used for 
CYP1A2 showed a faint or undetectable band in this experiment. The reasons for this 
are unknown.
CYP2B
Anti-CYP2B detected two distinct bands in liver microsomes from control and 
lansoprazole-treated animals (Figure 5.6). The higher molecular weight protein was 
detected as a faint band present in all samples with only minor iriteranimal variability 
in levels o f expression. The lower molecular weight protein was detected as a faint 
band in control animals and was induced in lansoprazole-treated rats. This protein 
appeared to show interanimal variability in the both the constitutive levels of 
expression and extent o f induction. The smaller protein co-migrated with the positive 
control sample (PB-induced rat liver microsomes). These findings together with the 
published literature suggest that the higher and lower molecular weight proteins 
correspond to CYP2B2 and CYP2B1 respectively (Wilson et al., 1987). The 
polyclonal anti-CYP2B primary antibody used in the current study would recognise 
CYP2B1 and 2B2 as these proteins share 97% amino acid sequence homology (Yuan 
et al., 1983). CYP2B1 and 2B2 can be distinguished due to slight differences in 
migration on SDS-polyacrylamide gels, depending on the specific conditions used 
(Wilson et al, 1987).
CYP2A
A  number of problems were encountered when Western blots were performed to 
detect CYP3A protein in liver microsomes from the current study. Initially, anti- 
CYP3A detected a single band present in microsomal samples from control and 
lansoprazole-treated animals (Figure 5.7). This band had a higher molecular weight 
than the positive control sample therefore the identity of this protein was unknown. 
No bands co-migrating with the positive control were detected. These bands might 
have been detected due to the anti-CYP3A primary antibody cross-reacting with 
another CYP protein. This polyclonal primary antibody would be expected to cross- 
react with other CYP3A proteins that are expressed in rat liver (CYP3A9, 3A18 and
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Figure 5.7: Western blot of rat liver microsomes developed with anti-rat CYP3A
primary antibody.
Lane 1 2 3 4 5 6 7
58100
39800
5|ag microsomal protein was loaded in each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from dexamethasone-treated rats
Lanes 3-5, Liver microsomes from three individual control animals
Lanes 6-8, Liver microsomes from three individual lansoprazole-treated animals
Figure 5.8: Western blot of rat liver microsomes developed with anti-rat CYP3A 
primary antibody.
Lane 1 2 3 4 5 6 7
58100
39800 ------ ►
lOpg microsomal protein was loaded in each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from dexamethasone-treated rats 
Lanes 3 & 4, Liver microsomes from two individual control animals 
Lane 5, Liver microsomes from a PCN-treated animal (model inducers study) 
Lanes 6-8, Liver microsomes from three individual lansoprazole-treated animals
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3A23). However, this band is unlikely to correspond to a CYP protein as it has a 
molecular weight greater than 58,00 daltons. The possibility that the higher molecular 
weight bands were detected due to non-specific binding of the secondary antibody was 
investigated by stripping the blots of primary antibody and re-probing with secondary 
antibody and streptavidin-HRP complex alone. No bands were detected under these 
conditions (data not shown).
The CYP3A blots were repeated to determine whether the higher molecular weight 
bands could be detected reproducibly. In this experiment, the positive control band 
was present, confirming that the immunodetection procedure had worked, but no 
CYP3A protein was detected in any of the microsomal samples (data not shown). The 
higher molecular weight bands were not detected in this experiment, therefore the 
identity o f the protein(s) detected in the previous experiment was not investigated 
further.
The amount of microsomal protein loaded on to the gel was increased firom 5pg to 
lOpg per lane to determine whether there was a sensitivity problem. A lane 
containing liver microsomes from a PCN-treated animal (firom the model inducer 
study) was included on each blot as an additional positive control. CYP3A protein 
was detected as a bright band in liver microsomes from the PCN-treated animal 
(Figure 5.8). Faint bands corresponding to CYP3A protein were detected in 
microsomes firom control and lansoprazole-treated animals, although this protein was 
present at very low levels and was not detected in some samples. These Western blots 
indicate that lansoprazole did not have a marked effect on the expression o f CYP3A 
protein. However, subtle effects o f this compound on CYP3A protein levels might 
have been missed due to the low and sometimes undetectable levels o f this protein in 
microsome samples firom this study.
Finally, an experiment was performed to test an anti-CYP3A2 primary antibody from 
a different supplier (Gentest). Gels were loaded with positive control samples and 
liver microsomes from both the lansoprazole study and model inducer study (Figure 
5.9). CYP3A2 was easily detected in liver microsomes firom a control animal from the 
model inducers study and this protein was markedly induced in PCN-treated animals.
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Figure 5.9: Western blot of rat liver microsomes developed with anti-rat CYP3A2
primary antibody from Gentest.
Lane 1 7
lOjLig microsomal protein was loaded in each lane.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from dexamethasone-treated rats (Amersham) 
Lane 3, Positive control liver microsomes from PB-treated rats (Gentest)
Lane 4, Liver microsomes from a control animal from the lansoprazole study 
Lane 5, Liver mierosomes from a lansoprazole-treated animal 
Lane 6, Liver mierosomes from a eontrol animal from the model inducers study 
Lane 7, Liver microsomes from a PCN-treated animal from the model inducers study.
Figure 5.10: Western blot of rat testis microsomes developed with anti-rat CYP4A1 
primary antibody.
Lane 1 2 3 4 5 6 7 8
58100
39800 ------ ►
The amount of microsomal protein loaded in to each lane is shown in brackets.
Lane 1, Molecular weight markers
Lane 2, Positive control liver microsomes from clofibrate-treated rats 
Lane 3 & 4, Pooled testis microsomes from control group (98pg protein)
Lane 5, Pooled testis mierosomes from control group (40pg protein)
Lane 6, Pooled testis microsomes from lansoprazole-treated group (45pg protein)
Lanes 7 & 8, Pooled testis microsomes from lansoprazole-treated group (113pg protein)
1 6 6
In contrast, faint bands corresponding to CYP3A2 protein were detected in liver 
microsomes from control and lansoprazole-treated animals, only following long 
exposures of the blot to the film (5 minutes). It was not possible to draw reliable 
conclusions concerning the effects of lansoprazole on CYP3A levels from these blots 
due to the low levels of expression of this protein and the small number of samples 
investigated (one control and one lansoprazole-treated animal). In addition, further 
experiments would be required to optimise the concentrations of primary and 
secondary antibodies used.
5.3.7.2 Testis microsomes
Western blotting with testis microsomes failed to detect any CYP3A or CYP2B- 
immunoreactive protein despite loading maximum amounts o f protein on to the gels 
(data not shown). CYP4A1 was detected in testis microsomes from control and 
lansoprazole-treated animals (Figure 5.10). Due to uneven protein loading it was not 
possible to conclude whether testicular CYP4A1 had been induced by lansoprazole 
treatment.
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5.4 Discussion
5.4.1 Final body and organ weights
Treatment of rats with lansoprazole was associated with lower body weight gain 
during the dosing period leading to a statistically significant reduction in final body 
weights compared to the control group (P<0.01). Lansoprazole treatment 
(> 50 mg/kg/day) has previously been found to produce a dose-dependent decrease in 
body weight gain associated with reduced food consumption in short- and long-term 
toxicity studies (Unpublished reports by Takeda Chemical Industries Ltd., Report 
numbers: A-29-167; A-29-452; A-29-438). In contrast, other studies have reported no 
consistent drug-related changes in these parameters at the same dosages (Unpublished 
reports by Takeda Chemical Industries Ltd., Report numbers: A-29-168; A-29-345). 
In the current study, all animals were examined daily for clinical signs related to 
treatment and appeared healthy throughout the dosing period.
Relative liver weights were significantly higher in lansoprazole-treated animals 
compared to the control group (-109% o f control) (P<0.05), however no change in 
absolute liver weights were observed. This apparent increase in relative liver weights 
might be an artefact due to the significant reduction in final body weights o f drug- 
treated animals. However, lansoprazole treatment (> 50  mg/kg/day for 4 weeks) has 
previously been shown to cause a dose-dependent increase in relative liver weights in 
male Wistar rats (Unpublished report by Takeda Chemical Industries Ltd., Report 
number A-29-167). Histopathological examination o f livers from lansoprazole-treated 
animals revealed a small increase in smooth endoplasmic reticulum of the 
centrilobular hepatocytes (Unpublished reports by Takeda Chemical Industries Ltd., 
Report number A-29-168). In the current study, lansoprazole had no significant effect 
on the hepatic microsomal protein yield but produced a significant increase in the 
specific microsomal CYP content (-1.2 fold) (P<0.01). These findings are consistent 
with the effects reported in female rats following 7 days of lansoprazole 
administration (300 mg/kg/day) (Masubuchi et al., 1997a).
Relative testes weights were significantly higher in lansoprazole-treated animals 
compared to the control group (P<0.05), but this was probably related to the reduced 
final body weights of drug-treated animals as previously discussed; ^  contrast to the
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current data, Fort et al. (1995) reported a significant reduction in testicular weights 
(-20% decrease) in rats treated with lansoprazole (150 mg/kg/day) for four weeks.
5.4.2 Effect of lansoprazole on hepatic CYP proteins
Two complementary techniques, namely ELISA and Western blotting, were employed 
to compare the levels of expression of CYP proteins in liver microsomes from control 
and lansoprazole-treated animals. The ELISA method was useful as it provided 
numerical data allowing statistical comparisons to be performed. The major 
disadvantage associated with this technique is that it is not possible to confirm that the 
antibody is only cross-reacting with the specific protein of interest. During the 
optimisation o f the ELISA method the binding specificity o f the anti-CYP primary 
antibodies was confirmed by Western blotting (see chapter 3). However, these results 
can only be used as a guide due to potential differences in antibody-antigen 
interactions between the denatured protein samples used for Western blotting and the 
solubilised proteins used for the ELISA. Western blotting was used in the current 
study to provide qualitative data concerning the effects o f lansoprazole on CYP 
expression with the advantage that the identity of the protein ' o f interest could be 
confirmed based on the molecular weight.
Lansoprazole treatment was associated with statistically significant increases in the 
expression of proteins belonging to the CYPIA (9.9 fold), 2B (1.5 fold), 3 A (1.4 fold)
and 4A (2 fold) subfamilies as determined by ELISA. Lansoprazole treatment had the
;
most prominent effect on CYPIA expression and Western blotting experiments 
confirmed that this compound induced both C Y PlA l and 1A2 protein levels. 
Western blotting also confirmed that lansoprazole induced CYP2B1, with little effect 
on CYP2B2 protein levels.
Liver microsomes from this study contained low or undetectable levels of CYP3A 
protein, as determined by Western blotting (Figures 5.8 and 5.9). The band 
corresponding to CYP3A that was detected in liver microsomes using the polyclonal 
anti-CYP3A antibody is likely to be composed of at least two proteins, namely 
CYP3A1 and 3A2, which have previously .been shown to co-migrate on SDS- 
polyacrylamide gels (Gemzik et al., 1992). According to the published literature
169
CYP3A2 is constitutively expressed at measurable levels whereas CYP3A1 is difficult 
to detect in liver microsomes from control animals (Cooper et al., 1993; Debri et al., 
1995). Western blotting data indicated that lansoprazole treatment had no marked 
effect on CYP3A protein levels, although subtle effects might have been missed due to 
the low levels of expression in liver microsomes from this study. These findings are 
inconsistent with the results obtained using the testosterone hydroxylase assay where 
lansoprazole treatment produced a statistically significant increase in microsomal 
testosterone 6 p-hydroxylase activity (1.4 fold), which is a more sensitive indicator of 
CYP3A expression. In addition, a significant increase in CYP3A protein levels 
(1.4 fold) was detected in liver microsomes from lansoprazole-treated animals 
compared to the control group by ELISA. Together these findings indicate that 
lansoprazole treatment caused a modest induction o f hepatic CYP3A proteins and 
associated catalytic activity, which was not detected by Western blotting. One 
possible explanation for the inconsistencies in the data obtained using the testosterone 
hydroxylase assay and the ELISA compared to Western blotting might be related to 
differences in the microsome processing required for these methods. On a Western 
blot, the primary antibody interacts with a denatured protein sample. Consequently, 
the processing required to denature the liver microsomes might have resulted in loss of 
the epitope(s) in the CYP3A proteins leading to reduced antibody binding. In 
contrast, the microsomal proteins are retained in a native conformation for the 
testosterone hydroxylase assay and the ELISA.
In conclusion, lansoprazole induced several CYP proteins across the CYPIA, 2B, 3A 
and 4A subfamilies and data from the testosterone hydroxylase assay suggests that this 
compound might also induce CYP2A (7a-hydroxylase activity) and CYP2C forms 
(2a-hydroxylase activity) in male rats. These findings are in agreement with 
previously published data for female Sprague Dawley rats (Masubuchi et al., 1997a). 
Treatment of female rats with lansoprazole (300 mg/kg/day) for 7 days increased the 
expression of CY PlA l (9.3 fold), 1A2 (6.3 fold), 2B1 (2.7 fold), 2B2 (2.4 fold), 2C6 
(2 fold), 3A2 (3 fold) and 4A1 (1.8 fold) proteins in liver microsomes (Masubuchi et 
al., 1997a). However, most o f these CYP forms show sex-dependent expression 
therefore it is not possible to directly compare male and female derived data. The 
ability o f lansoprazole to induce the expression of CYPs across at least four families
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suggests that this compound might represent a distinct type o f “mixed inducer”, as no 
other published examples o f compounds with this property could be identified.
A number of agents have been identified that induce CYP forms across three families, 
such as phenothiazine, indole-3-carbinol (13C), (methylthio) methylpyrazine (MTMP) 
and flavastatin. Phenothiazine and 13 C both induce hepatic CYPs belonging to the 
CYPIA, 2B and 3 A subfamilies in male rats, however 13 C itself might not be entirely 
responsible for the effects observed on the hepatic CYP complement (Tateishi et al., 
1999; Stresser et al., 1994). Following oral administration, 13C is transformed at 
gastric pH to a number o f condensation products (e.g. diindolylmethane and 2,3-bis 
(3-indolylmethyl)indole) and there is evidence to support a role for these derivatives in 
mediating at least some of the effects on the hepatic CYP complement (De Kruif et al., 
1991; Wortelboer et al., 1992; Renwick et al., 1999). Treatment o f male rats with the 
pyrazine derivative, MTMP, is associated with induction of CYP2B1, 3A and 2E1 
(Japenga et al., 1993). Fluvastatin treatment has been shown to induce the hepatic 
expression of C Y PlA l, 2B1/2 and 4A proteins with no effect on CYP3A levels in 
male rats (Kocarek & Reddy, 1996).
5.4.3 Effect of lansoprazole on hepatic testosterone metabolism
The profile of metabolites detected in incubation extracts from control liver 
microsomes from the current study was in good agreement with previously published 
data for male Sprague Dawley rats (Purdon & Lehman-McKeeman, 1997; Parkinson 
et al., 1992). Liver microsomes from this study showed higher absolute rates o f 
testosterone hydroxylation compared to samples from the model inducers study 
(Chapter 4), particularly with respect to 6 p-hydroxylase activity.
Treatment o f rats with lansoprazole produced significant increases in the activity of 
several pathways o f testosterone oxidation catalysed by liver microsomes. Increases 
in testosterone 6 p* and 2p-hydroxylase activities were consistent with CYP3A 
induction as previously discussed. Increased testosterone 16p-hydroxylase activity 
reflects induction of CYP2B, consistent with Western blotting and ELISA data. This 
compound also increased the rate of hydroxylation at the 7a- and 2a- positions.
171
suggesting induction of CYP2A and CYP2C forms respectively. This compound did 
not exert a large effect (< 2  fold induction) on any of the pathways studied but 
produced a generalised increase in the activity of several pathways of testosterone 
oxidation. This resulted in a significant increase in the total rate of 
hydroxytestosterone metabolite formation (-30% higher than controls) by rat liver 
microsomes from lansoprazole-treated animals (P<0.001), suggesting that this 
compound might have the potential to increase the rate of metabolic clearance of 
testosterone m vfvc>.
5.4.4 Effect of lansoprazole on testicular CYP proteins
Western blotting with testis microsomes resulted in the detection o f low levels of 
CYP4A1 protein. Due to uneven protein loading on the gel it was not possible to 
draw firm conclusions as to whether lansoprazole treatment altered the expression of 
testicular CYP4A1. However, the differences in protein loading were relatively small 
(98pg and 113pg/lane for control and lansoprazole groups respectively) therefore 
lansoprazole treatment did not appear to have any marked effects on CYP4A1 
expression in the testis.
Consistent with the published literature, CYP2B and CYP3A were not detected in 
testis microsomes by Western blotting (Bengtsson et al., 1990; Seng et al., 1996). 
This may be due to the fact that CYP2B and CYP3A proteins are not expressed in the 
testis or these forms might be expressed at levels that are below the limits o f detection 
on a Western blot. CYP2B1 mRNA has been detected in testis from Sprague Dawley 
rats, although this doesn’t necessarily mean that the corresponding protein will be 
expressed (Omiecinski, 1986). Western blotting with a testicular fraction enriched 
with Leydig cells (e.g. purified using a percoll gradient) might increase the sensitivity 
o f detection of CYP proteins.
5.4.5 Effect of lansoprazole on testicular testosterone metabolism
The profile of metabolites formed by pooled testis microsomes from the current study 
was consistent with previously published data for male Sprague Dawley rats 
(Sonderfan et al., 1989; Seng et al., 1996). Androstenedione formation was the major 
pathway o f testosterone oxidation catalysed by testis microsomes. Smaller amounts of
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6 p-, 7a-, 6 a-, 16a- and 2a-0H T  were also detected. As previously discussed in 
Chapter 4, the levels of metabolites present in testis incubations were generally close 
to the limits of detection of the assay resulting in less accurate quantification of 
metabolites. In the current study traces of testosterone 16a- and 2a-hydroxylase 
activity were detected in testis microsomes. These metabolites were not detected in 
blank incubations but were present in incubation extracts at levels that were close to 
the limits of detection with respect to radiochemical detection. Consequently, these 
metabolites were not detected in all incubation extracts therefore it was not possible to 
draw conclusions concerning the effects of lansoprazole treatment on these pathways.
Lansoprazole treatment had no marked effects on the pathways o f testosterone 
metabolism catalysed by testis microsomes. This was not entirely unexpected as 
lansoprazole produced relatively modest increases in the activity o f CYP-dependent 
pathways of testosterone metabolism in the liver and testicular CYPs appear to be less 
sensitive to the effects o f chemical inducers (Goldstein & Linko, 1984; Omiecinski, 
1986).
5.4.6 Plasma hormone levels
Testosterone
Lansoprazole treatment was associated with a significant reduction (6 6 % o f control 
values) in plasma testosterone levels (P<0.05). These results confirm the findings o f 
Fort et al. (1995) who reported significant reductions in serum testosterone levels 
(maximal decrease o f 50%) between 3.5 and 5 hours postdose in male rats following 
treatment with lansoprazole (150 mg/kg/day) for four weeks. Plasma testosterone 
levels reflect the balance between the rate o f hormone biosynthesis in the testis and 
clearance via the liver and kidneys. The reduced circulating testosterone levels 
observed following lansoprazole treatment are probably, at least in part, related to the 
ability of this compound to inhibit testosterone biosynthesis (Fort et al., 1995). 
However, our current data from the testosterone hydroxylase assay demonstrate that 
lansoprazole increases the activity of several CYP-dependent pathways o f testosterone 
metabolism. This might lead to enhanced metabolic clearance o f testosterone, which 
may represent an important mechanism involved the depression o f circulating 
testosterone levels by lansoprazole.
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LH
Lansoprazole had no statistically significant effects on plasma LH levels in the current 
study. In contrast, Fort et al. (1995) reported significant elevations in serum LH levels 
at 4 and 5 hours postdose in lansoprazole-treated rats (150 mg/kg/day for 4 weeks). In 
the current study, failure to detect an increase in plasma LH levels despite the 
significant reduction in circulating testosterone levels might have been related to 
factors such as the timing of blood sample collection and interanimal variability in 
hormone levels as discussed previously in Chapter 4. For the current study, blood 
samples were collected between 18 and 2 0  hours after the last dose o f lansoprazole, by 
which time the majority of the drug would have been cleared (half-life < 3 hours) and 
homeostatic regulation may have meant that plasma hormone levels were returning to 
the normal range. It would be useful to study the effects of lansoprazole on plasma 
hormone levels at a number of timepoints following the final dose of drug.
FSH
Lansoprazole-treated animals showed a trend towards higher plasma FSH levels 
compared to the control group, but this did not reach statistical significance. FSH has 
no direct effects on the Leydig cell but stimulates the Sertoli cells to secrete a variety 
o f paracrine factors, which may influence Leydig cell structure and function. 
Administration of FSH to immature hypophysectomised rats has previously been 
shown to have a positive effect on the Leydig cell population causing hypertrophy and 
hyperplasia and enhanced hCG-stimulated testosterone production in vitro (Kerr & 
Sharpe, 1985; Vihko et al., 1991). \
Prolactin
Lansoprazole-treated animals showed a trend towards lower plasma prolactin levels 
compared to the control group, but this did riot reach statistical significance. Prolactin 
appears to be essential for normal testicular function, maintaining Leydig cell LH 
receptor numbers and potentiating the effects of LH on the male reproductive system 
(Welsh et al., 1986; Bartke et al., 1978; Zipf et al., 1978a). Prolactin also has indirect 
effects on testicular function by suppressing LH and FSH secretion fi*om the pituitary 
gland (McNeilly et al., 1978). The trend towards lower plasma prolactin levels in 
lansoprazole-treated animals might be of particular interest as dopamine agonists are
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believed to induce LCTs in rats through their ability to reduce circulating prolactin 
levels (see 1.3.5).
5.4.7 Conclusions
Lansoprazole treatment produced effects on the liver consistent with an enhanced 
metabolic capacity, including significant increases in relative liver weight and total 
microsomal CYP content. Lansoprazole induced the expression of several hepatic 
CYP proteins (including CY PlA l, CYP1A2, CYP2B1, CYP3A and CYP4A1), 
suggesting that this compound may represent a distinct type of “mixed inducer”. This 
was associated with significant increases in the activity of several CYP-dependent 
pathways o f testosterone metabolism catalysed by liver microsomes leading to an 
increase in the total rate o f hydroxytestosterone metabolite formation in vitro. These 
findings suggest that lansoprazole might have the potential to enhance the metabolic 
clearance of testosterone in vivo. Indeed, circulating testosterone levels were 
significantly lower in lansoprazole-treated animals compared to the control group. No 
significant changes in plasma LH, FSH or prolactin levels were detected in 
lansoprazole-treated animals.
The effects of lansoprazole on testicular CYP enzymes have been studied, although 
the low levels of expression in the testis confounded the detection and accurate 
quantification of CYP proteins in this tissue. Lansoprazole treatment was not 
associated with any marked effects on CYP-dependent pathways o f testosterone 
metabolism catalysed by testis microsomes.
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Chapter 6
Effect of lansoprazole on gene expression in the liver and testis
6.1 Introduction
The previous study demonstrated that lansoprazole treatment induces the expression of 
proteins belonging to the CYPIA, 2B, 3A and 4A subfamilies in liver microsomes 
(chapter 5). This was associated with increases in the activity of several CYP- 
dependent pathways of testosterone metabolism catalysed by liver microsomes in 
vitro, indicating that lansoprazole might also induce enzymes belonging to the CYP2A 
(7a-hydroxylase activity) and 2C (2a-hydroxylase activity) subfamilies. The aim of 
the current study was to further characterise the effects of lansoprazole on the liver 
and testis.
The major objective o f this study was to examine the effects of lansoprazole on the 
hepatic and testicular expression of selected genes of relevance to the current 
hypothesis. The expression of C7P2^7, CYP2C11, CYP2C13, CYP2C6 2Lnd l7 f-H SD  
were studied in the liver and testis. In addition, selected genes involved in 
testosterone biosynthesis were examined in the testis, namely CYPscc (CYPllAJ), 
CYP17A1 and StAR. Further studies were also performed to characterise the effects of 
lansoprazole treatment on the hypothalamic-pituitary-testis axis by measuring 
intratesticular testosterone and plasma hormone levels (testosterone, LH, FSH and 
prolactin).
6.2 Study design
Male Sprague Dawley rats were dosed once daily with lansoprazole (150 mg/kg/day) 
or vehicle (0.5% (w / v) CMC) by oral gavage for 14 days. On day 15, blood samples 
were collected and livers and testes were removed. For each liver, a part of the left 
lobe was frozen in liquid nitrogen for total RNA extraction and the remaining tissue 
was used to prepare microsomes. Testes from soriie animals (n=5 per group) were 
frozen in liquid nitrogen for total RNA extraction whereas those from the remaining 
animals (n=5 per group) were used to measure intratesticular testosterone levels. 
More detailed experimental details concerning animal treatment, sample collection 
and the analytical methods used for this study can be found in chapter 2 .
177
6.3 Results
6.3.1 Body, liver and testes weights
Final body weights and relative liver and testes weights for control and drug-treated 
animals are shown in Table 6 .1 .
Table 6.1: Effect o f lansoprazole treatment on relative liver and testes weights
Control Lansoprazole-treated
Final body weight (g) 324.7 ± 27.7 309.7 ±17.6
Relative liver weight
(g/lOOg body weight)
4.16 ±0.23 4.24 ±0.53
Relative testes weight
(g/lOOg body weight)
0.87 ±0.15 0.85 ± 0.30
Results are expressed as mean ± SD for control and lansoprazole-treated animals (n=10 animals per 
group).
There were no statistically significant differences in initial (data not shown) or final 
body weights between the experimental groups. No statistically significant differences 
in absolute (data not shown) or relative liver and testes weights were observed 
between control and lansoprazole-treated animals.
6.3.2 Total CYP content of liver microsomes
The specific CYP contents of liver microsomes from control and lansoprazole-treated 
animals are shown in Table 6.2.
Table 6.2:, Effect of lansoprazole treatment on the total cytochrome P450 content of 
liver microsomes '
Treatm ent group Microsomal P450 content
(nmol/mg microsomal protein)
Control 0.79 ± 0.06
Lansoprazole 0.96 ±0 .17**
Results are expressed as mean ± SD from individual microsomal preparations from control and
lansoprazole-treated animals (n=10 animals per group). Statistical analysis was performed using a
Student’s t-test where asterisks (*) represent: ** P<0,01.
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6.3.3 ELISA
The levels of CYP proteins in liver microsomes from control and lansoprazole-treated 
animals were quantified by ELISA and the results are shown in Table 6.3.
Table 6.3: ELISA quantitation of CYP proteins in liver microsomes from control and 
lansoprazole-treated animals
Anti-CYP CYP content (pmoles/mg protein) Fold change
Control Lansoprazole
CYPIA 2.5 ±1.2 80.3 ±38.5 *** 32.1
CYP2B 34.0 ±4.1 47.0 ± 11 .9** 1.4
CYP3A 21.0 ±5.2 28.5 ± 4 .9 * * 1.4
CYP4A 14.5 ±2.8 28.0 ± 7 .3*** 1.9
Results are expressed as mean ± SD from individual microsomal preparations from control and 
lansoprazole-treated animals (n=10 animals per group). Fold changes were calculated by dividing the 
mean value in the lansoprazole-treated group by the mean value in the control group. Statistical analysis 
was performed using a Student’s t-test where asterisks (*) represent: ** P<0.01, *** P<0.001.
6.3.4 Plasma horm one levels
Blood samples were collected (~ 18 to 20 hours after the final dose) and assayed for 
plasma testosterone, LH, FSH and prolactin levels by radioimmunoassay (Figures 6.1 
and 6.2). Lansoprazole-treated animals showed a trend towards lower plasma 
testosterone levels compared to the control group, but this did not reach statistical 
significance. Lansoprazole treatment was associated with a significant decrease in 
plasma prolactin levels (P<0.05). No statistically significant changes in plasma FSH 
or LH levels were detected.
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Figure 6.1: Plasma testosterone levels in control and lansoprazole-treated rats
g 8
o  6
Control Lansoprazde-treated
Each bar represents the mean ± SEM from control (n=10) and lansoprazole-treated animals (n=10).
Figure 6.2: Plasma prolactin, follicle-stimulating hormone and luteinising hormone 
levels in control and lansoprazole-treated rats.
□  Contro
Lansoprazole 
treated
Prolactin
Hormone
Each bar represents the mean ± SEM from control (n=10) and lansoprazole-treated animals (n=10).
Statistical analysis was performed using a Student’s t-test where asterisks (*) represent, * P<0.05.
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6.3.5 Intratesticular testosterone levels
The effect of lansoprazole treatment on intratesticular testosterone levels was 
investigated in a subgroup of animals from this study (n=5 animals per group). Testes 
from each animal were homogenised and the supernatant was assayed for testosterone 
levels by radioimmunoassay.
The lansoprazole-treated group showed a trend towards lower intratesticular 
testosterone levels compared to controls, but this did not reach statistical significance 
(Figure 6.3). To enable comparison of the effects o f lansoprazole treatment on 
testicular and plasma hormone levels in these animals, plasma testosterone levels in 
this subgroup are shown in Figure 6.4. It was observed that intratesticular and plasma 
testosterone levels were markedly reduced in four of the lansoprazole-treated animals. 
In contrast, the fifth drug-treated animal exhibited intratesticular and plasma 
testosterone concentrations that were within the control range. I f  this animal was 
omitted from the statistical analysis, intratesticular testosterone ’ levels were 
significantly lower in the lansoprazole-treated group (37.7 ± 1 .0  ng/g testis (mean ± 
SD)) compared to the control group (70.8 ± 19.1 ng/g testis) (P<0.05).
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Figure 6.3; Intratesticular testosterone levels in control and lansoprazole-treated 
animals
Lansoprazde-treated
Each bar represents the mean ± SEM from control (n=5) and lansoprazole-treated (n=5) animals.
Figure 6.4: Plasma testosterone levels in the subgroup of control and lansoprazole- 
treated animals used to measure intratesticular hormone levels
Lansoprazole
Each bar represents the mean ± SEM from control (n=5) and lansoprazole-treated (n=5) animals.
Statistical analysis was performed using a Student’s t-test where asterisks (*) represent, * P<0.05.
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6.3.6 TaqMan analysis
6.3.6.1 Preparation of cDNA
Total RNA was extracted from each liver and testis sample and then purified using the 
RNAqueous™-4PCR kit as described in 2.2.14. Each total RNA sample was 
quantified by speetrophotometry and the quality of the sample was assessed by 
separation on a 1% agarose gel. Figure 6.5 shows a representative total RNA sample 
from this study. Two distinct bands corresponding to 28S and 18S ribosomal RNA 
(rRNA) with a ratio of approximately 2:1 are present, indicating that no significant 
degradation of the RNA has occurred. 3pg of each total RNA sample was used for 
cDNA synthesis as described in 2.2.14.4.
Figure 6.5: Total RNA extracted from rat testis
Lane 1 Lane 2
^ ______  28S rRNA
  18SrRNA
The total RNA sample was mixed with Gel Loading Solution (4pl:lpl RNA) and then loaded on 
to a 1% agarose gel. Electrophoresis was conducted at lOOV for approximately 45 minutes as 
described in 2.2.14.3.
Lane 1, 1Kb DNA ladder (6pl)
Lane 2, Total RNA (2 pi) extracted from testis from a control animal
6.3.6.2 Real-time PCR (TaqMan^^ quantitatation
Real-time PCR (TaqMan™) was used to study the levels of expression of the selected 
genes in liver and testis samples from control and lansoprazole-treated animals as 
described in 2.2.15. For each sample, the initial copy number of the target mRNA or 
18S rRNA was interpolated from the appropriate standard curve. The copy number of
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the target mRNA was then divided by the copy number for 18S rRNA to give a 
normalised target value. Fold changes in target mRNA levels were calculated by 
dividing the mean normalised target value in the drug-treated group by that in the 
control group. The data obtained for liver and testis samples is presented below.
Liver samples
Initially, the effect of lansoprazole on hepatic C YPlAl mRNA levels was studied as a 
positive control because this compound is known to produce a large induction of 
CYPl A1 protein levels (chapter 5 and Table 6.3). Lansoprazole treatment produced a 
significant increase in hepatic C YPlAl mRNA levels (16.8 fold induction) as shown 
in Figure 6 .6 .
The effects of lansoprazole treatment on the five candidate genes studied in the hver 
are shown in Figure 6.7.
Figure 6.6: Effect of lansoprazole treatment on liver C YPlAl mRNA levels as
determined by TaqMan
**
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Each bar represents the mean ± SEM from control (n=4) and lansoprazole-treated (n=4) animals. 
Statistical analysis was performed using a Student’s t-test, where asterisks (*) represent: ** P<0.01.
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Figure 6.7: Fold changes in hver mRNA levels of selected genes following treatment 
of rats with lansoprazole as determined by TaqMan
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Each bar represents the mean ± SEM fold change in mRNA levels of each gene compared to the control 
group (n=5 animals per group). Statistical analysis was performed using a Student’s t-test, where 
asterisks (*) represent; * P<0.05.
Testis samples
The effects of lansoprazole treatment on the expression of the eight candidate genes 
studied in the testis are shown in Figure 6 .8 . Data is not presented for CYPscc because 
the primer and probe set designed for the current study failed to amplify the target 
sequence, despite attempts to optimise primer and probe concentrations in the reaction 
mixture and the use of a cDNA standard curve.
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6.4 Discussion
6.4.1 Final body and organ weights
Lansoprazole treatment had no statistically significant effects on body weight gain or 
final body weights in the current study, in contrast to the significant reductions 
observed in the previous study (chapter 5). In addition, lansoprazole had no 
significant effects on liver and testes weights in the current study. In contrast, 
lansoprazole treatment produced a significant increase in relative liver weights and a 
reduction in relative testes weights in the previous study (chapter 5).
6.4.2 Effect of lansoprazole on hepatic CYPs
In the Current study, lansoprazole treatment produced a significant increase in the 
specific microsomal CYP content ( 1 . 2  fold) which was associated with induction of 
CYPIA, 2B, 3A and 4A proteins as determined by ELISA. These findings were in 
good agreement with data firom the previous study except that the fold increase in 
CYPIA levels calculated for liver microsomes firom the current study (32.1 fold) was 
markedly higher than for samples from chapter 5 (9.9 fold). This mainly resulted from 
differences in CYPIA levels in control samples (2.5 ± 1.2 and 5.2 ± 1 .3  pmoles/mg 
microsomal protein (mean ± SD) for control liver microsomes from the current study 
and chapter 5 respectively). The levels of CYPIA proteins present in control liver 
microsomes were low and despite being within the range o f the standard curve the 
levels o f CYPIA proteins were close to the limits o f detection of the ELISA assay. 
This might have resulted in less accurate quantitation of CYPIA levels in control 
samples. In addition, these differences between studies might have been related to 
interanimal variability in CYPIA levels and responses to drug treatment.
In conclusion, these results provide confirmation o f the previously observed effects of 
lansoprazole treatment on the hepatic CYP complement and also act as a surrogate 
marker for drug exposure in the current study.
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6.4.3 Plasma hormone levels
Lansoprazole-treated animals showed a trend towards lower plasma testosterone levels 
compared to the control group, but this did not reach statistical significance. The 
magnitude of the reduction in circulating testosterone levels in the current study (80% 
of control) was smaller than that observed in the previous study (6 6 % of control) 
(chapter 5). Lansoprazole treatment had no statistically significant effects on plasma 
LH levels, consistent with data from the previous study (chapter 5). Lansoprazole- 
treated animals showed a trend towards lower plasma FSH levels compared to the 
control group, but this did not reach statistical significance. In contrast, a trend 
towards higher plasma FSH levels was observed in the previous study (chapter 5).
In the current study, the most marked effect o f lansoprazole treatnient was the 
significant reduction in plasma prolactin levels (32% o f control) (P<0.05). In the 
previous study, there was a trend towards lower plasma prolactin levels in the drug- 
treated group, but this did not reach statistical significance (chapter 5). The ability o f 
lansoprazole to reduce circulating prolactin levels might be involved in the mechanism 
of LCT induction by this compound. Prolactin appears to play an important role in 
regulation of the male reproductive system through direct (e.g. maintenance o f Leydig 
cell LH receptors) and indirect effects (suppression of gonadotropin secretion from the 
pituitary gland) on testicular function (Zipf et ah, 1978a; McNeilly et ah, 1978; 
Winters & Loriaux, 1978; Smith & Bartke, 1987; Cheung, 1983). Therefore changes 
in plasma prolactin levels might lead to changes in circulating gonadotropin levels and 
modulation of the sensitivity o f the Leydig cells to ÉH stimulation. Indeed, induction 
of hypoprolactinaemia by treatment of rats with 2-bromo-a-ergocriptine (BR) has 
been reported to produce a reduction in testicular LH receptor numbers compared to 
control animals (Huhtaniemi & Catt, 1981; Pakarinen et ah, 1994). Huhtaniemi & 
Catt (1981) reported that this was not associated with a reduction in testicular 
steroidogenesis or circulating testosterone levels, which might be explained by the 
presence of a large excess of “spare” LH receptors. In contrast, Pakarinen et ah 
(1994) reported a significant reduction in serum testosterone levels following 8  days 
of BR-treatment in male rats. The apparent differences in the effects o f BR-induced 
hypoprolactinaemia on circulating testosterone levels between these two studies might 
have been related to differences in the experimental conditions used such as the animal
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age (60 days v 90 days old for Huhtaniemi & Catt (1981) and Pakarinen et ah, (1994) 
respectively).
Prolactin has previously been implicated in the aetiology of. LCT formation in rats. 
Dopamine agonists (or agents that enhance dopamine levels) may produce LCTs 
through their ability to reduce circulating prolactin levels. It has been proposed that 
this might cause downregulation o f Leydig cell LH receptors and a partial inhibition 
o f testosterone biosynthesis leading to a compensatory increase in LH secretion 
(Prentice et al., 1992). Consistent with this hypothesis, the dopamine agonist 
mesulergine has been reported to reduce circulating prolactin levels and Leydig cell 
LH receptor numbers, which was associated with sustained increases in circulating LH 
levels in rats (Prentice et ah, 1,992). Chronic treatment of rats with mesulergine is 
associated with an increased incidence of Leydig cell hyperplasia and tumours in rats 
(Dirami et ah, 1996). Interestingly, induction o f chronic hyperprolactinaemia has been 
reported to markedly reduce the incidence o f spontaneous LCTs in Fischer 344 rats 
and the authors postulated that this was due to suppression of circulating LH levels 
(Bartke et ah, 1985).
6.4.4 Intratesticular testosterone levels
Lansoprazole-treated animals showed a trend towards lower intratesticular 
testosterone levels (72% of control), but this did not reach statistical significance. 
These results confirm the findings of Fort et ah (1995) who reported significant 
reductions in intratesticular testosterone levels (67% of control) at 4 hours postdose in 
male Sprague Dawley rats following treatment with lansoprazole (I50mg/kg/day) for 
four weeks. Plasma testosterone levels were also significantly reduced in drug-treated 
animals firom this subgroup (6 6 % of control) (P<0.05). The overall magnitude o f the 
decrease in plasma and intratesticular hormone levels was reduced due to the fact that 
one o f the lansoprazole-treated animals did not show marked changes in testosterone 
levels. The reasons for the apparent lack of effect o f drug treatment on testosterone 
levels in this animal are unknown, but this is unlikely to be due to inadequate drug 
exposure as the levels o f CYP induction measured in liver microsomes (by ELISA) 
from this animal were within the range of the lansoprazole-treated group.
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Measurement of intratesticular hormone levels provides an indicator of the 
biosynthesis, secretion and bioavailability of testosterone within the testis. In contrast, 
plasma testosterone levels reflect the balance between the rate o f hormone 
biosynthesis in the testis and clearance via the liver and kidneys. Lansoprazole has 
previously been shown to inhibit several sites in the testosterone biosynthetic pathway 
in vitro, the most sensitive site being transport o f cholesterol to the CYPscc enzyme 
(Fort et al., 1995). Furthermore, treatment of rats with lansoprazole 
(50 or 150 mg/kg/day) for one or two weeks was associated a reduction in hCG- 
stimulated testosterone secretion in vivo (Fort et al., 1995). The ability of lansoprazole 
to inhibit testosterone biosynthesis is probably the major factor responsible for the 
reduction in intratesticular hormone levels in drug-treated animals. .Inhibition of 
testosterone biosynthesis would be expected to contribute to the decrease in circulating 
testosterone levels observed in lansoprazole-treated animals, but changes in other 
processes (e.g. metabolic clearance) might also contribute as previously discussed in 
chapter 5.
The ability of lansoprazole to reduce the local concentration o f testosterone might 
have important effects on the testis. Testosterone is essential for the maintenance of 
tubular spermatogenesis therefore sustained reductions in intratesticular hormone 
levels might be associated with suppression of spermatogenesis. Indeed, treatment of 
Sprague Dawley rats with lansoprazole has been reported to produce testicular atrophy 
and epididymal hypospermia in a 3 month study (> 300 mg/kg/day) and an increased 
incidence of seminiferous tubule atrophy in a 2 year study (> 75 mg/kg/day) 
(Unpublished reports by Takeda Chemical Industries Ltd., Report numbers: TA-90- 
151 and TA-91-024). There is evidence to suggest that the seminiferous tubules might 
have a regulatory influence on Leydig cell morphology and function. In rats, Leydig 
cells located adjacent to seminiferous tubules at certain stages of germ cell 
development (stages VII to VIII) have been reported to be larger and contain more 
smooth endoplasmic reticulum compared those lying close to tubules at other stages 
(Bergh, 1982; Fouquet, 1987). Since the volume of smooth endoplasmic reticulum is 
correlated to the steroidogenic capacity of the Leydig cell, stage VII and VIII 
seminiferous tubules may modulate the ability of adjacent Leydig cells to produce 
testosterone (Russell et al., 1992). Interestingly, Sharpe et al. (1992) identified several
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androgen-regulated proteins that were produced by stage VI to VIII seminiferous 
tubules, although the identity and cellular source (i.e. germ cells, Sertoli cells or 
peritubular cells) of these proteins was not confirmed in this study. These findings 
indicate that reciprocal regulatory pathways may exist between the seminiferous 
tubules and the Leydig cells. Furthermore, these pathways might be altered following 
lansoprazole treatment due to the ability of this compound to reduce the local 
testosterone concentration and produce tubular atrophy.
There is evidence that testosterone may modulate the production o f several potential 
regulatory molecules that are produced within the testis. PModS (Peritubular factor 
that Modulates Sertoli cell function) is produced by the peritubular cells and has been 
reported to act as a potent stimulator of Sertoli cell differentiated function in vitro (e.g. 
production o f transferrin, ABP and inhibin) (Norton & Skinner, 1989; Skinner & Fritz, 
1985; Skinner et ah, 1989). The peritubular cells express androgen receptors and there 
is evidence to suggest that androgens have a stimulatory effect on PModS secretion 
(Anthony et al., 1989; Skinner & Fritz, 1985; Verhoeven & Cailleau, 1988). At 
present this regulatory factor has only been partially characterised but it has been 
suggested that it might mediate some of the effects of androgens on the Sertoli cells 
(Skinner & Fritz, 1985). Other examples of potential testicular paracrine factors that 
might be modulated by testosterone include P-endorphin and oxytocin (Fabbri & 
Dufau, 1988; Nicholson et al., 1986). The ability o f lansoprazole to reduce 
intratesticular testosterone levels might have important effects on the paracrine 
environment of the testis, which could play a role in thé formation o f LCTs.
6.4.5 Effect of lansoprazole on gene expression in the liver and testis
Selection and quantitation o f  candidate genes
The major aim of the current study was to investigate the effect o f drug treatment on 
the expression o f selected genes to further characterise the effects o f lansoprazole on 
the liver and testis. Eight candidate genes of relevance to our hypothesis were chosen: 
CYP2A1, CYP2C11, CYP2C6, CYP2C13, 17P-HSD, CYPscc, CYP17A1 and StAR. 
CYP2C11, 2C6, 2C13 and 2A1 were selected because data firom the testosterone 
hydroxylase assay indicated that in addition to induction o f CYPIA, 2B, 3A and 4A 
proteins, lansoprazole might also induce CYP2A (7a-hydroxylase activity) and
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CYP2C (2a- and 16a-hydroxylase activity) forms (see chapter 5). Effects of drug- 
treatment on CYP2C forms might be o f particular interest, as this subfamily accounts 
for a major proportion of the total hepatic CYP content in untreated rats (Guengerich 
et ah, 1982). In addition, although the physiological roles o f constitutive CYPs have 
not been fully elucidated it has been suggested that CYP2C11 makes a substantial 
contribution to the overall rate of hepatic testosterone oxidation in rats and might even 
be responsible for the formation of specific hydroxylated metabolites with important 
physiological functions (Waxman, 1984).
17p-HSD enzymes appear to play an important role in androgen homeostasis by 
regulating the interconversion of high activity 17p-hydroxysteroids (e.g. testosterone) 
and low activity 17-ketosteroids (e.g. androstenedione). Several distinct 17p-HSD 
enzymes have been identified, which differ in their substrate specificity, cofactor 
requirements, preference for oxidative or reductive reactions and subcellular and tissue 
distribution (reviewed by Peltoketo et ah, 1999). For the current study, 17p-HSD type 
2  was selected because this form is known to be expressed at high levels in the liver 
and preferentially catalyses the oxidative pathway (i.e. conversion o f testosterone to 
androstenedione) (Akinola et ah, 1996). It has been suggested that 17p-HSD type 2 
might play a protective role in the tissues by lowering the intracellular concentration 
of active sex steroids (Akinola et ah, 1996).
As previously discussed, lansoprazole is known to inhibit testosterone biosynthesis 
therefore we decided to further investigate the effects on this compound on key 
components of this pathway. CYPscc (product o f the C Y P llA l gene) catalyses the 
conversion of cholesterol to pregnenolone, which is the first and rate-limiting 
enzymatic step in the testosterone biosynthetic pathway (Simpson, 1979). In mice, 
the ability o f the Leydig cells to synthesise androgens is significantly correlated to 
CYPscc protein levels therefore factors that regulate the expression of this protein 
would be expected to influence the steroidogenic capacity of the testis (Nolan & 
Payne, 1990). LH is required for maximal expression o f testicular CYPscc but a 
component of this activity appears to be constitutive (Anakwe & Payne, 1992; Payne 
et al., 1992; Anderson & Mendleson, 1985). CYP 17AI is considered to be rate 
limiting in the conversion of pregnenolone to testosterone and LH is essential for the
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maintenance of normal amounts of this enzyme in the testis (Anakwe & Payne, 1992; 
Payne et ah, 1992). In addition to gonadotropins, intratesticular autocrine and 
paracrine factors may modulate the expression of these steroidogenic enzymes 
(reviewed by Cook et al., 1999; Saez, 1994).
The StAR protein mediates the transfer of cholesterol to the inner mitochondrial 
membrane, which is the true rate-limiting step in steroid biosynthesis during periods 
of acute stimulation (Crivello & Jefcoate, 1980; Privalle et al., 1983; Clark et al., 
1994; Luo et al., 1998). StAR mRNA and protein levels are correlated to the acute 
increase in steroidogenesis following LH stimulation (Luo et al., 1998; Clark et al., 
1995). For the current study it was o f interest to examine the effects of lansoprazole 
treatment on StAR mRNA levels as an indicator o f effects on testosterone 
biosynthesis. In addition, stimulation of the Leydig cells by LH appears to induce 
StAR gene transcription therefore changes in StAR mRNA levels might provide a 
marker for the levels of endogenous LH stimulation (Clark et al., 1995; Caron et al., 
1997). However, StAR gene expression is also influenced by autocrine and paracrine 
factors such as IGF-1, TGF-P and TNF-a (reviewed by Christensen & Strauss, 2000).
For the current study it was decided to quantify mRNA levels for the selected genes 
using real-time PCR (TaqMan™) for a number of reasons. Firstly, the TaqMan assay 
has high specificity due to the fact that signal generation requires the binding of the 
two primers and the probe within the target sequence. In contrast, quantification of 
CYPs using immunochemical techniques, such as Western blotting, is often hindered 
by the high degree o f amino acid sequence similarity between individual CYP forms. 
This is particularly true for the discrimination of individual CYP2C forms for which it 
is difficult to reproducibly obtain good resolution by SDS-PAGE and primary 
antibodies show a high degree of cross reactivity with other members o f this 
subfamily (Waxman, 1991). Secondly, the TaqMan assay shows high sensitivity, 
which was particularly important with respect to the low levels of CYP expression in 
testis samples. Finally, this assay is rapid, reproducible and relatively simple to 
perform, allowing the expression of the eight candidate genes to be measured in 
samples from the current study. The timescale of the current project would not have 
been sufficient to allow the optimisation of Western blotting for the eight candidate 
proteins. Instead, the effects of drug treatment were investigated at the mRNA level
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with the intention of following up any significant changes with protein studies 
(e.g. Western blotting, immunohistochemistry).
Liver samples
In liver samples, the effect of lansoprazole treatment on the expression o f CYP2C11, 
CYP2C6, CYP2C13, CYP2A1 and lip-H SD  was studied. In addition, C YPlAl 
mRNA levels were measured as a positive control because lansoprazole is known to 
produce a marked induction of C Y PlA l protein in the liver (see chapter 5 and Table 
6.3). Indeed, a significant increase in hepatic C YPlA l mRNA levels (16.8 fold) was 
observed in the drug-treated group, compared to controls (P<0.01). In contrast, 
lansoprazole treatment had no statistically significant effects on hepatic CYP2A1, 
CYP2C11, CYP2C13 or 17p-HSD mRNA levels. CYP2C6 mRNA levels were 
significantly higher (P<0.05) in the lansoprazole-treated animals compared to the 
control group. However, the mean fold change did not reach the threshold value of 
two fold, which is generally accepted to be the minimum fold change that represents a 
true effect using the TaqMan assay.
The lack o f effect o f lansoprazole on the expression o f CYP2A1 m d  CYP2C forms 
was not consistent with the ability o f this compound to increase testosterone 7a- and 
2a-hydroxylase activity respectively. However, the extent of the induction o f these 
testosterone hydroxylase activities was relatively small (less than two fold) therefore it 
might be expected that any associated increases in mRNA levels would be of a similar 
magnitude. The statistically significant increase in CYP2C6 mRNA levels might 
therefore account for the increase in testosterone 2 a-hydroxylase activity in liver 
microsomes from lansoprazole-treated animals, although reliable conclusions cannot 
be drawn as discussed above. In addition, induction o f many cytochromes P450 
involves increased gene transcription but other mechanisms have been identified. Such 
as mRNA stabilisation (e.g. C Y PlA l, CYP2B1/2, CYP2C12), changes in translation 
(e.g. CYP2B1) and protein stabilisation (e.g. CYP2E1, CYP3A1/2) (reviewed by 
Lewis, 2001). Lansoprazole might alter the levels of CYP proteins by influencing 
processes other than gene transcription, highlighting the importance of combining 
studies performed at the mRNA level with protein studies.
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Testis samples
In testis samples, the effect of lansoprazole treatment on the expression of CYPlAl, 
CYP2C11, CYP2C6, CYP2C13, CYP2A1, 17P-HSD, CYPscc, CYP17A1 and StAR was 
studied. Unfortunately it was not possible to measure CYPscc expression because the 
primer and probe set designed for the current study did not amplify the target sequence 
despite attempts to optimise the assay. As lansoprazole treatment produced a marked 
induction of C YPlA l mRNA levels in the liver we investigated the effects of this 
compound on the expression of C YPlA l in the testis. CTPM 7 was detected at very 
low levels in testis samples and was not significantly affected by lansoprazole 
treatment. These findings provide further evidence that CYPs in the testis might be 
less sensitive to the effects of exogenous inducers than their hepatic counterparts.
CYP2C11, CYP2C13, CYP2C6, CYP2A1, 17f-H SD , CYP17A1 and StAR transcripts 
were detected in testis samples, however lansoprazole treatment did not significantly 
affect the expression o f any of these genes. Consistent with the detection of CYP2C11 
and CYP2A1 transcripts in testis samples from the current study, other investigators 
have reported the presence of the corresponding proteins in rat testis microsomes 
(Ryan et al., 1993; Seng et al., 1996; Sonderfan et al., 1989). Testicular CYP2A1 
levels are of particular interest with respect to the current project due to the potential 
physiological roles o f 7a-hydroxylated androgens and the possible involvement of 
high CYP2A1 expression in the aetiology of spontaneous Leydig cell hyperplasia in 
rats (see section 1.5.3). Lansoprazole treatment did not produce significant changes in 
CYP2A1 levels in the testis, which was consistent with the previously observed lack of 
effect of this compound on testicular testosterone 7a-hydroxylase activity (chapter 5). 
No other studies reporting the detection of CYP2C13 or CYP2C6 mRNA or proteins 
in rat testis could be identified in the published literature. Consistent with the 
detection of 17p-HSD type 2 mRNA in testis samples from the current study, other 
investigators have reported that testis preparations can catalyse the oxidation of 
testosterone to form androstenedione (Martel et al., 1992). In the current study, 17p- 
HSD showed marked interanimal variation in levels o f expression in testis samples, 
which was confirmed by repeat experiments.
Lansoprazole might be expected to influence the expression of enzymes involved in
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testosterone biosynthesis, either directly or as a consequence o f the reduction in 
testicular and circulating testosterone levels. In the current study, lansoprazole 
treatment had no effect on testicular C Y P llA l  or StAR mRNA levels, although this 
compound might have influenced processes other than gene transcription 
(e.g. translation or protein stability). However, in human tissues (including the testis) 
StAR mRNA levels have been reported to correlate well with protein levels as 
determined by immunohistochemistry (Pollack et al., 1997). The lack of effect of 
lansoprazole on StAR mRNA levels was consistent with the fact that no significant 
changes in plasma LH levels were detected in these animals.
6.4.6 Conclusions
The current study has further characterised the effects of lansoprazole on the liver and 
testis. Lansoprazole treated animals exhibited a significant increase in total 
microsomal CYP content and induction o f hepatic CYPIA, CYP2B, CYP3A and 
CYP4A proteins, confirming the findings o f the previous study (chapter 5). In the 
liver, no significant changes in CYP2C11, CYP2Ç12, CYP2C6, CYP2A1 or 17J3-HSD 
mRNA levels were observed in lansoprazole-treated animals compared to the control 
group. No significant changes in C YPlAl, CYP2C11, CYP2C13, CYP2C6, CYP2A1, 
lip-H SD , C Y P llA l or StAR were detected in testis samples firom lansoprazole-treated 
animals compared to the control group. However, lansoprazole might alter the levels 
o f the corresponding proteins by influencing processes other than gene transcription.
The effects o f lansoprazole on the endocrine control of the testis were also studied. 
Lansoprazole-treated animals showed a trend towards lower plasma testosterone 
levels, but this did not reach statistical significance. No statistically significant 
changes in plasma LH or FSH levels were detected in lansoprazole-treated animals 
compared to the control group, consistent with previous findings (chapter 5). 
Interestingly, lansoprazole-treated animals exhibited a marked reduction in plasma 
prolactin levels, which might play a role in the mechanism of LCT induction by this 
compound. Lansoprazole treatment was associated with a reduction in intratesticular 
testosterone levels, which was probably mainly due to the ability o f this compound to 
inhibit testosterone biosynthesis (Fort et al., 1995). The ability of lansoprazole to 
reduce the local concentration o f testosterone might have important effects on the 
paracrine environment o f the testis, which could play a role in the formation of LCTs.
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Chapter 7
Effect of lansoprazole on gene expression in the pituitary gland
7.1 Introduction
Previous studies have shown that treatment of rats with lansoprazole produces a 
significant reduction in plasma and testicular testosterone concentrations but we have 
failed to detect any significant changes in plasma LH levels (chapters 5 and 6 ). As 
previously discussed, this might be due to factors such as the timing of blood sampling 
relative to the final dose of drug and the marked interanimal variability in circulating 
hormone levels in rodents.
The aim of the current study was to further characterise the effects of lansoprazole 
treatment on the endocrine control of the testis. Firstly, plasma hormone levels 
(testosterone, LH, FSH and prolactin) were measured in blood samples collected 
approximately four hours after the final dose o f lansoprazole. Fort et al. (1995) 
reported a significant reduction in serum testosterone levels and a significant increase 
in LH levels at four and five hours after the final dose o f lansoprazole in Sprague 
Dawley rats that had been treated once daily with this compound (150 mg/kg/day) for 
four weeks. Secondly, the effect of lansoprazole treatment on LH  and prolactin 
mRNA levels in the pituitary gland was studied.
7.2 Study design
Male Sprague Dawley rats were dosed once daily with lansoprazole (150 mg/kg/day) 
or vehicle (0.5% (w / v) CMC/ 0.1% (v / v) Tween 80) by oral gavage for 14 days. On 
day 14 (~ 4 to 5 hours after the final dose of lansoprazole), blood samples were 
collected and liver, testes and pituitary glands were removed. Liver and testes were 
weighed and then snap frozen in liquid nitrogen. Pituitary glands were immediately 
placed in to tubes containing Trizol® reagent for total RNA extraction. More detailed 
experimental details concerning animal treatment, sample collection and analytical 
methods used for this study can be found in chapter 2 .
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7.3 Results
7.3.1 Body, liver and testes weights
Final body weights and relative liver and testes weights for control and drug-treated 
animals are shown in Table 7.1.
Table 7.1 : Effect of lansoprazole treatment on relative liver and testes weights
Control Lansoprazole-treated
Final body weight (g) 353.3 ±28.0 348.2 ±20.8
Relative liver weight
(g/lOOg body weight)
3.79 ±0.30 4.39 ±0.13 **
Relative testes weight
(g/lOOg body weight)
0.93 ± 0.07 0.83 ± 0.08
Results are expressed as mean ± SD for each group o f animals (n=5 animals per group). Statistical 
analysis was performed using a Student’s t-test where asterisks (*) represent: ** P<0.01.
There were no statistically significant differences in initial (data no shown) or final 
body weights between experimental groups. Relative liver weights were significantly 
higher in lansoprazole-treated animals compared to the control group, but no 
significant changes in absolute organ weights (data not shown) were observed. No 
significant changes in relative or absolute (data not shown) testes weights were 
observed between experimental groups.
7.3.2 Plasm a hormone levels
Blood samples were collected (~ 4 to 5 hours postdose) and assayed for plasma 
testosterone, LH, FSH and prolactin levels by radioimmunoassay (Figures 7.1 and 
7.2). Lansoprazole-treated animals showed a trend towards lower plasma testosterone 
and prolactin levels, but this did not reach statistical significance. No statistically 
significant changes in plasma FSH or LH levels were detected.
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Figure 7.1: Plasma testosterone levels in control and lansoprazole-treated rats
k m #
Lenscprazdo^restedCcrtrd
Each bar represents the mean ± SEM from control and lansoprazole-treated animals (n=5 animals per 
group).
Figure 7.2: Plasma prolactin, follicle-stimulating hormone and luteinising hormone 
levels in control and lansoprazole-treated rats.
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□  Lansoprazole- 
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y ■
Prolactin
Each bar represents the mean ± SEM from control and lansoprazole-treated animals (n=5 animals per 
group).
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7.3.3 TaqMan analysis
Total RNA was extracted from each pituitary gland and then purified using the 
RNAqueous™-4PCR kit as described in 2.2.14. The quahty of each total RNA sample 
was assessed by separation using a 1% agarose gel. The samples were run alongside a 
standard curve that was constructed using material (brain RNA) for which the total 
RNA content had been accurately quantified (data not shown). This allowed the 
concentration of each total RNA sample to be estimated. Approximately Ipg of each 
total RNA sample was used for cDNA synthesis as described in 2.2.14.4.
Real-time PCR (TaqMan™) was used to study the expression of LH  and prolactin in 
pituitary glands taken from control and lansoprazole-treated animals and the results 
are shown in Figure 7.3.
Figure 7.3: Fold changes in pituitary gland mRNA levels for LH  and prolactin
following treatment of rats with lansoprazole as determined by TaqMan
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Each bar represents the mean ± SEM fold change in mRNA levels of each gene compared to the control 
group (n=5 animals per group).
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7.4 Discussion
7.4.1 Final body and organ weights
Lansoprazole treatment had no statistically significant effects on body weight gain or 
final body weights but produced a significant increase in relative liver weights (116% 
o f control) (P<0.01). This indicates that the increase in relative liver weight is not 
solely an artefact due to the ability o f lansoprazole to reduce final body weights. 
Lansoprazole treatment had no significant effects on relative or absolute testes weights 
in the current study.
7.4.2 Plasma hormone levels
To further characterise the effects of lansoprazole on the endocrine control of the 
testis, plasma hormone levels were measured in blood samples collected 
approximately four hours after the final dose o f drug. Lansoprazole-treated animals 
showed a trend towards lower plasma testosterone levels (58% of control), but this did 
not reach statistical significance. Failure to attain statistical significance was probably 
due to the marked interanimal variation in plasma testosterone levels and the' small 
numbers o f animals used in this study. Fort et al. (1995) previously reported 
significant reductions in serum testosterone levels at 3.5, 4 and 5 hours after the final 
dose of lansoprazole in Sprague Dawley rats that had been treated once daily with 
lansoprazole (150 mg/kg/day) for four weeks. However, at 4.5 hours postdose the 
reduction in testosterone levels did not reach statistical significance due to the high 
degree o f interanimal variability in serum hormone levels (Fort et al., 1995). The 
magnitude of the reduction in plasma testosterone levels at four hours postdose (58% 
of control) appeared to be slightly larger than that previously observed at 18 to 2 0  
hours postdose (6 6 % and 80% of control in chapter 5 and 6  respectively), suggesting 
that homeostatic regulation might have been beginning to restore normal circulating 
hormone levels by the later timepoint.
Lansoprazole treatment had no statistically significant effects on plasma LH levels, 
consistent with findings from my previous studies (chapters 5 and 6 ). In contrast. Fort 
et al. (1995) reported significant increases in serum LH levels in lansoprazole-treated 
animals at 4 and 5 hours postdose. Lansoprazole-treated animals showed a trend 
towards lower plasma prolactin levels (79% of control), but this did not reach
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statistical significance. No significant effects were observed on plasma FSH levels in 
the current study. These findings are consistent with data from previous studies 
(chapters 5 and 6 ).
7.4.3 Effect of lansoprazole on gene expression in the pituitary gland
Real-time PCR (TaqMan™) was used to examine the effects of lansoprazole treatment 
on the expression of selected genes in the pituitary gland, namely LH and prolactin. 
LH was selected due to the central role of this hormone in the hypothalamic-pituitary- 
testis axis and the failure of previous studies to detect statistically significant changes 
in plasma LH levels in lansoprazole-treated animals. LH is a heterodimeric 
glycoprotein composed of an a-subunit that is common to all pituitary glycoproteins 
(LH, FSH, TSH) and a p-subunit, which is responsible for the unique properties o f this 
hormone (Pierce & Parsons, 1981). Separate genes encode the two subunits and for 
the current study TaqMan primers and probes were designed to recognise the 
hormone-specific P-subunit of LH. Lansoprazole treatment had no significant effect 
on LH  mRNA levels in pituitary gland samples from this study, which was consistent 
with the lack of effect on plasma LH levels observed in these animals. In contrast. 
Fort et al. (1995) reported significant increases in pituitary and serum LH levels four 
hours after the final dose of lansoprazole in Sprague Dawley rats that had been treated 
once daily with lansoprazole (150 mg/kg/day) for four weeks.
Prolactin was selected as the second gene of interest due to the fact that lansoprazole 
has previously been shown to produce a marked reduction in plasma prolactin levels 
(chapter 6 ), which might play a role in , the mechanism of LCT induction. 
Lansoprazole treatment had no significant effects on prolactin mRNA levels in 
pituitary gland samples. There was a trend towards lower plasma prolactin levels in 
the lansoprazole-treated group firom this study, but this did not reach statistical 
significance. LH and prolactin are both stored in secretory granules in the pituitary 
gland therefore short-term changes in hormone secretion might occur in the absence of 
changes in hormone biosynthesis.
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7.4.4 Conclusions
The current study was designed to further characterise the effects o f lansoprazole on 
the endocrine control o f the testis. Lansoprazole treatment was associated with a 
significant increase in relative liver weight, consistent with findings from previous 
studies (chapter 5). Lansoprazole-treated animals showed a trend towards lower 
plasma testosterone and prolactin levels compared to the control group in blood 
samples collected approximately four hours after the final dose of drug. No 
statistically significant changes in plasma LH or FSH levels were detected in 
lansoprazole-treated animals, consistent with previous findings (chapter 5 and 6 ). No 
significant changes in LH  or prolactin mRNA levels were observed in pituitary gland 
samples from lansoprazole-treated animals, therefore the decrease in plasma prolactin 
levels might have resulted from changes in hormone secretion and/or elimination.
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Chapter 8
Effect of lansoprazole on the plasma clearance of '^‘C-testosterone
8.1 Introduction
In previous studies, treatment of rats with lansoprazole induced the expression of 
several hepatic CYP P450 proteins from the CYPIA, 2B, 3A and 4A subfamilies 
(chapter 5 and 6 ). This was associated with significant increases in the activity of 
several CYP-dependent pathways of testosterone metabolism and in the overall rate of 
testosterone hydroxylation catalysed by liver microsomes in vitro (chapter 5). The 
ability of lansoprazole to induce hepatic steroid metabolising enzymes might 
contribute to the reduction in plasma testosterone levels previously observed in drug- 
treated rats. The aim of the current study was to determine whether treatment of rats 
with lansoprazole is associated with an increase in the rate o f /"^C-testosterone 
clearance from the plasma m vzvo.
8.2 Study design
Male Sprague Dawley rats were dosed once daily with lansoprazole (150 mg/kg/day) 
(n=4) or vehicle (0.5% (w / v) CMC/ 0.1% (v / v) Tween 80) (n=5) by oral gavage for 
14 days. On day 15, each animal was administered 50pCi ^"^C-testosterone (0.254mg 
testosterone) as an intravenous bolus injection in to the right tail vein. This dose of 
^"^C-testosterone was selected based on the limits of detection o f the methods used to 
analyse plasma samples. Serial blood samples were collected at the following 
timepoints after the dose o f ^"^C-testosterone: 5, 15, 20, 30, 40, 50, 60, 90, 120, 180 
and 260 minutes. These sampling times were selected based on the half-life of 
testosterone in rats obtained from the published literature (Pirke et al., 1982; Wang & 
Bulbrook, 1967; Henderson et al., 1980). Blood samples were collected from the left 
tail vein except for the final sample (260 minutes) which was taken by cardiac 
puncture. More detailed experimental details concerning animal treatment, sample 
collection and analytical methods used for this study can be found in chapter 2 .
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8.3 Results
8.3.1 Body and liver weights
Final body weights and relative liver weights for control and lansoprazole-treated 
animals are shown in Table 8 .1 .
Table 8.1 : Effect of lansoprazole treatment on relative liver weights
Control Lansoprazole-treated
Final body weight (g) 367.4 ±18.6 351.2 ±18.9
Relative liver weight
(g/lOOg body weight)
3.84 ±0.23 3.79 ±0.14
Results are expressed as mean ± SD for control (n=5) and lansoprazole-treated animals (n=4).
There were no statistically significant differences in initial (data not shown) or final 
body weights between experimental groups. No statistically significant differences in 
absolute (data not shown) or relative liver weights were observed between control and 
lansoprazole-treated animals.
8.3.2 Analysis of plasm a samples by HPLC
Selected plasma samples were subjected to HPLC analysis to determine whether any 
metabolites of ^"^C-testosterone were present at any of the timepoints. Samples from 
one control animal (at every timepoint) and one lansoprazole-treated animal (at 5, 20 
and 180 minutes) were analysed. Plasma samples were extracted using ethyl acetate 
(as described in 2.2.10.1) and 95pl of the reconstituted extract was injected on to the 
HPLC column with 5pi of an authentic testosterone standard. Each chromatogram 
was then examined for the presence of peaks other than ^'^C-testosterone.
Representative HPLC profiles o f plasma extracts from a control animal from this 
study are shown in Figure 8.1. For all plasma samples analysed, no peaks other than 
^"^C-testosterone were identified by radiochemical detection.
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Figure 8.1: Representative HPLC profiles of serial plasma samples collected
following an intravenous injection of ^"^C-testosterone in a control rat
a) 5 minutes cprii
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Each plasma sample (SOpl) was extracted using ethyl acetate (as described in 2.2.10.1) and 95pi o f the reconstituted 
extract was injected on to the HPLC column. Analytes were detected by radiochemical detection. Testosterone was 
identified by co-chromatography with an authentic standard injected on to the column with each sample (5pi) (detected 
by optical absorbance at 240nm (data not shown)).
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8.3.3 Quantification of ^"^C-testosterone in plasma samples
HPLC analysis of plasma extracts confirmed that metabolites of ^"^C-testosterone were 
not present at detectable levels in plasma samples firom this study. It was therefore 
decided to quantify the amount of ^"^C-testosterone in plasma samples by liquid 
scintillation counting (LSC), which allowed a higher sample throughput compared to 
analysing the samples by HPLC. Plasma samples were extracted using ethyl acetate 
(as described in 2 .2 .1 0 .1 ) and aliquots of the ethyl acetate (i.e. extractable 
radioactivity) and aqueous phases (i.e. unextractable radioactivity) were counted by 
LSC.
The levels of ^"^C-testosterone present in the ethyl acetate phase (i.e. extractable 
radioactivity) following extraction of plasma samples firom control and lansoprazole- 
treated animals are shown in Figure 8.2. The mean plasma concentrations of "^^ C- 
testosterone were generally lower in the lansoprazole-treated group compared to the 
control group.
A representative profile of the levels of radioactivity remaining in the aqueous phase 
(i.e. unextractable radioactivity) following extraction o f plasma samples is shown in 
Figure 8.3. In general, the absolute amount o f radioactivity remaining in the 
postextraction aqueous phase reached a maximum between 30 and 40 minutes after 
the injection of ^"^C-testosterone and declined thereafter (Figure 8.3a). The 
unextractable proportion of the total plasma radioactivity increased with time 
eventually reaching a plateau (Figure 8.3b).
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Figure 8.3: Unextractable radioactivity present in serial plasma samples collected
following an intravenous injection of ^"^C-testosterone in a control rat
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Serial blood samples were collected from a control animal following administration o f an intravenous dose o f ''*C- 
testosterone (SOpCi). Plasma samples were extracted three times using ethyl acetate (as described in 2.2.10.1) and 
aliquots o f the postextraction aqueous phase (i.e. unextractable radioactivity) were counted by LSC. Each data 
point represents the average value derived from duplicate extractions o f each plasma sample.
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8.3.4 Calculation of kinetic parameters
Plasma ^"^C-testosterone concentration-time curves were analysed by non- 
compartmental analysis (i.v. bolus model) using WinNonlin software. The non- 
compartmental approach does not require a specific compartmental model for the 
system and therefore enables the estimation of various pharmacokinetic parameters 
without making assumptions about any o f the pharmacokinetic properties o f the 
behaviour of the drug in the body.
Table 8.2 summarises the relevant kinetic parameters that were derived from the 
testosterone plasma concentration-time curves from control and lansoprazole-treated 
animals.
Table 8.2: ^^C-testosterone plasma elimination kinetics in control and lansoprazole- 
treated rats
Parameter Control Lansoprazole-treated
AUCjast
(dpm/min/ml)
7499 ± 2492 4423 ±1418*
Plasma Clearance
(ml/min/kg)
46.7 ±18.3 76.4 ± 1 9 .7 *
(ml/kg)
3869 ±1234 5931 ± 1427*
*‘^ C-testosterone plasma concentration-time curves were analysed by non-compartmental analysis using 
WinNonlin software as described in 2.2.10.4, AUCiast, area under the plasma concentration-time curve 
from the time of dosing to the last measured concentration; Vg;, volume o f distribution at steady state. 
Results are expressed as mean ± SD from individual control and lansoprazole-treated animals (n=4 
animals per group): Statistical analysis was performed using a Student’s t-test where asterisks (*) 
represent: * P<0,05.
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8.4 Discussion
8.4.1 Analysis of plasma samples
Initially, selected plasma samples were extracted and the reconstituted extracts 
subjected to HPLC analysis to determine whether any metabolites of ^"^C-testosterone 
were present at any of the timepoints. For all plasma samples analysed, no peaks 
other than ^"^C-testosterone were identified by radiochemical detection. In contrast, 
some other groups have reported the presence of testosterone metabolites in plasma 
samples collected from rats following intravenous administration o f ^H-testosterone 
(Henderson et al., 1980; Bruchovsky & Wilson, 1968; Hobbs et al., 1992). Henderson 
et al. (1980) reported that the percentage of the total extractable plasma radioactivity 
associated with the parent compound decreased from 6 8 % at one minute postdose to 
23% at 64 minutes following intravenous administration of ^H-testosterone. 
Unfortunately, the identity of the remaining extractable radioactivity was not reported 
in this paper. In contrast, Hobbs et al. (1992) reported that testosterone constituted 
the majority (80%) of the total extractable plasma radioactivity with smaller amounts 
of dihydrotestosterone (9%) and estradiol (11%) being present in blood samples 
collected 45 minutes after administration of ^ H-testosterone.
There are a number o f factors that might explain the differences between data from the 
current study and that reported by other groups. Firstly, one crucial difference 
between the current study and much of the published literature is related to the 
radioisotope employed. ^H-testosterone is used in the majority of studies reported in 
the published literature due to factors such as the higher specific activity and relative 
cheapness o f tritiated material. However, the major problem associated with the use 
of tritium is the possibility o f loss of the isotope from the compound as a result of, 
metabolism and chemical exchange. In contrast, ^"^C-testosterone was used for the 
current study because the metabolic stability of this compound is more predictable. 
Consequently, the type of radioisotope employed might have an impact on the 
proportion of the total plasma radioactivity that is detected in association with the 
parent compound (i.e. testosterone). Secondly, animals were anaesthetised during the 
experiments conducted by Henderson et al. (1980) and Hobbs et al. (1992) whereas no 
anaesthetic was used in the current study. Treatment of rats with an anaesthetic might 
have significant qualitative and quantitative effects on the pathways of steroid
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metabolism. Indeed, Tapper & Brown-Grant (1975) reported markedly lower 
0 estradiol plasma clearance rates in female rats under ether anaesthesia compared to 
animals that had been anaesthetised with tribromoethanol.
Thirdly, each study used different methods to process and analyse plasma samples, 
which might have contributed to the differences in the data obtained. One possible 
explanation for the apparent absence of metabolites in plasma extracts from the 
current study is that the ethyl acetate extraction procedure might have been less 
efficient at recovering neutral transformation products o f testosterone 
(e.g. dihydrotestosterone) compared to the parent compound. This would result in 
these metabolites largely remaining in the postextraction aqueous phase and 
consequently not being detected during HPLC of plasma extracts. In addition, 
Henderson et al. (1980) and Bruchovsky & Wilson (1968) used thin layer 
chromatography (TLC) followed by LSC to separate and quantify radiolabelled 
compounds present in plasma extracts. In contrast, Hobbs et al. (1992) analysed 
plasma extracts by HPLC. Interestingly, the two studies employing TLC yielded 
similar data with respect to the percentage of extractable plasma radioactivity that was 
associated with testosterone (10% parent at 60 minutes postdose (Bruchovsky & 
Wilson, 1968) compared to 23% parent at 64 minutes postdose (Henderson et al., 
1980)). In contrast, Hobbs et al. (1992) reported that testosterone constituted a much 
larger proportion (80%) o f the total extractable plasma radioactivity at 45 minutes 
postdose. In the current study, it cannot be completely ruled out that plasma extracts 
contained traces o f metabolites that were below the limits of detection of the HPLC 
method. However, such trace amounts of metabolites would not be expected to 
contribute significantly to the total amount o f radioactivity measured in the plasma 
extracts.
Following confirmation by HPLC that metabolites o f ^"^C-testosterone were not 
present at detectable levels in plasma samples from this study, it was , decided to 
quantify the amount o f ^"^C-testosterone present in plasma extracts by liquid 
scintillation counting (LSC). This method enabled a higher sample throughput 
compared to analysing samples by HPLC. Each plasma sample was extracted using 
ethyl acetate and the levels of extractable (i.e‘ ^"^C-testosterone) and unextractable 
radioactivity were measured by LSC.
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8.4.2 Extractable radioactivity
8.4.2.1 ^'^C-Testosterone plasma concentration-time profiles
Plasma concentrations of extractable ^"^C-testosterone showed an exponential decline 
following intravenous administration to rats (Figure 8.2). When this data was plotted 
semi-logarithmically (data not shown) it became apparent that the decline in plasma 
^"^C-testosterone concentrations was biphasic, indicating that testosterone is distributed 
to more than one pharmacokinetic “compartment” within the body. The biphasic 
plasma concentration decay curves suggest that testosterone is distributed in to two 
compartments: a central (rapidly equilibrating) and a peripheral (more slowly 
equilibrating) compartment. In addition to the systemic circulation, the central 
compartment might include tissues such as the liver, prostate and seminal vesicles as 
these tissues show rapid uptake (from 1 minute postdose) o f testosterone following 
administration o f the radiolabelled steroid to rats (Bruchovsky & Wilson, 1968; Lee et 
al., 1974). In a two-compartment model the first phase o f the plasma concentration­
time plot (i.e. steeper slope) includes the distribution of drug from the central to the 
peripheral compartment and the second phase (i.e. shallower slope) represents 
elimination from the central compartment. In reality, both o f these processes occur 
simultaneously and the relative rates of distribution and elimination determine what 
each phase represents. Following intravenous administration, testosterone is rapidly 
cleared from the systemic circulation therefore the first phase in the ^"^C-testosterone 
plasma concentration decay curve probably represents a significant proportion o f the 
elimination of this steroid.
The two-compartment pattern of testosterone clearance observed in the current study 
is consistent with previously published literature for rats (Henderson et al., 1980; 
Wang & Bulbrook, 1967; Bruchovsky & Wilson, 1968). However, it is difficult to 
compare data between studies due to different experimental designs, particularly with 
respect to blood sampling regimens. In the current study, blood samples were 
collected at various timepoints between 5 and 260 minutes following the 
administration of ^"^C-testosterone. In contrast, Henderson et al. (1980) collected 
blood samples at 1, 2, 4, 8 , 16, 32 and 64 minutes following an intravenous injection
3 '  3
of H-testosterone. This group reported a biphasic decline in plasma H-testosterone 
concentrations with a rapid decline in plasma radioactivity up to 4 minutes postdose
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and a slower decline thereafter. These findings indicate that distribution may occur 
very rapidly following intravenous administration of testosterone and might therefore 
have occurred significantly before the first blood sample was collected in the current 
study (i.e. 5 minutes postdose). This example illustrates how experimental design can 
influence the number of compartments that are used to describe drug disposition 
profiles.
LSC provided a sensitive method for quantification of the radioactivity present in 
plasma samples. However, the levels of '"^C-testosterone present in plasma samples 
from lansoprazole-treated animals at the later timepoints (i.e. 180 and 260 minutes) 
were close to the limits o f detection and therefore subject to greater analytical error. 
This might explain the apparent increase in plasma ^"^C-testosterone concentrations 
observed in some animals between 180 and 260 minutes. In addition, the final blood 
sample (260 minutes) was collected by a different route (cardiac puncture) compared 
to the other samples (tail vein), which may also have had some effect.
S.4.2.2 Kinetic analysis
Two different approaches can be used to estimate pharmacokinetic parameters from 
plasma drug concentration-time profiles, namely compartmental and non- 
compartmental analysis. For the current study the non-compartmental approach was 
used to analyse ^"^C-testosterone plasma concentration-time curves. Non- 
compartmental analysis does not require a specific compartmental model for the 
system and therefore enables the estimation of various pharmacokinetic parameters 
without making assumptions about any of the properties o f the pharmacokinetic 
behaviour of the drug in the body. In addition, this approach does not require the use 
of complicated non-linear regression processes. Alternatively, a two-compartment 
model could have been applied to this data set based on the biphasic appearance o f the 
semi-log ^"^C-testosterone plasma concentration-time profiles. However, this approach 
would not have allowed non-extrapolated area values to be calculated, which was 
necessary for this data set (see below).
Initial studies confirmed that for the current data it was most appropriate to calculate 
pharmacokinetic parameters using non-extrapolated area values (e.g. AUChst). This
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was necessary because extrapolation of the terminal portion of the ^"^C-testosterone 
plasma concentration-time curves tended to lead to overestimation o f the AUChf. This 
was probably due to the fact that the last few data points were subject to greater 
analytical error due to the low levels of ^"^C-testosterone present in plasma samples 
collected at the later timepoints, particularly in the lansoprazole-treated group.
Three pharmacokinetic parameters were estimated from the ^"^C-testosterone plasma 
concentration-time profiles, namely AUCiast, clearance and Vgg. The area under the 
plasma concentration-time curve (AUCiast) is an important pharmacokinetic parameter 
in quantifying the extent o f drug exposure and clearance. Plasma clearance is defined 
as the volume of plasma cleared of drug per unit time and is a measure of the 
efficiency of drug elimination from the body. The AUC is inversely related to the 
extent of systemic clearance. In the current study, lansoprazole-treated animals 
showed a significant reduction in AUCiast and a significant increase in plasma 
clearance compared to control animals following intravenous administration of 
^"^C-testosterone (P<0.05). The plasma clearance calculated for control animals from 
the current study is consistent with previously published data for male Sprague 
Dawley rats (Wang & Bulbrook, 1967).
The volume of distribution at steady state (Vss,) represents the ratio between the 
amount o f drug in the body and its plasma concentration once distribution equilibrium 
is achieved between the plasma and tissues. This parameter provides a measure o f the 
extent o f drug distribution from the plasma in to the tissues and is influenced by 
factors such as the extent of binding to blood (e.g. plasma proteins, blood cells) and 
tissue components. Two important observations were made concerning the Vss of 
^"^C-testosterone in rats from the current study. Firstly, ^"^C-testosterone has a 
relatively large volume of distribution (Vss) in rats, indicating that this hormone is 
extensively distributed from the plasma in to the tissues and may become concentrated 
in certain tissues. This finding is consistent with the physiological roles of 
testosterone and the fact that this hormone has previously been reported to be rapidly 
taken up by tissues such as the liver, prostate and seminal vesicles in rats (Bruchovsky 
& Wilson, 1968; Lee et al., 1974).
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Secondly, the Vss of ^"^C-testosterone was significantly higher in lansoprazole-treated 
animals compared to the control group (P<0.05). The reason for the observed increase 
in Vss following lansoprazole treatment is currently unknown but it could be due to 
some effect of this compound on the binding of ^"^C-testosterone to blood and tissue 
components. Lansoprazole might have an effect within the tissues leading to an 
increase in tissue binding or uptake of ^"^C-testosterone. Previous studies have 
demonstrated that this compound produces effects on the liver consistent with an 
increase in metabolic capacity (e.g. increase in relative organ weight, induction of 
cytochromes P450), which might be associated with enhanced hepatic uptake of 
testosterone. In addition, treatment o f rats with lansoprazole has previously been 
shown to deplete endogenous testosterone levels (plasma and intratesticular). This 
might lead to increased uptake of ^"^C-testosterone by androgen-dependent tissues 
(e.g. testis, prostate) in an attempt to restore normal hormone levels. Lansoprazole 
could also have an effect on the extent o f binding o f ^"^C-testosterone to plasma 
proteins. For example, a reduction in the plasma albumin concentration might lead to 
a decrease in the amount of testosterone retained in the systemic circulation with a 
consequent increase in the volume o f distribution. However, there is currently no 
evidence to suggest that treatment of rats with lansoprazole produces changes in 
plasma protein concentrations (Atkinson et al., 1990).
Finally, it is worthwhile to discuss the reasons why the terminal half-life of 
^"^C-testosterone was not used to interpret data from the current study. Firstly, using 
the non-compartmental approach the terminal half-life of a drug is estimated using the 
equation below:
0.693
Terminal half-life =
The terminal elimination rate constant, Xz, is estimated by linear regression o f the last 
few data points in the terminal portion of the plasma concentration-time curve, which 
were subject to greater analytical error as previously discussed. In addition, following 
intravenous administration the elimination of testosterone is an exponential process 
such that the rate o f elimination is proportional to the concentration o f testosterone at 
any given time (i.e. first order process). At the later timepoints, plasma 
^"^C-testosterone concentrations were lower in the lansoprazole-treated animals
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compared to the control group therefore the terminal elimination rate would also be 
expected to be slower. These factors would result in the generation of terminal half- 
life values that do not reflect the data. Finally, following intravenous administration 
testosterone is rapidly cleared from the systemic circulation therefore the first phase in 
the ^"^C-testosterone plasma concentration decay curve (the so-called “distribution” 
phase) probably represents a significant proportion of the elimination o f this steroid, 
which would not be reflected in the terminal half-life value. Consequently, plasma 
clearance was considered to provide a more accurate index of testosterone elimination 
for the current data.
8.4.3 Unextractable radioactivity
The amount of radioactivity remaining in the aqueous phase following extraction of 
plasma samples increased rapidly until 30 to 40 minutes after the dose of 
testosterone, declining thereafter (Figure 8.2). This unextractable radioactivity 
constituted up to 40% of the total plasma radioactivity at the later timepoints 
(> 90 minutes). Failure o f ethyl acetate to extract all o f the radioactivity from plasma 
samples was probably mainly due the presence o f steroid conjugates. In the liver, 
testosterone is conjugated with glucuronic acid or sulphate, either directly or 
subsequent to hydroxylation, in reactions catalysed by UDP-GT and ST enzymes 
respectively. These pathways produce more polar testosterone conjugates, facilitating 
excretion in the urine or bile. Extraction of plasma samples using ethyl acetate would 
be expected to yield all o f the free testosterone whereas any conjugated steroids would 
remain in the aqueous phase. Indeed, when plasma samples were spiked with 
testosterone the extraction efficiency was approximately 95% using the current 
procedure (data not shown).
The observed decline in the extractable proportion of the total plasma radioactivity 
with time is consistent with the published literature (Bruchovsky & Wilson, 1968; Lee 
et al., 1974; Henderson et al., 1980). Bruchovsky & Wilson (1968) reported that 
following treatment of male Sprague Dawley rats with an intravenous injection of 
^H-testosterone, the proportion o f the plasma radioactivity that was recovered by 
chloroform-methanol extraction decreased with time in normal animals. In contrast, 
the entire plasma radioactivity was recovered in the chloroform-methanol phase at all
219
timepoints in functionally hepatectomised animals. These findings confirm that 
testosterone is rapidly metabolised by the liver to form polar derivatives that appear in 
the plasma.
In the current study no attempts were made to identify the ^"^C-testosterone derivatives 
present in the postextraction aqueous phase. To determine whether the unextractable 
radioactivity was composed of testosterone conjugates, aliquots o f the aqueous phase 
could have been incubated with p-glucuronidase/sulfatase, which would enzymatically 
. cleave glucuronyl or sulfate groups. These samples could then have been re-extracted 
using ethyl acetate and the amount o f extractable and unextractable radioactivity 
quantified by LSC. Analysis of the ethyl acetate phase by HPLC would also enable 
identification of liberated ^"^C-testosterone and metabolites (e.g. hydroxytestosterones).
In the current study, it was not possible to conclude whether there were any significant 
differences in the levels of unextractable radioactivity present in plasma samples fi*om 
control and lansoprazole-treated animals. This was due to the fact the absolute levels 
of radioactivity measured in the postextraction aqueous phase might contain a 
relatively high degree o f experimental error for a number of reasons. Firstly, the 
aqueous phase was contaminated with varying amounts of residual ethyl acetate, 
which was not removed when the samples were decanted. Secondly, the aqueous 
phase was not a homogenous solution due to the presence of precipitated plasma 
proteins, meaning that it was difficult to pipette this phase consistently. Finally, due 
to the small volume of the aqueous phase it was not possible to count replicate 
samples by LSC. Due to these factors this data could only be used to identify trends in 
the levels o f radioactivity measured in the postextraction aqueous phase during the 
timecourse of this study.
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8.4.4 Conclusions
In the current study, lansoprazole-treated rats exhibited a significantly smaller AUCiast 
and significantly higher plasma clearance and volume of distribution (Vgg) following 
intravenous administration of ^"^C-testosterone (P<0.05). These findings indicate that 
lansoprazole increases the capacity of the body to eliminate testosterone firom the 
systemic circulation, consistent with our hypothesis. However, further studies need to 
be conducted to confirm that this increase in ^"^C-testosterone plasma clearance is a 
consequence o f increased activity of hepatic CYP-dependent pathways o f testosterone 
metabolism. This could be investigated by performing a mass balance study, which 
would involve intravenous administration of ^"^C-testosterone followed by 
measurement o f the rate of elimination o f radioactivity in the urine and faeces. Firstly, 
this would confirm that the increase in plasma ^"^C-testosterone clearance is associated 
with an enhanced rate o f elimination o f testosterone and its metabolites in the urine 
and faeces. Furthermore, identification and quantification of testosterone metabolites 
present in the urine and/or faeces would provide further information regarding the 
quantitative and qualitative effects o f lansoprazole treatment on pathways of 
testosterone metabolism in vivo. If  these studies confirmed that lansoprazole 
treatment was associated with an increase in the rate o f elimination o f hydroxylated 
testosterone metabolites, this would provide convincing evidence that induction o f 
hepatic cytochromes P450 was responsible for the increase in plasma ^"^C-testosterone 
clearance observed in the current study.
9
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Chapter 9
Final Discussion
9.1 Introduction
Leydig cell hyperplasia and adenomas are frequently observed in rodents during 
chronic toxicity and carcinogenicity studies with new therapeutic agents. A diverse 
range of chemicals have been shown to increase the incidence of Leydig cell 
hyperplasia and adenomas in rodent bioassays, however the significance of this effect 
to humans is currently a matter o f debate. A common mechanism of tumour induction 
appears to involve disturbance of the hypothalamic-pituitary-testis (HPT) axis at 
various points leading to a sustained increase in circulating LH levels. However, for 
many compounds their mode of tumour induction is currently unknown. Elucidation 
o f a biochemical mechanistic explanation for this effect would aid human risk 
assessment.
A common property o f chemicals that cause Leydig cell hyperplasia and tumours is 
that they induce hepatic cytochromes P450 (e.g. oxazepam, felbamate, lansoprazole 
and methyl ^er/-butyl ether (MTBE)) but it is currently unclear whether these two 
phenomena are causally related (Diwan et al., 1986; reviewed by Glue et al., 1997; 
Masubuchi et al., 1997a; Williams & Borghoff, 2000). The aim o f the current project 
was to investigate the existence of a liver-testis axis wherein microsomal enzyme 
inducers enhance the metabolic clearance o f testosterone causing a compensatory 
increase in LH secretion. It is widely accepted that chronic elevation of circulating 
LH levels is associated with the formation of Leydig cell hyperplasia and tumours in 
rodents (Christensen & Peacock, 1980; Chatini et al., 1990; reviewed by Cook et al., 
1999). Lansoprazole was selected as the model compound for studies designed to 
investigate the existence of a liver-testis axis because it induces hepatic cytochromes 
P450 and chronic exposure produces Leydig cell hyperplasia and tumours in rats 
(Masubuchi et al., 1997a; Atkinson et al., 1990; Unpublished report by Takeda 
Chemical Industries Ltd., A-29-681). A series of experiments were conducted to 
investigate the effects of lansoprazole on the liver, testis and the endocrine control of 
the testis.
9.2 Effects of lansoprazole on the liver
Treatment of rats with lansoprazole produced effects on the liver consistent with an 
enhanced metabolic capacity, including significant increases in relative liver weight 
and total microsomal CYP content. Lansoprazole induced the expression of several
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hepatic CYP proteins, including C Y PlA l, CYP1A2, CYP2B1, CYP3A and CYP4A1, 
as determined by ELISA and Western blotting. This was associated with significant 
increases in the activity o f several CYP-dependent pathways o f testosterone 
metabolism (i.e. formation of 6(3-, 7a-, 16a-, 16(3-, 2a- and 2P-0HT and 
androstenedione) and a significant increase in the total rate of hydroxytestosterone 
metabolite formation catalysed by liver microsomes in vitro. Such effects on the 
pathways of testosterone metabolism indicate that lansoprazole might also induce 
enzymes belonging to the CYP2A (7a-hydroxylase activity) and CYP2C (2a- 
hydroxylase activity) subfamilies. Lansoprazole treatment was not associated with 
significant changes in hepatic CYP2A1, CYP2C6, CYP2C11 or CYP2C13 mRNA 
levels compared to the control group, however this compound might increase the 
levels of the corresponding proteins by influencing processes other than gene 
transcription and mRNA stability.
The ability of lansoprazole to induce the expression of CYP proteins belonging to four 
families suggests that this compound may represent a distinct type o f “mixed inducer” 
as no other published examples of chemicals with this property could be identified. 
Furthermore, the effects o f lansoprazole treatment on microsomal testosterone 
metabolism were distinct from those observed following treatment o f rats with the 
four model CYP inducers (P-NF, PB, PCN and ciprofibrate). Firstly, each of the 
model inducers exhibited differential effects on the pathways of hepatic testosterone 
metabolism, inducing the activity of certain pathways whilst suppressing or having no 
effect on other pathways. Secondly, the model inducers tended to exert marked effects 
on the activity of specific pathways (e.g. 1 2  fold increase in testosterone 6 p~ 
hydroxylase activity in PCN-treated animals). In contrast, lansoprazole treatment did 
not exhibit a large effect on any of the pathways studied (< 2  fold change) but rather 
produced a generalised increase in the activity o f several pathways o f testosterone 
oxidation. Consequently, the increase in the total rate o f hydroxytestosterone 
metabolite formation produced by lansoprazole treatment (1.3 fold) was of a similar 
magnitude to that observed in PB- (1.3 fold) and PCN-treated (1.6 fold) animals.
Finally, a common finding in livers from rats treated with model CYP inducers is 
reduced expression of CYP2C11 protein and associated catalytic activities (Waxman
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et al., 1985; Yeowell et al., 1987). Indeed, treatment o f rats with each of the model 
inducers caused suppression o f hepatic testosterone 2 a-hydroxylase activity, albeit to 
different extents. In contrast, treatment of rats with lansoprazole was associated with a 
significant increase in testosterone 2 a-hydroxylase activity, indicative of induction of 
CYP2C11 or another CYP2C form. CYP2C11 is the major constitutive CYP 
(~ 40% total hepatic CYP) found in male rat liver and this form probably makes a 
substantial contribution to the overall rate of testosterone oxidation by rat liver 
(Guengerich et al., 1982; Waxman, 1984). Furthermore, it has been postulated that 
CYP2C11 might be responsible for the formation of specific hydroxylated metabolites 
with important physiological functions (e.g. 7a-hydroxylated androgens may regulate 
testosterone biosynthesis) (Waxman, 1984; Inano et al., 1973; Inano & Tamaoki, 
1971; Sunde et al., 1982; Rosness et al., 1977; Mittler, 1985). Consequently, 
xenobiotic-induced changes in the expression of CYP2C11 and associated testosterone 
hydroxylase activities might have an important impact on androgen homeostasis.
In conclusion, treatment o f rats with lansoprazole was associated with a unique profile 
of hepatic CYP induction and enhanced CYP-dependent testosterone metabolism, 
consistent with the current hypothesis. The different effects of lansoprazole and the 
model inducers on hepatic testosterone hydroxylase activities might result in these 
compounds having diverse effects on testosterone elimination and ultimately, 
androgen homeostasis within the animal.
9.3 Effect of lansoprazole on the plasma clearance of ^"*C-testosterone
Following the observation that lansoprazole treatment enhanced the capacity of the 
1 _ 
liver to metabolise testosterone in vitro, a study was conducted to determine whether
this was associated with an increase in the plasma clearance o f ^"^C-testosterone in
vivo. Indeed, lansoprazole-treated rats exhibited a significantly smaller AUCiast and a
significantly higher plasma clearance and volume of distribution (Vss) following the
intravenous administration of '"^C-testosterone. These findings indicate that
lansoprazole treatment increases the capacity of the body to eliminate testosterone
from the systemic circulation, consistent with the current hypothesis. However,
further studies are required to confirm that this increase in ^"^C-testosterone plasma
clearance is a direct consequence of the enhanced activity o f hepatic CYP-dependent
pathways o f testosterone metabolism (see Future Work).
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9.4 Effects of lansoprazole on plasma hormone levels
9.4.1 Testosterone
Treatment of rats with lansoprazole was associated with a reduction in plasma 
testosterone levels. Circulating testosterone levels, reflect the balance between the rate 
o f hormone biosynthesis in the testis and elimination via the liver and kidneys. The 
reduced plasma testosterone levels observed following lansoprazole treatment are 
probably, at least in part, related to the ability of this compound to inhibit testosterone 
biosynthesis (Fort et al., 1995). However, the ability o f lansoprazole to enhance 
hepatic CYP-dependent testosterone metabolism and ^^C-testosterone plasma 
clearance suggests that enhanced metabolic clearance of testosterone might also play a 
role in lowering circulating testo.sterone levels. At present, the relative contributions 
o f inhibited biosynthesis and enhanced metabolic clearance to the observed decrease 
in plasma testosterone levels are unknown.
In contrast, treatment of rats with the model CYP inducers did not have a significant 
impact on plasma testosterone levels despite the marked effects o f these compounds 
on hepatic testosterone hydroxylase activities. Such differences between the effects of 
lansoprazole and the model inducers might be related to the divergent effects of these 
compounds on the pathways o f testosterone hydroxylation or could be a consequence 
of effects on other pathways o f testosterone metabolism (e.g. reductive pathways, 
glucuronidation, sulfation). Consistent with the latter hypothesis, treatment of humans 
with A-phenylbarbital produces a significant increase (> 60%) in the urinary excretion 
of polar testosterone metabolites but has no significant effect on the plasma clearance 
o f testosterone (Bammel et al., 1992). Alternatively, initial effects of these 
compounds on circulating testosterone levels may be rapidly compensated for through 
changes in testosterone biosynthesis and/or secretion from the testis. Such 
homeostatic regulation might be sufficient to maintain normal circulating hormone 
levels despite the xenobiotic-induced changes in the metabolic clearance of 
testosterone.
To date, a limited number o f studies have been performed to investigate the impact,of 
microsomal enzyme inducers on androgen homeostasis in rodents. Wilson & LeBlanc 
(1998) examined the effects of the organochloride pesticide, endosulfan, on steroid
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metabolism in female CD-I mice. Endosulfan treatment increased the total rate of 
hydroxytestosterone metabolite formation catalysed by liver microsomes and 
enhanced the urinary elimination of ^"^C-testosterone (-3.6 fold). No significant 
changes in the rate of direct glucuronic acid or sulfate conjugation to testosterone were 
observed in endosulfan-treated mice (Wilson & LeBlanc, 1998). However, this 
marked increase in androgen elimination was associated with a small, non-significant 
decrease in serum testosterone levels, suggesting that homeostatic feedback 
mechanisms were able to compensate for the effects of this compound in female mice 
(Wilson & LeBlanc, 1998). Wilson & LeBlanc (1998) postulated that xenobiotic- 
induced increases in testosterone biotrarisformation and elimination might not be 
sufficient to perturb androgen homeostasis within the animal. However, simultaneous 
exposure to a compound that enhances testosterone elimination (e.g. endosulfan) and 
an agent that interferes with the feedback regulation of testosterone biosynthesis 
(e.g. ketoconazole) might have a significant impact on circulating testosterone levels. 
Accordingly, the reduced plasma testosterone levels observed in lansoprazole-treated 
animals might be a consequence o f the combined ability o f this compound disrupt the 
HPT axis at more than one site through inhibition of testosterone biosynthesis and 
enhanced testosterone clearance. A similar hypothesis has been proposed to explain 
the reduction in circulating testosterone levels observed following chronic exposure of 
animals to PCBs, which also enhance hepatic testosterone hydroxylase activity and 
inhibit testosterone biosynthesis (Machala et al., 1998). ^
9.4.2 Luteinising hormone (LH)
In the current project, no statistically significant changes in plasma LH levels were 
detected despite the reduction in circulating testosterone levels in lansoprazole-treated ' 
animals. Failure to detect a statistically significant increase in plasma LH levels in 
lansoprazole-treated animals might reflect the true situation, however subtle changes 
might not have been detected due to factors such as the timing o f blood sample 
collection and interanimal variability in plasma hormone levels. Plasma LH levels 
measured at a single timepoint will be subject to a high degree o f variability due to the 
pulsatile pattern of LH secretion from the pituitary gland (Ellis & Desjardins, 1982). 
Indeed, Wilson et al. (1999) postulated that the marked interanimal variability in 
circulating hormone levels observed in rodent models might result in subtle
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disturbances of steroid hormone homeostasis remaining undetected until more 
profound irreversible effects are manifested. The studies conducted during this project 
were not primarily designed to detect subtle changes in plasma hormone levels 
therefore it would be beneficial to perform a specialised study to further characterise 
the effects of lansoprazole on circulating hormone levels (see Future Work).
In contrast to the current findings, Fort et al. (1995) provided evidence to support the 
involvement o f LH in Leydig cell tumorigenesis following treatment o f rats with 
lansoprazole. This group reported statistically significant increases in serum LH 
levels in blood samples collected four and five hours after the final dose from rats 
treated with lansoprazole (150mg/kg/day) for four weeks (Fort et al., 1995). 
Furtherrhore, providing testosterone supplementation to lansoprazole-treated Fischer 
344 rats lowered serum LH levels and completely suppressed the induction o f LCTs 
(Fort et al., 1995). These findings indicate that increased LH secretion, secondary to 
reduced negative feedback of testosterone at the hypothalamus and pituitary gland, 
might be responsible for the induction of LCTs by lansoprazole.
Fort et al. (1995) proposed a compensation-decompensation mechanism to explain the 
sequence o f events leading to the formation of LCTs in lansoprazole-treated rats. 
Lansoprazole-treated animals exhibit significant reductions in circulating testosterone 
levels in short-term studies (< 1 month), however no significant changes are observed 
in longer-term studies (> 3 months) (Fort et al., 1995; Unpublished reports by Takeda 
Chemical Industries Ltd., A-90-151; A-29-I863). Leydig cell hyperplasia and 
adenomas are observed following approximately one year o f lansoprazole treatment 
(Atkinson et al., 1990). Fort et al. (1995) postulated that Leydig cells might initially 
be able to compensate for the partial inhibition o f testosterone biosynthesis produced 
by lansoprazole treatment through increasing the net responsiveness o f the Leydig cell 
population to LH stimulation (i.e. compensation). Indeed, repeated treatment of rats 
with low levels of LH enhances LH-stimulated testosterone biosynthesis in vivo, 
despite downregulation of LH receptor numbers (Zipf et al., 1978b). This 
compensation process might involve changes in LH receptor signalling, steroidogenic 
enzyme induction or recruitment of an initially unresponsive population of Leydig 
cells in to the responsive pool (Lin et al., 1982; Payne et al., 1980a,b). Normal
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deterioration of these homeostatic mechanisms during ageing would result in loss of 
the ability to maintain circulating testosterone concentrations without an increase in 
Leydig cell mass, resulting in the formation of Leydig cell hyperplasia and tumours 
(i.e. decompensation). This compensation-decompensation model might explain the 
apparent absence of elevated plasma LH levels in lansoprazole-treated animals from 
the current project. Homeostatic regulation might have meant that plasma testosterone 
and LH levels were returning towards their normal ranges due to an increase in the 
steroidogenic responsiveness o f the Leydig cell population to LH stimulation. 
However, no significant changes in StAR or CYP17A1 mRNA levels were observed in 
testis samples from lansoprazole-treated animals compared to the control group. In 
addition, the duration o f lansoprazole treatment ( 2  weeks) in the current studies might 
not have been sufficient to attain this apparent homeostatic state. Indeed, Fort et al. 
(1995) reported that rats treated with lansoprazole (50 or 150mg/kg/day) for one or 
two weeks exhibited reductions in hCG-stimulated testosterone secretion m vivo (Fort 
et al., 1995).
In conclusion, failure to detect a significant increase in plasma LH levels in 
lansoprazole-treated animals from the current project might be a consequence o f the 
inherent variability in circulating hormone levels or the result o f adaptive responses 
occurring at the level o f the testis. There is evidence in the published literature to 
support the involvement of LH in the mechanism of LCT induction by lansoprazole, 
therefore further studies are required to characterise the effects of lansoprazole 
treatment on plasrna LH levels (Fort et al., 1995).
9.4.3 O ther hormones
The effects of lansoprazole treatment on other hormones involved in the endocrine 
control of the testis were examined. Treatment of rats with lansoprazole did not have 
a significant impact on plasma FSH levels but was associated with a reduction in 
plasma prolactin levels (reduced to 32% control values in study 3). No significant 
changes in prolactin mRNA levels were detected in pituitary gland samples from 
lansoprazole-treated animals, therefore the decrease in plasma prolactin levels might 
have resulted from changes in hormone secretion and/or elimination.
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The ability of lansoprazole to reduce circulating prolactin levels might play a role in 
the mechanism of LCT induction by this compound. Prolactin appears to play an 
important role i n , regulation of the male reproductive system through direct 
(e.g. maintenance of Leydig cell LH receptors) and indirect effects (e.g. suppression of 
gonadotropin secretion from the pituitary gland) on testicular function (Zipf et al., 
1978a; McNeilly et al., 1978; Winters & Loriaux, 1978; Smith & Bartke, 1987; 
Cheung, 1983). Consequently, changes in plasma prolactin levels might lead to 
changes in circulating gonadotropin levels and modulation of the sensitivity o f the 
Leydig cells to LH stimulation. Indeed, prolactin has previously been implicated in 
the aetiology o f LCT formation in rats. Dopamine agonists, such as mesulergine, 
might produce LCTs through their ability to reduce circulating prolactin levels leading 
to downregulation o f LH receptors (Prentice et al., 1992). This might result in a 
partial inhibition of testosterone biosynthesis and a consequent increase in LH 
secretion (Prentice et al., 1992). Furthermore, induction of chronic 
hyperprolactinaemia has been reported to markedly, reduce the incidence o f 
spontaneous LCTs in Fischer 344 rats and the authors postulated that this was due to 
suppression of circulating LH levels (Bartke et al., 1985). It is currently unknown 
whether the ability of lansoprazole to reduce plasma prolactin levels contributes to the 
mechanism of LCT induction in rats.
9.5 Effects of lansoprazole on the testis
The main objective o f the current project was to investigate the effects of lansoprazole 
treatment on the liver and the endocrine control o f the testis. In addition, studies were 
performed to characterise the effects of lansoprazole treatment on testicular CYP 
expression, testosterone metabolism and intratesticular testosterone concentrations. 
The contribution of the testis to the overall rate of testosterone metabolism is probably 
relatively small, but the local concentration of hydroxylated testosterone metabolites 
might be important for testicular androgen homeostasis. For example, there is 
evidence to support a role for 7a-hydroxylated androgens in the regulation o f 
testicular testosterone biosynthesis (Inano et al., 1973; Inano & Tamaoki, 1971; Sunde 
et al., 1982; Rosness et al., 1977; Mittler, 1985). Consequently, xenobiotic-induced 
changes in testicular testosterone metabolism might have important local effects on the 
testis.
230
Cytochromes P450 are expressed at low levels in the testis hence Western blotting was 
not sensitive enough to detect GYP proteins other than CYP4A1 in pooled testis 
microsomes. Consequently, real-time PCR (Taqman) was employed as sensitive and 
specific method to examine the effects of lansoprazole treatment on the expression of 
CYPlAl, CYP2A1, CYP2C11, CYP2C6, CYP2C13, IJP-HSD, CYP17A1 and StAR in 
the testis. Each mRNA was present at detectable levels in testis samples but no 
significant changes in gene expression were detected in lansoprazole-treated animals 
compared to the control group.
Experiments were performed to characterise the effects o f lansoprazole treatment on 
testicular testosterone metabolism. However, the low levels of testosterone 
hydroxylase activity present in testis microsomes confounded the accurate 
quantification o f testosterone metabolites present in incubation extracts. 
Consequently, the derived enzyme activities were less reliable and subtle effects o f 
drug treatment might not have been detected due to the use o f pooled testis 
microsomes. Treatment o f rats with lansoprazole did not exert any marked effects on 
the pathways of testicular testosterone metabolism studied, consistent with the absence 
of changes in testicular CYP mRNA levels. This was not entirely unexpected as 
lansoprazole treatment produced relatively modest effects on the activity o f CYP- 
dependent pathways of testosterone metabolism in the liver and testicular CYPs 
appear to be less sensitive to the effects of chemical inducers (Goldstein & Linko, 
1984; Omiecinski, 1986).
The most pronounced testicular effect of lansoprazole treatment was a trend towards 
lower intratesticular testosterone concentrations in drug-treated animals compared to 
the control group (72% of control value). Measurement o f intratesticular hormone 
levels provides an indicator of the biosynthesis, secretion and bioavailability of 
testosterone within the testis. Fort et al. (1995) reported that lansoprazole has direct 
effects on the rat testis, inhibiting testosterone biosynthesis by cultured Leydig cells 
and reducing hCG-stimulated testosterone secretion in vivo. Hence, the reduction in 
intratesticular testosterone levels in drug-treated animals is probably mainly due to the 
ability of lansoprazole to inhibit testosterone biosynthesis.
231
The ability of lansoprazole to reduce the local concentration o f testosterone might 
have important effects on the testis. Testosterone is essential for the maintenance of 
normal spermatogenesis therefore sustained reductions in intratesticular hormone 
levels are probably responsible for the increased incidences of epididymal 
hypospermia and seminiferous tubule atrophy reported in lansoprazole-treated rats 
(Unpublished reports by Takeda Chemical Industries Ltd., Report numbers: TÀ-90- 
151 and TA-91-024). Such effects might influence Leydig cell morphology and 
function through disturbance of the reciprocal regulatory pathways that appear to exist 
between the seminiferous tubules and the Leydig cells. In addition, testosterone may 
modulate the production of several potential regulatory molecules that are produced 
within the testis (e.g. PModS, p-endorphin, oxytocin). Consequently, the ability of 
lansoprazole to reduce intratesticular testosterone concentrations might have important 
effects on the paracrine environment of the testis, which could play a role in the 
formation of LCTs. .
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9.6 Conclusions
The current project has generated data that significantly increases our current 
understanding of the effects o f lansoprazole on the liver and testis in male rats. 
Lansoprazole treatment induced hepatic CYP proteins belonging to four families, 
suggesting that this compound might represent a distinct type o f “mixed inducer”. 
Lansoprazole-treated rats exhibited significant increases in hepatic CYP-dependent 
testosterone metabolism in vitro and enhanced plasma clearance o f ^"^C-testosterone in 
vivo. These findings demonstrate that lansoprazole treatment increases the capacity of 
the body to eliminate testosterone from the systemic circulation, however further 
studies are required to confirm that this effect was a direct consequence of enhanced 
hepatic CYP-dependent testosterone metabolism. Reductions in plasma testosterone 
levels were observed in lansoprazole-treated animals compared to the control group, 
confirming that this compound has the potential to perturb androgen homeostasis 
within the animal. This effect has previously been attributed to the ability of 
lansoprazole to inhibit testosterone biosynthesis, but data from the current project 
suggests that enhanced clearance might also play a role in lowering circulating 
testosterone levels. At present, the relative contribution o f these two mechanisms to 
the depletion o f circulating testosterone is unknown.
Despite the reduction in circulating testosterone levels, no significant changes in 
plasma LH levels were detected in lansoprazole-treated animals from the current 
project. However, there is evidence in the published literature to support the 
involvement o f elevated LH levels in the mechanism of LCT induction by 
lansoprazole (Fort et al., 1995). As the current studies were not primarily designed to 
detect subtle changes in plasma hormone levels, it would be beneficial to perform a 
specialised study to further characterise the effects of lansoprazole on plasma LH 
levels.
In conclusion, the current project has generated data to support the hypothesis that 
hepatic CYP induction contributes to the reduction in circulating testosterone levels 
observed in lansoprazole-treated rats. Hence, this effect might play a role in the 
mechanism by which lansoprazole interferes with the HPT axis and produces Leydig 
cell hyperplasia and tumours in rats. These findings are not inconsistent with the
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existence of a liver-testis axis, however further studies are required to determine 
whether enhanced metabolic clearance o f testosterone alone is sufficient to perturb 
androgen homeostasis in rats.
9.7 Future Work
The current project has generated data to support the hypothesis that hepatic CYP 
induction contributes to the reduction in circulating testosterone levels observed in 
lansoprazole-treated rats. The following studies would provide additional information 
concerning the mechanism of LCT induction in lansoprazole-treated animals.
The following experiments would be of interest to further characterise the effects of 
lansoprazole on testosterone biotransformation and elimination processes and the 
endocrine control of the testis.
a) Mass balance study
This study would confirm whether the increase in plasma ^"^C-testosterone 
clearance observed in lansoprazole-treated animals is a, direct consequence of 
enhanced hepatic CYP-dependent testosterone metabolism. The elimination of 
radiolabelled testosterone would be measured in the urine and faeces following 
administration of an intravenous injection of ^"^C-testosterone to control and 
lansoprazole-treated rats. Identification and quantification o f testosterone 
metabolites present in the urine and faeces would provide further information 
concerning the quantitative and qualitative effects of lansoprazole treatment on the 
pathways o f testosterone metabolism in vivo. If  enhanced elimination of 
hydroxylated testosterone metabolites was observed in the lansoprazole-treated 
group, this would provide convincing evidence that hepatic CYP induction was 
responsible for the increase in plasma ^"^C-testosterone clearance.
b) Other pathways of testosterone metabolism
It would be of interest to examine the effects of lansoprazole treatment on other 
pathways that contribute to testosterone biotransformation and elimination 
(e.g. reductive pathways, glucuronidation, sulfation). These studies could be 
performed in vitro using liver microsomal or cytosolic fractions prepared from 
control and lansoprazole-treated animals.
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c) Endocrine study
It would be beneficial to perform a well-designed study to further characterise the 
effects of lansoprazole treatment on the endocrine control of the testis, particularly 
plasma LH levels. The design of these studies might include larger numbers of 
animals, pair-matched controls (i.e. blood samples collected at exactly the same 
time) and collection of serial blood samples from each animal.
In addition, other potentially interesting endocrine changes were identified in 
lansoprazole-treated animals from the current project. It would be o f interest to 
further investigate whether these effects play a role in the mechanism o f LCT 
induction by lansoprazole as follows.
d) Decrease in plasma prolactin levels
There is some evidence that changes in circulating prolactin levels might play a 
role in aetiology o f LCT formation in rats, therefore it would be o f interest to 
further investigate the significance of the reduction in plasma prolactin levels in 
lansoprazole-treated animals (Prentice et al., 1992; Bartke et al., 1985). For 
example, a prolactin supplementation study could be conducted to investigate the 
effects o f the reduction in plasma prolactin levels on plasma hormone levels 
(e.g. LH, testosterone), the sensitivity o f the Leydig cells to LH-stimulation and 
the incidence o f Leydig cell hyperplasia and tumours in lansoprazole-treated 
animals.
e) Reduction in intratesticular testosterone levels
It would be interesting to investigate whether the reduced intratesticular 
testosterone concentrations in lansopraozle-treated animals are associated with 
changes in the paracrine environment of the testis. This might include comparing 
the expression of various paracrine factors in testis samples from control and
I  ' '  .
lansoprazole-treated animals (e.g. using real-time PCR (TaqMan)). The 
significance of any changes could be further investigated by examining the effects 
o f the paracrine factor on Leydig cell numbers and function.
Finally, to further investigate the existence of a liver-testis axis, it would be beneficial
to treat rats with a series o f compounds known to induce hepatic cytochromes P450
and produce Leydig cell tumours in rodents. The effects of these compounds on
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hepatic CYP proteins, microsomal testosterone metabolism, ^"^C-testosterone plasma 
clearance and elimination in vivo and circulating hormone levels could be examined. 
Such studies might enable the identification of a subset o f compounds that induce 
LCTs as a consequence of enhanced metabolic clearance of testosterone. In addition, 
studying the quantitative and qualitative effects of these compounds on the pathways 
of testosterone metabolism and elimination might indicate whether compounds that 
induce LCTs alter specific pathways or metabolites.
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